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ABSTRACT 
Several studies in the literature suggest that the biotrans-
formation of foreign compounds in man is more similar to that in 
the non-human primate than to that in other laboratory animal species. 
However, published information about the pharmacokinetics of foreign 
compounds in non-human primates is limited and usually derived from 
one species, the rhesus monkey. In view of the often limited avail-
ability of this species for use in the development and safety evaluation 
of new drugs, pesticides, etc., it is necessary to search for potential 
replacement species for future use. This thesis compares the pharmaco-
kinetics of seven well-known or commonly used drugs, i.e. antipyrine, 
diazepam, frusemide, ibuprofen, isosorbide dinitrate, paracetamol and 
pentobarbitone in the rhesus monkey, cynomolgus monkey and baboon with 
a view to defining further the suitability of these species for the 
study of newer substances. These three non-human primate species are 
those that are most frequently used in pharmacology and toxicology 
studies. The drugs were chosen for study because they are extensively 
used clinically and related human pharmacokinetic data are available 
for comparison. 
Primary pharmacokinetic data are best obtained after intravenous 
doses when all the drug is injected into the bloodstream. Following 
intravenous injection of each compound alone at a dose level that would 
possibly be used in toxicology studies, plasma concentrations of drug 
were measured using established analytical techniques. The plasma 
concentration-time data was processed using non-linear least squares 
curve fitting techniques. Pharmacokinetic parameters were estimated 
using a two-compartment open model and in some cases, when appropriate, 
a one-compartment open model. 
A statistical analysis of variance of pharmacokinetic parameters 
obtained for each drug showed that there were few significant 
pharmacokinetic differences (P<o.OS) between the rhesus monkey, the 
cynomolgus monkey and the baboon. In general, volumes of distribution 
adjusted for bodyweight differences, and half-lives of elimination 
were similar in the three non-human primate species studied. However, 
the clearance of those compounds with low rates of systemic clearance, 
i.e. antipyrine, frusemide, ibuprofen and pentobarbitone was lower in 
the cynomolgus monkey than in the other two species. The clearance of 
those compounds with higher clearance rates, i.e. diazepam, isosorbide 
dinitrate and paracetamol, was similar in all three species of non-
human primate. 
A review of the literature of the pharmacokinetics of the 
compounds studied, in man and the commonly used laboratory animal 
species, reveals that, in general, the same pharmacokinetic model 
applies to the data for non-human primate species as for other species. 
With respect to volumes of distribution adjusted for bodyweight 
differences, the non-human primate is in general similar to man and 
to the commonly used laboratory animal species. In the non-human 
primate species, clearances adjusted for bodyweight differences tend 
to be similar to those in other commonly used laboratory animal species 
except in the rat. However, clearances of these drugs in humans appear 
to be lower than in animal species. Biological half-lives in the non-
human primate species are closer to those in the laboratory animal 
species than to those in man. In particular, those compounds that 
have long biological half-lives in man (t~ >12 hours) have considerably 
shorter half-lives in the non-human primate species studied and in 
other commonly used laboratory animal species cited in the literature. 
Using pharmacokinetic criteria, and with respect to the compounds 
studied, it can be concluded that the cynomolgus monkey and the baboon 
are suitable alternatives to the rhesus monkey for drug evaluation 
studies. However, these non-human primates are pharmacokinetically 
more similar to other commonly used laboratory animal species than to 
man. Nevertheless, factors such as differences in the pattern and 
nature of biotransformation, distribution in target tissues and receptor 
and protein binding need also to be considered when selecting an animal 
model for man for use in the development and safety testing of drugs. 
CHAPTER 1 
GENE~ INTRODUCTION 
Food additives, pesticides, pharmaceuticals, etc., are foreign 
to man in that they are non-nutrient. Such compounds could be hazardous 
if they were not rendered harmless by detoxication and thus eliminated 
(Williams, 1959). 
The safety evaluation now required for such substances before 
man is exposed to them involves studying their effects in animals. 
Species such as the rat, dog and non-human primate are exposed to 
foreign substances for long periods and any toxic effects determined. 
Ideally, animal species used for laboratory testing would metabolise 
foreign compounds in the same way as man but unfortunately this is not 
so. There are many factors that can influence the fate of a compound 
in an organism, e.g. species, strain, age, sex, stress and disease, and 
species is one of the more important. 
The subject of species variations in biotransformation has been 
reviewed many times (Williams, 1959; 1974; 1978; Hathway, 1970; 
Moore, 1972; Smith and Williams, 1974; Baty, 1975; 1977; 1979; Smith 
and Caldwell, 1977). No one animal species has been found in which the 
metabolism of all compounds is the same as that in man. The best that 
can be achieved is a compromise in which data obtained from different 
animal species is extrapolated to man (Smith, 1966; Burns, 1968; 
Conney et al, 1974; Gillette, 1976). 
As non-human primates are closest to man in evolutionary status, 
these species might be considered good models for man. However, because 
of the expense and difficulty of their maintenance, non-human primate 
species have not been studied as thoroughly as they deserve. Indeed 
information on the pharmacokinetics of many well known drugs in non-
human primate species is lacking. Reported pharmacokinetic data on 
drugs studied in non-human primate species are discussed in the 
appropriate sections of this thesis. 
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Wagner (1968) has stated that the purpose of pharmacokinetics 
is to study the time course of drug and metabolite concentrations 
and amounts in the biological fluids, tissues, excreta and to 
relate them to the time-course of drug action (pharmacological 
and toxic effects). 
Absorption 
Substances administered to an animal, unless injected directly 
into the bloodstream,.- must be absorbed before they enter the 
circulating blood. Absorption is the transfer of molecules from 
the site of administration, across the barrier membranes and into 
the circulation. The most common route of administration is 
orally via the gastrointestinal (G.I.) tract (enteral administration). 
Factors that can affect G.I. absorption are many (Riegelman 
and Rowland, 1973; Wagner, 1975; Welling, 1977; Houston and Wood, 
1980). However, some of the more important factors that alter the 
rate and extent of absorption are the particle size of the foreign 
compound, pKa, lipid solubility, the presence of other substances, 
motility of the G.I. tract, gut microflora and splanchnic blood flow. 
Absorption from the alimentary tract can take place from the 
mouth, from the stomach, the intestine, the colon or from the rectum. 
The mechanisms for absorption are those for the transfer of compounds 
across membranes (Schanker et al, 1957; 1958; Hogben et al, 1959; 
Schanker, 1959; Kakemi et al, 1965). For the absorption from the 
G.I. tract, the main barrier membrane is the gastrointestinal 
epithelium. 
Absorption from the mouth and the lower sectiollS of 
the rectum differs from that from other sections of the alimentary 
tract in that compounds absorbed via these routes are not trans-
ported directly to the liver, nor are they exposed to the gastric 
juices before absorption. Both these factors can significantly 
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affect the amount of a foreign compound that enters the circulation 
(Adamson et al, 1966; 1970a; Rowland, 1977; Schwartz, 1966). 
Absorption occurs from the G.I. tract by mechanisms other than 
simple diffusion of small non-ionised molecules. For example, 
quaternary ammonium compounds are absorbed from the intestine to an 
appreciable extent although they are completely ionized at the pH of 
the intestinal lumen (Levine, 1966; and Waldeck, 1969). Macromolecules, 
such as diphtheria, tetanus and botulinus toxins have also been shown 
to be absorbed enterally (Lammanna, 1960). Examples of active 
intestinal transport are the absorption of foreign sugars structurally 
similar to glucose (Wilson and Landau, 1960), and the 
anti-tumour agents such as 5-fluorouracil and 5-bromouracil by the 
process which transports the natural pyrimidines (Schanker and Jeffrey, 
1962; Schanker and Tocco, 1960; 1962). 
Parenteral absorption. Absorption from sites in the body such as the 
lung (Enna and Schanker, 1969) and muscle(Renkin, 1952; Pappenheimer, 
1953) also involves transfer from the site of administration across 
barrier membranes and into the bloodstream. Apart from absorption 
through the skin this process is quite efficient and absorption is 
limited mainly by the supply of blood to the site of administration. 
Again simple diffusion and filtration are the most common mechanisms 
for absorption of substances from these parenteral sites. 
Distribution 
-Once a foreign compound has entered the circulation, it will 
be carried to all regions of the body. The time taken to reach 
equilibrium between solute concentrations in the blood and tissues 
depends principally on the rate of supply of blood to the tissue. 
Other factors that will influence the distribution of a foreign 
compound are the ease of membrane transfer and interactions with 
constituents of the body, e.g. tissue and plasma proteins, nucleic 
acids and melanin. 
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For convenience, the tissues in the body can be grouped into 
three main categories. The first group (or compartment) usually 
consists of the highly perfused tissues e.g. the liver, the kidney and 
the lung. The second compartment normally comprises the less well 
perfused tissues, e.g. fat, muscle and skin. Those tissues with a 
negligible supply of blood, e.g. bone, teeth, hair, normally form the 
third compartment. In time, foreign compounds will fully distribute 
throughout the available space until a distribution equilibrium is 
obtained. The amount of drug in the different compartments at 
equilibrium will depend on the relative sizes of the intercompartmental 
transfer rate constants defined on pages 26 and 27. 
It is assumed that the transfer rate constants for most drugs 
between tissues within a compartment are much greater than those 
between tissues.in different compartments and that the former can be 
ignored. This approach simplifies the mathematical description of 
distribution and requires only blood (plasma or serum) concentration-
time data, because at equilibrium it can be assumed that the drug 
concentration in the blood is proportional to that in the tissues 
(Gibaldi and Perrier, 1975). Blood is relatively easy to sample, and 
measurement of drug concentrations in blood provides a convenient method 
for studying the distribution of compounds in the body. By contrast, 
tissue samples are not usually available. 
The apparent volume of distribution is defined as that volume 
in which the total administered dose would be uniformly distributed 
into, to give the observed concentration in the blood (or plasma), 
equation 1 : 1. 
V = Dose (l l) d c . . . . . . : 
0 
where vd is the apparent volume of distribution, and c
0 
is the intercept 
at zero time of the whole blood (or plasma) concentration-time curve 
after intravenous injection of the compound. 
The value of Vd will depend on the degree of extravascular 
distribution. In man, therefore, it can vary from as little as 3 litres 
for a compound that is restricted almost entirely to the circulating plasma 
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e.g. Evans Blue (Goldstein et al, 1974) to a value of the order of 
1000 times the volume of the body, e.g. quinacrine (Butler, 1971). 
Membrane transfer. The blood capillary wall is relatively permeable 
and provides little resistance to the transfer of small molecules. 
Most compounds do, therefore, gain access to the extra-cellular 
interstitial space of tissues in a rather short time. The cellular 
membranes provide more resistance to penetration by foreign compounds 
than the capillary wall and usually control the rate of distribution 
into the tissue. The rate at which a molecule enters the tissue is 
dependent on the physical properties of the molecule. An exception 
is the brain which is protected from the harmful effects of many 
substances by a sheath of connective-tissue cells, called glial 
cells, around the cerebral capillaries (Rall, 1971). Only those 
molecules with the desired physical properties to enter the cellular 
membranes readily enter the extracellular fluid of the brain. 
Disposition in fat. Compounds that are highly lipid soluble, e.g. 
organochlorine pesticides, have been shown to deposit in the fatty 
areas of the body (Brodie et al, 1950; 1952; Hayes et al, 1956; 
Chenoweth et al, 1962; Eger and Shargel, 1963; Radomski et al, 1968). 
Accumulation of a compound in the fat results in lower circulating 
levels and therefore a reduced effective concentration. For example, 
it has been suggested that the localization of the short acting 
barbiturate thiopentone in fat, and not its elimination, determines the 
duration of action of this compound in the body (Goldstein and Aronow, 
1960). 
Protein binding. Compounds usually vary in the extent to which they 
bind to proteins such as albumin and ~ 1-acid glycoprotein. As only 
free (unbound) molecules transfer readily across membranes, so the 
extent of protein binding of a molecule can affect its distribution. 
The volume of distribution equation 1:1 can be modified to account 
for differences in the degree of protein binding equation 1:2 
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= Vp + VT (£) 
"T 
•.••••. (1:2) 
where VP is the plasma volume, VT is the volume outside the plasma 
into which the compound distributes and " and ~T are the fractions 
unbound in the plasma and outside the plasma respectively (Wilkinson 
and Shand, 1975; Gibaldi and McNamara, 1978). 
A number of compounds have been shown to interact with nucleic 
acids, e.g. quinacrine and chloroquine, and therefore be localized 
within cells (Parker and Irvin, 1952; Kurnick and Radcliffe, 1962; 
Hahn et al, 1966). Chloroquine has also been shown to interact with 
melanin as do phenothiazines and many other basic compounds (Lindquist, 
1973). Accumulation of compounds such as chloroquine and phenothiazines 
in cells and melanin containing tissue has the effect of increasing 
the apparent volume of distribution of these compounds, although in 
·true physiological terms their distribution may be rather small. 
Elimination 
There are many routes that a foreign compound can take to leave 
the body. The most common is via the kidney into the urine (renal 
excretion). Other routes of elimination inclurebiliary excretion, 
excretion in the expired air, via sweat, tears and saliva and by 
secretion into the stomach and other parts of the gastrointestinal 
tract. 
Renal excretion. The kidney is a member of the highly perfused group 
of tissues. The high blood flow through the kidney (in man about 
1300 ml/minute, Goldstein et al, 1974) ensures that a large proportion 
of the circulating molecules pass through the kidney every minute. The 
mechanism by which molecules pass from the blood into the kidney nephron 
are, glomerular filtration, passive tubular transfer and active tubular 
transport. 
In a normal man, approximately 130 ml of plasma is filtered each 
minute through the glomerular membranes (Goldstein et al, 1974). These 
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membranes appear to offer little resistance to the transfer of solute 
molecules. Only those molecules that are bound to plasma proteins, 
or of similar size as protein molecules, are not capable of entering 
the renal tubule. Reabsorption of the glomerular filtrate takes 
place across the tubular epithelium. The principles that control the 
reabsorption into the bloodstream are the same as for the transfer of 
molecules across other membranes. Highly lipid soluble molecules will 
therefore be reabsorbed but polar compounds and ions will be excreted, 
unless actively reabsorbed. 
Passive tubular transfer of non-ionized molecules takes place 
along the entire length of the renal tubule. Solute molecules can pass 
in either direction (from the renal tubule into the body or from the 
body into the renal tubule) at a rate that is dependent on the lipid 
solubility of the molecule (Weiner et al, 1960). As only the non-
ionized molecule passes through the tubular epithelium by this 
mechanism, variations in urinary pH will affect the rate of transfer 
in both directions (Milne et al, 1958). 
The epithelial cells of the proximal tubules are particularly 
well adapted for active transfer. This mechanism is responsible for 
the reabsorption of many polar and ionic molecules, e.g. glucose, 
amino acids, sodium ions and water. Both acids and bases are actively 
secreted into the distal tubules by carrier mechanisms provided by the 
epithelial cells (Cafruny, 1971). 
Biliary excretion 
Because the membrane wall of the hepatic parenchymal cells is 
highly permeable, foreign compounds that have entered the liver can 
leave the blood and enter these cells. The foreign compound (or its 
metabolite) is then either returned to the blood, or excreted in the 
bile. 
The mechanism by which some compounds are directed to the bile and 
others to the urine is as yet unclear. However, it is apparent .that 
highly polar compounds, such as the bile salts and certain dyes, and 
conjugates of foreign compounds, which are ionic and which have a 
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molecular weight greater than 300, are secreted in the bile in higher 
concentrations than they are present in the plasma, presumably by 
active secretion (Brauer, 1959; Sperber, 1965). For example, 
sulphobromophthalein, a dye used to test hepatic function (Rosenthal 
and White, 1925) is secreted into bile in concentrations far exceeding 
those present in plasma (Brauer, 1959). 
Cations such as quaternary ammonium compounds are probably 
secreted into the bile by active processes that are different from 
those for anions (Schanker and Solomon, 1963; Schanker, 1965). Indeed, 
different mechanisms may exist for the biliary secretion of different 
types of anions and cations. Furthermore, the biliary excretion of 
non-charged substances may sometimes be affected by presence of organic 
anions. Thus it would appear that pathways of biliary excretion are 
indeed quite complex and they may not be entirely independent of each 
other (for a review see Levine, 1978). 
Biliary excretion is an important route of elimination of certain 
anions and cations that are largely ionized at intestinal pH and are 
therefore poorly reabsorbed from the intestine. This subject has been 
reviewed by Smith (1973). 
Foreign compounds excreted into bile may be converted into a form 
that is capable of reabsorption. For example, enzymes in the bile or 
more often those in the intestine, produced either by intestinal 
secretions or gut flora (Smith, 1973) are capable of hydrolysing 
conjugates (e.g. glucuronides, sulphates) of foreign compounds and the 
free compound may be reabsorbed. Those compounds that are reabsorbed 
will be transported back to the liver where they may be conjugated and 
as conjugates again secreted into bile. The cyclic process thus set 
up is known as enterohepatic circulation. In this cycle, the amount 
of the foreign compound in the body is nevertheless gradually decreasing 
due to other biotransformations and urinary and faecal excretion. 
There are notable species variations in the extent of biliary 
excretions of some substances. In a review of this subject Smith (1973) 
and later Hirom et al (1976) indicate that molecular weight is an 
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important factor. A minimum molecular weight of approximately 325 
is required for significant biliary excretion in the rat, while 400 
and 475 are the corresponding approximate figures in the guinea pig 
and rabbit, respectively (Millburn et al, 1967; Aziz et al, 1971). 
A molecular weight above 500-600 is probably required in man; for 
examples see Klaasen et al (1981). Thus, biliary excretion is the 
major route of elimination of the orally active anti-arrhythmic 
drug a,a-dimethyl-4-a,a,S,S-tetrafluorophenethyl benzylamine 
( after conjugation) in the rat and dog, but this compound is 
excreted mainly in the urine in the rhesus monkey, the baboon and 
man (Zacchei et al, 1976). 
a,a-dimethyl-4-a,a,S,S-tetrafluorophenethyl benzylamine. 
These molecular weight criteria were established mainly using 
organic anions. However, Hughes et al (1973) have indicated that 
organic cations of molecular weight as low as 200 are excreted in the 
bile of the rat and species differences have not been observed. 
Clearance 
At low concentrations biotransformation and excretion are normally 
assumed to proceed by first order processes, (i.e. the rate is propor-
tional to the concentration of the solute at the site of elimination). 
These processes are described by the elimination rate constant Kel 
(see page 27). Clearance (defined by equation 1:3) describes 
elimination in physiological terms. 
Cl 
organ 
cin - cout 
= Qorgan C = Qorgan Eorgan •••••.• (1:3) 
in 
where Cl is the clearance of a compound by an eliminating organ, 
organ 
c,n and C are the concentrations of the solute in the blood entering ~ out 
and leaving the organ respectively, Q is the organ blood flow and 
organ 
E is the organ extraction ratio (Rowlands et al, 1973; Wilkinson 
organ 
and Shand, 1975). The total clearance of a compound from the body is 
the sum of the individual organ clearance (Rowland, 1972; Rowland 
et al, 1973). 
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Biotransformation 
Elimination of a foreign compound from an organism is assisted 
by biotransformation usually to increase its water solubility and so 
facilitate elimination from the body (Williams, 1959). 
The common routes of metabolism include oxidation, reduction and 
hydrolysis (phase I reactions) and conjugation (phase II reactions). 
These reactions may take place in parallel and they may also occur 
sequentially. Several different metabolites may, therefore, be formed 
from the same compound. Metabolism usually occurs in the liver although 
enzymes contained in other tissues, e.g. kidney, lung and adrenal glands 
and the gut flora, are also catalysts-in metabolic reactions (Gram, 1980). 
Phase I and phase II reactions are elimination processes, but because 
of the possible formation of metabolites that are more toxic than the 
parent compound (for examples see Shuster, 1964), it is important to select 
a species with a pattern of metabolism which is similar to that in man 
when evaluating the toxicity of a foreign compound. Unfortunately, the 
sometimes unpredictable nature of species differences in metabolism makes 
the selection of a suitable species difficult. 
The same general biphasic pattern of metabolism occurs in all animal 
species, but there are species variations in the metabolism of the many 
compounds. An examination of the metabolism of amphetamine and coumarin 
in different animal species exemplifies species differences in phase I 
metabolism. Amphetamine is metabolized in the rat by hydroxylation at the 
para position on the aromatic ring. In man and the non-human primate 
deamination of amphetamine occurs, the main product of metabolism being 
hippuric acid (Ellison et al, 1966; Dring et al, 1970). The metabolism 
of coumarin also shows species variations. In man and the baboon coumarin 
is metabolized mainly by hydroxylation at the 7 position in the coumarin 
ring and about 70% of the dose is excreted in the urine as 7-hydroxycoumarin 
(almost completely as the glucuronic acid conjugate). In other species, 
including the squirrel monkey, but not including one strain of mouse 
(DBA/2J strain), 7-hydroxycoumarin is only a minor metabolite. In species 
such as the rat and rabbit, the metabolism of coumarin proceeds via a 
pathway leading ultimately to o-hydroxyphenylacetic acid (for review see 
Cohen, 1979) . 
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CH -CH-I 2 CH3 5 4 
0 6 3 7 :::::o 
8 1 
Amphetamine Coumarin 
In addition to species differences in phase I metabolism there 
are also many reported examples of species differences in phase II 
metabolism (Hartiala, 1955; Robinson and Williams, 1958; Williams, 1967; 
Capel et al, 1962; Dutton and Burchell, 1977). Table 1:1 lists eight 
conjugation reactions that occur in most animal species, except for 
glutamine conjugation which appears to be restricted to man and the 
non-human primates. Table 1:2 lists a number of reported species defects 
in conjugation reactions. These species deficiencies in phase II 
metabolism do however appear to be dependent on the substrate. For 
example, it has recently been shown that the cat can conjugate phenol-
phthalein, diphenylacetic acid and hydratropic acid extensively with 
glucuronic acid and that the pig forms about 30% of a sulphate conjugate 
of a-naphthol (Williams, 1974; Dixon et al, unpublished data, cited in 
Williams, 1978). 
There are some conjugation mechanisms that are regarded as peculiar 
to certain animal species, namely ornithine conjugation of aromatic acids 
in certain birds and reptiles, and glucose conjugation of phenols in 
insects (Baldwin et al, 1960; Dutton, 1966; Smith, 1968). 
From comparative studies of the quantitative nature of biotrans-
formation in several species it appears that differences in metabolism are 
difficult to predict. However, once a certain pathway for metabolism has been 
shown for a particular compound, it is probable that structurally 
similar compounds will follow the same route in the same species. For 
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Table 1:1 
Common conjugation mechanisms 
Mechanism 
Glucuronidation 
Sulphation 
Glycine conjugation 
Glutamine conjugation* 
Glutathione conjugation 
(mercapturic acid synthesis) 
Methylation 
Acetylation 
Thiocyanate synthesis 
Conjugating entity 
Glucuronic acid 
sulphate 
Glycine 
Glutamine 
Glutathione 
Methyl group 
Acetyl group 
Thiosulphate 
* Occurs only in man, apes and New and Old World monkeys. 
Table 1:2 
Species defects in conjugation reactions 
(From Caldwell, 1980) 
Species 
Cat, lion, lynx, 
civet, genet 
Defective reaction 
Glucuronidation 
Pig 
Indian fruit bat 
Dog 
Guinea pig 
Non-primate mammals 
(genera11fl 
~ 
Sulphation 
Hippuric acid formation 
N-Acetylation of aromatic amines and 
hydrazines 
N-Acetylation of S-substituted cysteines (last 
step of mercapturic acid formation) 
1. N1-glucuronidation of sulfonamides 
2. Glutamine conjugation 
3. 0-Methylation of 4-hydroxy-3,5-diiodo-
benzoate 
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example, lormetazepam (Mayo et al, 1980; Humpel et al, 1979) has 
been shown to resemble other N1-alkylated benzodiazepines such as 
medazepam (Schwartz and Carbone, 1970: Schwartz and Kolis, 1972), 
diazepam (Garattini et al, 1973) and pinazepam (Comi et al, 1977) 
in that N1-dealkylation is the major phase 1 biotransformation in 
man and most laboratory animal species except possibly the rat. 
_....Cl 
Lormetazepam Diazepam 
CH2-c=:cH 
I -:Yo 
OCb-c \ CH2 / C-N~ 
Cl ~-
0 0 
Medazepam Pinazepam 
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There are some indications that the non-human primates, 
particularly the Old World monkeys, provide the best model for 
studying the pattern of metabolism in man. Although only a few of 
the available primate species have been studied and information is 
often scanty, most metabolic reactions that occur in man can be found 
in the non-human primates (Smith and Williams, 1974; Smith and Caldwell, 
1977). However, differences in the relative importance of certain routes 
of metabolism occur. For example, simple phenols are metabolized by 
conjugation with sulphate and glucuronic acid in most animal species 
following small doses, but in man, rhesus monkey and cynomolgus monkey 
phenol and a-naphthol are excreted mainly as the sulphate conjugate, 
whereas in two species of New World monkey these phenols were excreted 
mainly as the glucuronide (Capel et al, unpublished data, Smith and 
Williams, 1974; Hirom and Mehta, unpublished data; Williams, 1978). 
Of particular interest are those conjugation reactions that show 
some correlation with evolutionary status. For example, the formation 
ofN~lucuronides is a major route of metabolism for certain sulphon-
amide drugs, e.g. sulphadimethoxine, sulphamethomidine and sulpha-
dimethoxypyrimidine, in man, New and Old World monkeys and prosimians, 
but it is at a low level or even absent in non-primate species (Bridges 
et al, 1969a; 1969b; Adamson et al, 1970b; Walker and Williams, 1972). 
The occurrence of glutamine conjugation seem~ to be correlated 
with evolutionary status since it appears to be confined to anthropoid 
apes and New and Old World monkeys and is not seen in prosimians or lower 
species. Thus several arylacetic acids are excreted as their glutamine 
conjugates in man ard the New and Old World monkeys but as glycine 
conjugates in prosimians and non-primates (Smith and Caldwell, 1977; 
Williams, 1978). 
a-Methylation has also been shown to be an important metabolic 
reaction of phenols in man and the non-human primates, but has not been 
found to occur in non-primate species (Weld et al, 1973). 
Many more examples of species variations in biotransformation 
have been reported (e.g. for reviews see Baty 1975; 1977; 1979) but it is 
not the intention of this thesis to discuss these in any detail. However, 
species variations in pharmacokinetics will be described more fully in the 
relevant sections, Chapters 3 - 10. 
- 14 -
Pharmacokinetics 
Pharmacokinetics as described by Wagner (see page 2) is the 
study of the relationship between the physiological disposition of 
a drug in the body and its pharmacological effect. 
The mathematical expressions of pharmacokinetics are based on 
models that represent the animal body as a series of compartments and 
it is presumed that the foreign substance and/or its metabolite(s) are 
distributed in several tissues (Rescigno and Segre, 19661 Riggs, 1972). 
Any group of tissues which acts as if it is kinetically homogeneous is 
termed a 'compartment'. These compartments are separate and diffusion 
of compound between them is usually assumed to proceed by a first order 
process. 
Although some complex models have been used to define the kinetics 
of absorption, distribution, biotransformation and excretion (Riegelman 
et al, 19681 Gibaldi et al, 19711 Levy and Gibaldi, 1972) and to account 
for certain metabolite plasma concentration-time profiles following drug 
administration (Rowland et al, 1970; Boxenbaun et al, 1974) the simple 
one and two compartment open models suffice for most purposes (Nooney, 
19661 Majensohn and Gibaldi, 19711 Westlake, 1971). 
Initially, pharmacokinetic data are obtained following intravenous 
administration. of a drug, because when administered by this route 
the entire dose of the drug reaches the bloodstream without losses during 
absorption. The pharmacokinetic data, thus obtained, may be used as the 
primary standard for comparison with that obtained following other routes 
of administration. 
The most useful pharmacokinetic parameters obtained following intra-
venous administration are half-life, clearance, area under the drug plasma 
(blood) concentration-time curve, and volume of distribution. The half-
life of a drug is the most frequently quoted pharmacokinetic parameter, 
because of its importance in designing suitable dosing regimens for use 
in toxicology studies and in the clinic. It must be stressed, however, 
that many factors can influence the half-life of a drug (e.g. environmental 
factors that might cause stress). 
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The half-life of a drug might also vary as a function of dose, due 
to non-linear pharmacokinetics and/or by irregularities in the rate and 
extent of absorption. Variation in the half-life, for any reason, will 
produce changes in the drug plasma (blood) steady state concentration 
obtained following chronic administration (see equations 2:16 and 2:17; 
Chapter 2). 
other pharmacokinetic parameters such as clearance and volume of 
distribution, both of which are related to half-life as shown in equation 
1:4, might also vary as a function of dose, environmental factors, diet, 
11,= 
ln2. vd 
Cl 
••••••••• ( 1:4 ) 
the presence of other drugs, etc., and variations in these pharmacokinetic 
parameters also could influence the amount of benefit or undesirable side 
effects obtained from the drug following any dosing regimen. It would be 
advantageous, therefore, to determine the pharmacokinetic profile of the 
drug at an early stage in its development. It is also desirable to 
demonstrate that the drug is being absorbed from a given dosing formulation 
and/or via the route of administration. A knowledge of the relationship 
between the drug's pharmacokinetic parameters and pharmacological 
(therapeutic/toxic) effects is then obtainable. 
Aim of the thesis 
The objective of this thesis is to evaluate possible species-related 
pharmacokinetic differences between the rhesus monkey, the cynomolgus monkey 
and the baboon and to compare pharmacokinetic data obtained from these non-
human primate species with those reported in the literature for man and 
other commonly used laboratory animal species. By this comparison, this 
thesis defines the pharmacokinetic suitability of the non-human primate 
species studied for use in pharmacological and toxicological studies of 
newer substances. Additionally the thesis aims to define the pharmaco-
kinetic suitability of the cynomolgus monkey, and the baboon as alternative 
species to the more commonly used rhesus monkey which is becoming difficult 
to obtain. 
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CHAPTER 2 
EXPERIMENTAL 
Animals 
Five mature females of each species of non-human primate, the 
rhesus monkey (Macaca mulatta), the cynomolgus monkey (Macaca 
fascicularis) and the baboon (Papio anubis) were obtained from a 
commercial supplier (Shamrock Farms (GB) Ltd., Henfield, Sussex, U.K.). 
All animals had been quarantined for 12 weeks and subjected to 
veterinary examination before and after arrival at the Huntingdon 
Research Centre. 
Accommodation 
The animals were housed individually in cages specially designed 
to house small non-human primates. Each cage measured 73 cm wide, 
68.5 cm deep and 91.5 cm high and was constructed of aluminium and 
electropolished stainless steel, incorporating squeeze back system, 
food hopper, bottle holder and 2.5 cm x 2.5 cm floor grid. 
The cages were entirely wall-mounted, in two tiers, each tier 
combined with an excreta removal flushing system, and automatic 
drinking valves. Each animal was identified by a number tattooed on 
its chest and each cage was identified by a label which displayed the 
animal's individual identity number, study number and licencee's'name. 
The room in which the animals were kept was relatively isolated 
from external disturbances and was maintained at a temperature of 
22°C + 1°C. Although normal daylight was available to the animal rooms, 
artificial lighting was also used throughout the working day. 
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Diet 
Individual animals were given free access to water and fed a 
controlled diet, This·diet varied between the species as follows: 
The rhesus monkey ~ daily ration of 300g per animal of mixed dry 
diet, containing 200g F •. P.I. (Dixon and Sons Ltd., Ware, U.K.); 
SOg primate mazuri (Coopers Nutritional Products, Witham, Essex), 
and a Sog Bonio dog biscuit (Spillers Ltd., Barking, Essex) was 
offered, 200g in the morning and a further lOOg in the afternoon. 
This basic ration was supplemented on week days with one slice 
(35g) of wholemeal bread, and daily with fresh fruit or vegetable 
produce. Vitamin c, approximately 53mg (concentrated blackcurrant 
juice, Boots, Ltd., Nottingham) and Cytacon, a vitamin B12 preparation 
containing 140(.tgeyanocobalamin B.P. (Glaxo Ltd., Greenford, Middlesex), 
were added to the drinking water on one day in each week. 
The cynomolgus monkey The daily ration per animal was SOg F.P.I. 
and a SOg Bonio biscuit in the morning and 50g F.P.I. and SOg Mazuri 
in the afternoon. This basic ration was also supplemented on week 
days with one slice (35g) of wholemeal bread, and daily with fresh 
fruit or vegetable produce and on one day a week with drink contain-
ing vitamins. 
The baboon The daily ration per animal was lSOg F.P.I. in the 
morning and lOOg F.P.I., 50g Mazuri and 50g Bonio biscuit in the 
afternoon. Again, this basic ration was supplemented on week days with 
one slice (35g) of wholemeal bread, and daily with fresh fruit or 
vegetable produce and on one day a week with drink containing vitamins. 
Dosage 
Commercial preparations for intravenous injection were used when 
available, otherwise a suitable solution for intravenous injection was 
prepared. The dosage forms and manufacturers are listed in Table 2:1. 
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Drugs were administered at two-weekly intervals by bolus 
intravenous injection into a cephalic vein at levels above the 
normal therapeutic doses. Dose levels were chosen as those which 
might be selected for administration during chronic toxicity studies 
of theae compounds (Table 2:2). The order of dosing was the same as 
that shown in Table 2:1. 
Blood sampling 
After the animals had been fed, all food was removed from the 
cages at 16 hours before dosing and not replaced until 7 hours 
afterwards, but water was provided ad libitum. The animals were 
dosed with the respective drugs as described in Table 2.2 and blood 
samples were collected at fixed time intervals for measurement of 
the unchanged drug in plasma. Blood (2.5 ml) was withdrawn from a 
femoral vein, dispensed into heparinised tubes and cooled in ice-cold 
water as soon as possible after mixing. Blood cells, which were 
discarded, were removed without delay by centrification, and the 
supernatant plasma was separated and stored at -20°C until assayed. 
Technical assistance was required for the dosing of the animals and in 
maintaining the extremely rapid bleeding schedule. For their help 
during this stage of the experimental work the author is grateful to 
colleagues in the Department of Primate Toxicology, Huntingdon 
Research Centre. 
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Table 2:1 
Dosage forms and manufacturers of test compounds 
DRUG 
(in order of dosing) MANUFACTURER 
Antipyrine Sigma Chemical Company 
Poole, Dorset, U.K. 
Diazepam 
FrUsemide 
Roche Products Ltd., 
Welwyn Garden City, U.K. 
Hoechst Pharmaceuticals 
Hounslow, Middlesex,U.K. 
FORMULATION 
Solution prepared: 92 mg per ml, in dextrose 
4% w/v in Saline 0.18 w/v 
Valium 10: Ampoules, 10 mg per 2 ml, for 
injection 
Lasix: Ampoules, 20 mg per ml, for injection 
-------------------------------------------------------- ------------------------------------------------
Isosorbide dinitrate 
Paracetamol 
Ibuprofen 
Sanol Schwarz Gmb!l 
Monheim, Germany. 
BD!! Chemicals Ltd. 
Poole, Dorset, U.K. 
The Boots Company Ltd. 
Nottingham, U.K. 
Solution prepared: 2 mg per ml, in 10% ethanol: 
90% water 
Solution prepared: 70 mg per ml,in .. l5% ethanoh 
85% water 
Solution prepared: 15 mg per ml, in solution* 
Pentobarbitone May & Baker Ltd. Sagatal: 60 mg in 1 ml, for injection, 
Dagenham, Essex, U.K. veterinary product 
*Solution consists of 0.1 M NaOH(l3 ml), just sufficient to dissolve the ibuprofen (600 mg) plus 
o.lM citric acid (1 ml) to adjust the pH of the solution to pH7 and water (26 ml) to make the 
value up to that required to give a concentration of 15 mg/ml. 
TABLE 2:2 
Therapeutic and administered dose 
Drug Normal Daily 
Therapeutic Oral Dose* 
(mg/kg) 
+ Administered Dose 
(mg/kg) 
Antipyrine 4 - 9 lOO 
Diazep'am 0.05 - 0.5 o. 2 and l.O 
Frusemide 
Isosorbide 
dinitrate 
Paracetamol 
Ibuprofen 
0.6 - 2.3 
up to 1.7 
7 - 5 7 
9 - 17 
Pentobarbitone 1.4 - 3 
_____________________ L _______________________ _ 
*Data in humans obtained from Martindale (1977). 
+ Dose to the rhesus monkey, bodyweight 4-6 kg. 
+ Dose to the cynomolgus monkey, bodyweight 3-4 kg 
+ Dose to baboon, bodyweight 4.5 - 7 kg. 
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3 
1 
70 
15 
12 
Analytical instrumentation 
A wide selection of analytical instrumentation was used for this 
study. All instruments (listed in Table 2:3) were in the Department 
of Metabolism and Pharmacokinetics, Huntingdon Research Centre. 
TABLE 2:3 
Analytical instrumentation used in the study 
Drug 
Antipyrine 
Diazepam and 
desmethyldiazepam 
Frusemide 
Isosorbide 
dinitrate 
Paracetamol 
Ibuprofen 
SP 500 Spectrophotometer 
High pressure liquid 
chromatograph 
Aminco Bowman Spectro-
photofluorimeter 
Pye 104 Gas chromato-
graph 
SP 500 Spectrophotometer 
Hewlett-Packard 5750G 
Gas chromatograph 
Unicam Instruments, 
Cambridge, U.K. 
+ 
American Instruments Cc. 
Silver Spring, Maryland 
u.s.A. 
Pye Unicam, Cambridge 
U.K. 
Unicam Instruments 
Cambridge, U.K. 
Hewlett-Packard Ltd. 
Wokingham, Berks., U.K. 
Pentobarbitone Perkin-Elmer F.ll Perkin-Elmer Ltd., 
Gas chromatograph Beaconsfield, Bucks., 
U.K. 
------------------- -------------------------- ----------------------------
+ Consisting of an M 6000A pump (Waters Associates, Cheshire, U.K.), 
a Cecil 212 u.v. detector (Cecil Instruments, Cambridge, U.K.) and 
a Waters U6K injector (Waters Associates, Cheshire, U.K.). 
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All solvents were obtained from Fisons Scientific Apparatus 
Limited, Loughborough, Leicestershire, U.K. ~!though obtained 
highly pure (Distol·grade), these solvents were redistilled before 
use. All reagents and glassware ·u,.ed in this studY. were-also 
obtained from Fisons Scientific Apparatus Limited, whenever possible. 
Gas chromatographic column packings were obtain~d from Phase Separations 
Limited, Clwyd, U.K, and a high pressure liquid chromatographic column 
packed with Cl8 f"-Bonda~<3k was obtained from Waters. Associates, · .. · .. 
Cheshire, U.K. 
Determination of method parameters 
The plasma calibration line for each compound was prepared 
by adding known amounts of drug, dissolved in a suitable solvent, 
to control non-human primate plasma at several different concen-
trations over the appropriate range and analysing the resultant 
plasma. Five values were obtained at each concentration and 
standards were analysed at the upper and lower ends of the range 
with at least three other points on the calibration line. The overall 
least squares regression line of instrument response (Y) against 
concentration (X) was constructed as described under Data Processing 
(page 24) and the accuracy of the methods for the measurement of the 
respective drugs in plasma was defined by the 95% confidence limits 
of the regression line. The precision of each assay was defined as 
the coefficient of variation of replicate assays of the same plasma 
sample containing ·known amounts of the appropriate drug. The 
sensitivity of the respective methods was defined by the limit of 
detection, set at twice the apparent concentration of test compound 
due to interfering substances present in blank predose plasma, i.e. 
antipyrine, frusemide and paracetamo~or by a signal to noise ratio 
·of at least two, i.e. diazepam, desmethyldiazepam, isosorbide dinitrate, 
ibuprofen and pentobarbitone. 
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The mean recovery of each drug was determined by the repeated 
analysis of five standards of control non-human primate plasma 
containing the drug to be assayed and by comparing the instrument 
response from extracted plasma samples with that from known amounts 
of drug. When a method was used involving an internal standard, the 
recovery of the internal standard was determined and the recovery of 
the drug was calculated by comparing the gradient of the calibration 
line obtained from non-extracted standard with that from the cali-
bration line obtained from extracted standards of plasma corrected 
for losses of the internal standard. The details of the methods used 
and the method parameters are reported in the ~esults Sections 
(Chapters 3 to 9). 
Data processing 
Optimal calibration lines were fitted by least squares regression 
analysis (Davies, 1961) using a Hewlett-Packard 9821A programmable 
calculator (Hewlett-Packard, Wokingham, U.K.) which also calculated the 
95% confidence limits of the fitted line. Statistical analyses were 
performed with the aid of the same Hewlett-Packard 9821A programmable 
calculator. 
Analysis of variance was performed on groups of pharmacokinetic 
parameters (i.e. Volumes of distribution, vd(ss). and V d (~) unadjusted 
and adjusted for bodyweight, clearance unadjusted and adjusted'for 
bodyweight, areas under the curve, half-lives and the elimination rate 
constantKer If heterogeneity of variance was present at the l% level 
of significance (Bartlett, 1937) the data was transformed using the 
logarithmic or square root transformation in order to stabilize the 
variance. If transformation of the data was unsuccessful in stabilising 
the varianc~ non-parametric methods, based on Kruskal-Wallis mean ranks 
(1952),were used since these are more robust than classical methods of 
analysis of variance. The group means were compared using the method 
of L.S.D.'s in conjunction with Newman-Keuls multiple comparison 
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procedure (1939, 1952). The Kruskal-Wallis mean ranks were compared 
using a non-parametric version of Newman-Kuels. Significance testing 
was carried out at the 5% and l% levels. 
Pharmacokinetics 
The non-linear least squares curve fitting programme BLUD 
(kindly provided by Glaxo Group Research, Ltd., Greenford, U.K.) and 
adapted to suit an ICL 2903 computer (International Computers Ltd., 
London, U.K.) was used to fit a hypothetical model to the observed 
plasma concentrations. This programme not only fitted a curve to the 
·observed data, it also calculated several pharmacokinetic parameters. 
In addition, it enabled an estimate of the error of these parameters 
to be made. 
Following intravenous injection the plasma concentration time 
curve could be described either in terms of a one-compartment open 
model Equation 2:1, Scheme 2:1. 
-Kelt 
c = c e 
0 
............... (2:1) 
where C is the plasma concentration at any time 't' after injection, 
C
0 
is the concentration immediately after injection and Kel is the 
elimination constant; or as a two-compartment open model with elimin-
ation from the central compartment Equation 2:2,,Scheme 2:2 . 
-or.t -~t C=Ae +Be ............ (2:2) 
where C is the plasma concentration at any time 't' after injection, 
A and B are the zero time intercepts and the microscopic rate 
constants "'and [> are the slopes of the initial and terminal log 
. e 
linear phases respectively. 
- 25 -
Dose Body 
Scheme 2:1. Schematic representation of a one-compartment open model. 
Dos 
Central Kl2 
' 
Peripheral 
e-~ Compartment Compartment 
K21 
Scheme 2:2 Schematic representation of a two-compartment open model 
with elimination from the central compartment. 
The remaining pharmacokinetic parameters were calculated using 
the estimates of the slopes and intercepts, using standard equations 
2:3 - 2:12 for the two-compartment open model (see Gibaldi and Perrier, 
1975). 
AUC = 
Cl = 
= 
= 
= 
A 
"' 
+ B 
Dose 
AUC 
if 
A(l + Boc 
A+B 
( 2: 3) 
• • • • • • • • • ( 2: 4) 
• • • • • • • • • ( 2. 5) 
• • • • • • • • • ( 2. 6) 
"' + ~ - K21 - Kel •. • • • • • • • ( 2 • 7) 
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= 
= 
= 
= 
t~, = 
Dose 
---A+ B 
Cl/~ 
ln2 
-~-
•••••••••• (2.8) 
• • • • • • • • • • (2. 9) 
•••••••••• (2.10) 
• • • • • • • • • • (2 .11) 
••.••••••• (2 .12) 
where AUC is the area under the plasma concentration time curve; 
Cl is the clearance of the drug; K12 , K21 are the intercompartmental 
transfer rate constants and Kel is the elimination rate constant (see 
Scheme 2:2); v1 is the apparent volume of the central compartment; 
v2 is the apparent 
the apparent total 
volume of the peripheral compartment, V ) is d (ss 
volume of distribution for a two-compartment model 
at steady state, and Vd(~) is the volume of distribution after 
distribution equilibrium. For the one-compartment open model, ~ 
approximates to ~ and K 1 is the slope of the log -linear decline e e 
with C as the zero time intercept. The areas under the plasma 
0 
concentration time curve for a one-compartment open model were esti-
mated using equation 2:13 
AUC = •••••••• •• (2.13) 
the half-life of elimination was estimated using equation 2:14. 
= •••••••••• (2.14) 
and the apparent volume of distribution and the clearance for a one-
compartment model were estimated using equations 1:1 and 2:4 
respectively. 
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Concentrations of drug in the peripheral compartment (Cp) 
were calculated using equation 2:15 (Gibaldi and Perrier, 1975). 
Cp = 
K12 Dose 
---v2(«-~) 
-!>t -«t (e -e ) ..••••.•• (2.15) 
The BLUD programme selected a model by comparing the relative 
sizes of « and ~ but does not allow independent selection of a model. 
In fact, this programme tended to select a two-compartment model even 
though the distribution phase was quite small and a one-compartment 
model would be adequate (Rowland et al, 1971; Wagner, 1974 
1975; Loughnan et al, 1976; Dvorchik and Vesell, 1978). In 
the latter case the one-compartment model was fitted to the data 
by normal regression techniques (Davies, 1961). 
Mean steady state plasma drug concentrations (C ) obtained 
ss 
during a fixed dosing regime were predicted for a one-compartment open 
model and a two-compartment open model using equations 2:16 and 2:17 
respectively. 
c 
ss 
c 
ss 
= 
= 
••••••·•• (2.16) 
•••••••• (2 .17) 
where~ is the dosing interval (Gibaldi and Perrier, 1975). 
Metabolites. Plasma concentrations of a metabolite that obeys one-
compartment kinetics following intravenous injection of a compound 
that distributed into the·body according to either a one- or a two-
compartment model (Schemes 2:3, 2:4) are described by equation 2:18 
(Gibaldi and Perrier, 1975; Pang and Gillette, 1980). 
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I· 
Kf ~ Km Dose X = CV M = cruvm 
~ 
el 
Scheme 2:3: Pharmacokinetic model describing plasma concentrations 
of a drug and its metabolite that both distribute into the body 
according to one-compartment kinetics. 
x2 
Dose 
Kf K m 
xl = cvl M = cm vnr 
' 
Scheme 2:4: Pharmacokinetic model describing plasma concentrations 
e 
of a drug that ob~ys two-compartment kinetics and its metabolite 
that obeys one-compartment kinetics. 
c = m 
Kf. Dose. 
V (K 1-K ) m e m 
-Kmt -Kelt (e -e ) ••••••••• (2:18) 
where X is the amount of drug in the body for a one-compartment model; 
x1 and x2 are the amounts of drug in the central and peripheral 
compartments, respectively, for a two-compartment model; M. is the 
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amount of metabolite in the body, c and V are the metabolite con-
m m 
centration at any time and the apparent volume of distribution of 
the metabolite respectively and Kf and Km are the first order rate 
constants of formation and elimination of the metabolite, respect-
ively. When the rate constant for elimination of the metabolite is 
less than the rate of formation, the former is obtained from the 
terminal slope of a plot of the logarithm of metabolite levels versus 
time using the equation 2:19 
Slope 
-K 
m 
2.303 (2:19) 
and Kf is estimated by the method of residuals (Gibaldi and Perrier, 
1975). When Km >Kf' then Kf is obtained from equation 2:19 and Km 
is estimated by the method of residuals. 
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CHAPTER 3 
l\NTIPYRINE 
Introduction 
Antipyrine (2,3-dimethyl-1-phenyl-3-pyrazoline-5-one) is a drug, 
possessing both analgesic and antipyretic properties, that is 
also used as a means of assessing oxidative enzyme induction (or 
inhibition) in animals (Conney, 1967) and in man (Hunter and Chasseaud, 
1976; Vesell, 1979). It is a weak base (pK 1.4) that is rapidly 
a 
and completely absorbed from the gastrointestinal tract (Stevens, 
1977) distributes into the total body water and is only slightly 
bound to plasma proteins (Brodie and Axelrod, 1950) • 
Antipyrine is extensively metabolised in animals and in ~n. 
The complex pattern of metabolism involves oxidation as described in 
scheme 3 : 1 followed by conjugation with glucuronic acid to form 
possibly both 0- and N-glucuronic acid conjugates (Brodie and Axelrod, 
1950; Yoshimura et al, 1971; Baty and Price-Evans, 1973; Huffman 
et al, 1974; Stafford et al, 1974; Eichelbaum et al, 1976; Horning et al, 
1976; Aarbakke, 1978; Kellermann and Luyten-Kellermann, 1978; 
Danhof and Breimer, 1978; Danhof et al, 1978). Danhof and Breimer 
(1979) have shown also that the pattern of metabolism following an 
oral dose appears to be dose-independent. 
Comparison of the rate of metabolism of antipyrine in different 
animal species and man, using the biological half-life as an index of 
oxidative metabolic rate, shows that there are large species differences 
in the kinetics of antipyrine metabolism (Quinn et al, 1958; Hunter 
and Chasseaud, 1976) • 
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HO - C~G - CH3 
I \ 
0 =c...._ ~- CH3 
N 
I 
0 
4-hydroxy~antipyrine 
,-;:/" 
3,4-dihydroxy-antipyrine 
antipyrine 
HC-C- CH3 ;- \ 
0 = C N - H 
'-.N/ 
N-desmethyl-
antipyrine 
3-hydroxymethyl-antipyrine 
HC-=C- COCH 
I \ 
/c. /N Q'/ '-N ..._ CH3 
I, 
' 
3-carboxy -antipyrine 
Scheme 3:1 Metabolic pathways of antipyrine. 
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Measurement of concentrations of antipyrine in plasma 
Plasma concentrations of antipyrine were measured using a 
modification of the spectrophotometric method of Welch et al (1967). 
Plasma (1 ml) was diluted in the distilled water (to 1.5 ml) 
and made alkaline by the addition of sodium hydroxide (0.5 m~ lM). 
Chloroform (15 ml) was added and the mixture was vigorously shaken 
for 2 minutes using a rotary mixer (Fisons Scientific Supplies Ltd., 
Loughborough, Leicestershire, U.K.). The organic phase was removed 
by filtration through phase-separation paper (Whatmans IPS Whatman 
Limited, Maidstone, Kent, U.K.) and evaporated to dryness under a 
stream of nitrogen at 50°C. The residue was dissolved in dilute 
sulphuric acid (6.0 ml, O.OSM) and an aliquot (3.0 ml) of this 
solution was transferred to a second tube. Sodium nitrite {0.1 ml of 
a 0.2% (w/v} solution in water) was added to the transferred sample, 
and the solution was left for 20 minutes at room temperature. After 
20 minutes, the optical density of the 4-nitroso-antipyrine derivative 
was measured using the underivatised fraction as a reference. 
Table 3:1 
Method parameters for the measurement of concentrations of 
antipyrine in plasma 
linear range 
calibration linea 
accuracy 
precision 
sensitivity 
recovery of antipyrine 
2'-. 200 >Jg /ml 
Y ~ (0.0053 + O.OOOl}X 
+ 14% at 200 ~g/ml and + 55% 
at SO fl.g/ml 
~ 6% at 50 ~g/ml,~ 3% at lOO ~g/ml 
and + 4% at 200 ~g/ml 
2 ~g/ml 
87% + l% 
a Least squares regression line where Y = absorbance and 
X = plasma concentration of antipyrine. 
- 33 -
Results 
Plasma concentrations. After a single intravenous injection of anti-
pyrine at a level of 92 mg/kg peak of mean concentrations of anti-
pyrine in plasma 132 ~g/ml, 137 Vg/ml and 155 ~g/ml in the rhesus 
monkey, the cynomolgus monkey and the baboon, respectively, were 
not reached until 5 minutes post administration (the second time of 
blood withdrawal) in all three species, (Table 3:2, Figures 3:1-3:3). 
Thereafter, mean plasma concentrations declined with an apparent half 
life of elimination of 1.5- 2 hours (Table 3:3, Figures 3:1- 3:3). 
Pharmacokinetic parameters. Evaluation of the observed plasma anti-
pyrine concentrations using the non-linear least squares curve 
fitting programme BLUD indicated that the data was adequately 
described by a hi-exponential equation (equation 2:2). The pharmaco-
kinetic parameters shown in Table 3:3 were therefore calculated using 
equations 2:3 - 2:12 for a two-compartment open model with elimination 
from the central compartment (Scheme 2:2). However, inspection of the 
observed data shows that the contribution of the distribution phase 
A/« to the total area under the curve was generally less than 8% and 
that the two-compartment open model could collapse to a one-compart-
ment opeR model described by equation 2:1. Comparison of the pharmaco-
kinetic parameters estimated for both models (Table 3:4) shows that 
no notable improvements in data processing were obtained byutllising 
a two-compartment open model. Plasma concentrations of antipyrine 
predicted by both models were generally in good agreement with the 
observed values except at 7 hours after administration to the rhesus 
monkey,but this observed value was near the limit of detection of the 
analytical method (Figure 3:1- 3:3). 
Analysis of variance of groups of pharmacokinetic parameters 
showed that there was a statistically significant difference in the 
clearance which was lower in the cynomolgus monkey (P < 0.05 Newman-
Keuls multiple comparison procedure) than either of the other two 
species. The volumes of distribution were significantly smaller in 
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the cynomolgus monkey (P .( 0.01, Newman-Keuls multiple comparison 
procedure) than in the other species,but this difference disappeared 
when values were adjusted for bodyweight variations (P > 0.05). Although 
not so significant (P>0.05)areas under the concentration were greater 
in the cynomolgus monkey than in the other two species. 
The mean total volume of distribution at steady state vd(ss) varied 
between the species accounting for 88, 73 and 66% of the total body-
weight in the rhesus monkey, the cynomolgus monkey and the baboon 
respectively (Table 3:3). Although antipyrine is not an ideal 
substance for the estimation of total body water (Soberman et al,l949) 
these values approximate to what would be expected as an estimate of 
total body water in these non-human primate species, except that it 
is rather large in the rhesus monkey; and are similar to those found 
previously in man 60% (Vesell et al, 1975; Soberman,l949) and in the 
rat 76% and in other animal species 60-99% (McManus and Ilett, 1979). 
Adopting the two-compartment model, the compartment volume ratio 
(central:peripheral) for the two-compartment open model was 4.0, 
3.3 and 6.2 in the rhesus monkey, the cynomolgus monkey and the 
baboon respectively, emphasizing the lack of importance of distribution 
into the peripheral compartment in the disposition of antipyrine in 
these non-human primates; and this fact is supported further by the 
similar values obtained for Vd(ss) and for the volume of distribution 
estimated after attainment of pseudo-distribution equilibrium Vd(p) 
(Table 3: 3). 
The measured clearance of antipyrine adjusted for bodyweight 
differences 5.5 ml/minute/kg, 4.4 ml/minute/kg and 5 ml/minute/kg in 
the rhesus monkey, the cynomolgus monkey and the baboon, respectively, 
are less than those found previously in the rhesus monkey (8.4 ml/minute/ 
kg, Branch et al, 1974) in the rat (approximately 9 ml/minute/kg, 
Danhof et al, 1979, McManus and Ilett, 1979) and in other species 
(9 ml/minute/kg, McManus and Ilett, 1979) but are higher than that in 
man (0.9 ml/minute/kg, Vesell et al, 1975). 
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The mean biological half-lives of antipyrine shown in Table 3:3 
are similar to those previously reported in the rhesus monkey (80-100 
minutes, Hucher et al, 1972; Branch et al, 1974; Miller et al, 1978) 
and showed that in this respect the non-human primate species are 
closer to other laboratory animals such as the rat (~ = 144 minutes), 
the guinea pig (~ = 107 minutes) and the dog (~ = 110 minutes) 
Quinn et al (1958) than to man in which the half-life of elimination 
is about 12 hours (see Hunter and Chasseaud, 1976). 
Adopting the two-compartment model, the ratio of P /kel of 
0.76, 0.72 and 0.86 for the rhesus monkey, the cynomolgus monkey 
and the baboon, respectively, indicated that if a two-compartment open 
model is assumed, these fractions of antipyrine in the body were in 
the central compartment and were available for elimination once 
distribution was complete (Gibaldi et al, 1969). 
Discussion 
The plasma concentration-time course for antipyrine was thought 
for many years to be adequately described by a one-compartment model 
(Brodie and Axelrod, 1950). Swartz et al (1974) has however, suggested 
that a two-compartment model provides a better description of anti-
pyrine pharmacokinetics in humans and this comment might also apply to 
non-human primates (Table 3:3). 
In the non-human primates studied here the mean contribution 
from distribution phase A/«, to the mean total area under the plasma 
concentration-time curve was 2%, 13% and 3% in the rhesus monkey, the 
cynomolgus monkey and the baboon, respectively (Table 3:3). The 
higher value of 13% observed for the cynomolgus monkey was mainly due 
to the large contribution from one animal in this group. With the 
exception of this one animal the contribution of the distribution 
phase was small, and therefore the pharmacokinetic parameters of 
antipyrine were estimated using a one-compartment model and found to 
be similar to those estimated using a two-compartment model. The 
systemic clearance of antipyrine mainly reflects hepatic 
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clearance since antipyrine is eliminated mostly by metabolism in the 
liver. The values for the clearance of antipyrine in non-human 
primates are about seven-fold lower than the liver blood flow and it 
would therefore be unlikely that any hepatic first-pass effects would be 
an important feature of antipyrine disposition in the non-human primate 
after oral doses particularly if some extrahepatic metabolism of 
antipyrine occurs. 
Inspection of these relatively short half-lives of elimination 
of antipyrine in several species shows that during the once-daily dosage 
regimen, common to most chronic toxicity studies, antipyrine would not 
accumulate in the body in the common laboratory animal species, since 
each dose would have been eliminated before the next is received. In 
contrast, some accumulation of antipyrine would occur in humans with 
such a regimen and during normal therapy 250 mg antipyrine twice daily 
for the treatment of migraine for example; an average steady 
state plasma concentration of approximately 5.5 ~g/ml would be achieved 
three days after commencement of treatment. To achieve the same 
steady state plasma concentration of antipyrine in non-human primates 
it would be necessary to administer this drug at more frequent 
intervals. A possible dosing regimen estimated using equation 2:16, 
would be an injection of antipyrine 16.6 mg intravenously every 108 
minutes to the rhesus monkey, 10.4 mg every 108 minutes to the 
cynomolgus monkey and 14.3 mg every 90 minutes to the baboon. 
These considerations apply to antipyrine given intravenously. If 
administered orally and particularly at much larger doses other 
factors (such as release from the dosage form) have to be considered. 
Antipyrine is an enzyme inducer in man (Breckenridge et al, 1971) 
and would, therefore, be eliminated more rapidly when induction 
occurred. However, it is unlikely that enzyme induction would be 
sufficient to prevent accumulation if antipyrine in man receiving 
a normal twice daily dose of the drug. On the basis of those studies 
it can be concluded that the non-human primate is not a more 
suitable pharmacokinetic model for man than are the other commonly 
used laboratory animal species. 
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TABLE 3:2 
Mean concentrations ( 2:. S.D.) of antipyrine in the plasma of the 
rhesus monkeys, the cynomolgus monkeys and the baboons after a single 
blus intravenous injection of antipyrine at a level of 92 mg/kg. 
Results expressed as ~g/ml. 
--------------------------------------------------------------------Species 
Time Rhesus Cynomolgus Baboons 
--------------- ------------------ ------------------r-------------
2 minute 
5 minute 
10 minute 
20 minute. 
40 minute 
1 hour 
1.5 hour 
2 hour· 
3 hour· 
4 hour• 
5 houx 
7 hour 
113 + 33 
132 + 36 
114 + 30 
lOO + 29 
86 + 21 
73 + 17 
NS* 
50+ 14 
36 + 10 
23 + 8 
14 + 10 
3 2:. 6 
104 + 31 
137 + 8 
135 + 6 
121 + 11 
102 + 14 
89 + g·· 
72 + 7 
62 + 9 
39 + 6 
29 + 4 
21 + 4 
12 + 6 
142 + 26 
155 + 24 
143 + 28 
124 + 6 
102 + 16 
87 + 13 
74 + 17 
57 + 12 
38 + 14 
23 + 10 
16 + 5 
6 + 3 
---------------- -------------------------------------~--------------
*NS Indicates that no sample was taken at this time period. 
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Table 3:3 
Mean pharmacokinetic parameters (~SD) of antipyrine determined for a 
two-compartment open model in the rhesus monkey, the cynomolgus monkey 
and the baboon after a single bolus intravenous injection of anti-
pyrine at a level of 92 mg/kg. The data are presented as means of 
results from individual animals. 
-------------------------------------------------------;· 
Parameter a Species 
Rhesus Cynomolgus Baboon 
--------------------r------------------ ---------------- -------------------
Bodyweight {kg) 4.7 + 1.1 3.6 + 0.3 5.4 + 0.7 
Dose (mg) 434 + 101 332 + 21 499 ~ 76 
Dose (mg/n) 94 + 2 94 + 4 92 + 3 
A (!J.g/n) 30 + l3 57 + 32 47 + 97 
B (]Jg/ml) 107 + 27 127 + 35 136 + 9 
-1 0.130 + 0.088 0.064 + 0.054 0.092 + 0.085 
"' 
(minute ) 
-1 0.006 + 0.001 0.006 0.008 + 0.002 (3 (minute ) + 0.001 
-1 0.030 + 0.023 0.015 0.014 + 0.015 K12 (minute ) ~ 0.015 
-1 
K21 (minute ) 0.099 + 0.069 0.047 + 0.041 0.076 + 0.070 
-1 
Kel (minute ) 0.008 + 0.002 0.008 + 0.002 0.009 + 0.002 
AUC (\lg/ml/hour) 291 + 84 357 + 45 318 + 75 
Cl (ml/minute) 26 + 5 16 + 3b 27 + 8 
t, (minutes) 111 + 17 132 + 41 95 ~ 26 
v1 (litres) 3.2 + 0.9 2.0 ~ 0.2 3.1 + 0.6 
v2 (litres) 0.8 + 0.5 0.6 + 0.3 0.5 + 0.3 
vd(ss) (litres) 4.1 + l.O 2.6 + 0.4C 3.6 + 0.8 
vd (p l (l·itres) 4.3 + 0.8 2. 7 .:': o. se 3.4 + l.O 
A/x (]Jg/ml/hour) 
I 
6 + 4 45 + 70 8 + 6 
B/~ (]Jg/ml/hour) 285 + 84 311 + 60 310 + 75 I . . 
-------------------~-----------------------------------L--------------------
a. For details of abbreviations used see Chapter 2. 
b. Significance level (analysis of variance), cynomolgus monkey·· compared 
with the other two species (P <: o. OS) • 
c. Significance level (analysis of variance), cynomolgus monkey compared 
with the other two species (P < 0 .01) 
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- -------------------------------------------------------------------------------------~ 
Table 3:4 
Mean pharmacokinetic parameters of antipyrine in the rhesus monkey, 
the cynomolgus monkey and the baboon for a one-compartment open model 
compared to those for a two-compartment open model following a single 
intravenous injection of antipyrine (92 mg/kg). The data are 
presented as means of results from individual animals. 
----------------~~9~!-~9 ~~~=!~~------------------
Parameter a One-compartment Two-compartment 
-------- ------
---------
-------- ------- --------
Rhesus Cyno- Baboon Rhesus Cyno- Baboon 
molgus molgus 
----------------
-------- ------
---------
-------- ------- --------
AUC (Jlg/ml/hour) 285 345 315 291 357 318 
Cl (ml/minute) 26 16b 28 26 16b 27 
t~, (minutes) 106 106 92 111 132 c 95 
vd 
d (litres) 4.0 2.5e 3.6 4.1 2.6e 3.6 
-1 
Kel (minute ) 0.007 0.007 0.008 0.008 0.008 0.009 
----------------
--------
----------------
--------
-----------------
a 
For details of abbreviations used see Chapter 2. 
b Significance level (analysis of variance) cynomolgus monkeys 
compared to the other two species P~ 0.05. 
c Reduce to t~, = 114 minutes if a high value from one animal is not included. 
d Vd = total volume of distribution = Vd(ss) for the two-compartment model. 
e Significance level (analysis of variance) cynomolgus monkey compared 
to the other two species P< 0.01 
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CHAPTER 4 
DIAZEPAM 
Introduction 
Diazepam: 7-chloro-l, 3-dihydro-l-methyl-5-phenyl 2H-l,4-
benzodiazepin-2 one, is effective in the symptomatic relief of 
tension and anxiety states as well as for the relief of skeletal 
muscle spasm (Zbinden and Randell, 1967). It is a weak base 
(pKa 3.4), a long-acting lipophilic drug, primarily non-ionized 
at physiological pH, and has a high affinity for plasma proteins 
(Klotz et al, 1976). It has been shown to be an inducer of 
certain.drug-metabolising enzymes in man (Heubel and Frank, 1970).. 
and in animals (Heubel and Frank, 1970; Heubel and Patutschnick, 
1972) and even to induce its own metabolism (Kanto et al, 1974; 
and Sellman et al, 1975). 
The major metabolic pathways of diazepam have been described 
for several animal species including man (Ruelius et al, 1965; 
Schwartz et al, 1965; Coutinho et al, 1973; Garattini et al, 1973), 
As indicated in Scheme 4:1, the usual metabolism of diazepam is that 
of N1-demethylation and c3-hydroxylation, the two metabolites formed 
from these reactions undergoing further metabolism to form a common 
metabolite known as oxazepam (Kvetina et al, 1968; Marcucci et al, 
1969, 1970; Mussini et al, 1971; Trebbi et al, 1975; Comi et al, 
1977). The two hydroxylated metabolites are conjugated with 
glucuronic .. acid and excreted in the urine (Schwartz et al, 1965; 
Kanto et al, 1974). 
In the rat, N1-demethylation does not appear to be a major 
route of metabolism for diazepam (Marcucci et al, 1969, 1970; Comi 
et al, 1977) and therefore, plasma levels of desmethyidiaz~pam•are 
lower in the rat than in other species. This species difference in 
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the metabolism of diazepam is important as the N1-demethylated 
metabolites of diazepam have been shown to be pharmacologically 
active (Zbinden and Randell, 1967). 
Species related differences in the proportions of metabolites 
excreted in the bile have also been reported (Schwartz et al, 1965) 
and this might reflect species differences in the rate of glucuronide 
formation, and/or variations in the threshold of urinary as compared 
to the biliary excretion of glucuronides (Smith and Williams, 1966). 
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4'hydroxylation and conjugation 
diazepam 
1 
CHOH 
C = N/ 
N-desmethyldiazepam 
l 
3-hydroxydiazepam oxazepam 
~ ~ 
conjugation 
Scheme 4:1 Metabolic pathways of diazepam. 
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Measurement of concentrations of diazepam and desmethyldiazepam in plasma 
Plasma concentrations of diazepam and desmethyldiazepam were 
measured by a modification of the high pressure liquid chromatographic 
method of Brodie et al, (1978). 
Plasma (1 ml) was mixed with internal standard (l-cyclo-propyl-
methyl-l,3-dihydro-5-phenyl-7-chloro-2H-l,4-benzodiazepin-2-one 
(prazepam); 400 ng, 40 ~l of a 10 ~1/ml solution in spectrograde 
methanol) and buffered to pH 9 with borate buffer (2 ml, lM). The 
mixture was extracted with freshly redistilled diethyl ether (10 ml) 
by shaking for 15 minutes using a mechanical shaker (Griffin and 
George Ltd., London, U.K.). After centrifugation, the ether phase 
(9 ml) was transferred to a pointed centrifuge tube and evaporated to 
dryness under a stream of nitrogen at 35°C. The sides of the dry centri-
fuge tube were washed with redistilled ether and again blown to 
dryness under nitrogen. The residue concentrated at the bottom of 
the tube was redissolved in spectrograde methanol~5 ~l) and injected 
into the chromatograph. A stainless steel column (30 cm x 4 mm id) 
packed with c18 ~-Bondapak was used and the mobile phase was spectre-
grade methanol: water (v/v 60/40). The water was freshly redistilled 
from an all-glass still and the mixture was refluxed to remove 
dissolved air, and cooled, before use. Varying amounts (depending on 
the concentration of diazepam, and desmethyldiazepam, in the residue; 
from 1-25 ~1) were injected onto the column. Quantitation was by the 
internal standard technique using peak height ratios. 
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TABLE 4:1 
Method parameters for the measurement of concentrations 
of diazepam and desmethyldiazepam in plasma. 
-------------------- ------------------------
Parameter Diazepam 
-------------------- ------------------------
linear ranae 2-500 ng/ml 
calibration linea Y=(0.0091 ~ O.OOOl)X 
accuracy ~ 4% at 200 ng/ml 
~ 67% at 10 ng/ml 
precision ~ 1.6% at 400 ng/ml 
+ 7.1% at 10 ng/ml 
sensitivity 2 ng/ml 
recovery of IS 99% + 2.8 SD 
recovery of test lOO~ 2.6 SD 
-----------------------1 
Desmethyldiazeoam 
2-500 ng/ml 
Y = O.Ol02X 
~ 3% at 200 ng/ml 
+ 66% at 10 nq/ml 
+ 2.1% at 400 ng/ml 
+ 10.8% at 10 ng/ml 
2 ng/ml 
98 + 2.8 SD 
a Least squares regression line where Y = instrument response 
(peak height ratio,diazepam or desmethyldiazepam to 
Internal Standard) and X = plasma concentration of 
diazepam (or desmethyldiazepam). 
I S Internal Standard 
Results 
Plasma concentrations. After bolus intravenous injection of diazepam 
at two dose levels, 0.2 mg/kg and 1 mg/kg, peak of mean concentrations 
of diazepam were reached 2 minutes after injection (the first time 
of blood withdrawal) in all groups of animals except in the baboon 
after the higher dose. In this group, peak of mean 0 lasma concen-
trations were not reech"d until 5 minut-es after injection (the 
second time of blood withdrawal). Mean olasma concentrations of 
diazepam declined in a biohasic manner in all thre" sp.,cies with 
With an apparent half-life of elimination of about 1 hour which 
was similar after both dose levels. Concentrations of diazepam in 
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plasma were detectable for 3-'4 hours in the rhesus monkey and the 
cynomolgus monkey after the0.2 mg/kg dose and up to 5 hours in 
these species after the 1 mg/kg dose. However, concentrations of 
diazepam in the baboon remained above the limit of detection (2.0 ng/ml) 
for 7 hours post-administration after administration of both the 
0.2 mg/kg dose and the 1 mg/kg dose (Tables 4:2 and 4:3, Figures 4:1 -
4 :6). 
Pharmacokinetic parameters of diazepam. Observed plasma concentrations 
of diazepam following a single intravenous injection of diazepam at two 
dose levels (0.2 mg/kg and 1 mg/kg) were fitted by a biexponential 
equation (equation 2:2). The pharmacokinetic parameters shown in 
Tables 4:4 and 4:5 were, therefore, calculated using equations 2:3-
2:12 for a two compartment-open model with elimination from the 
central compartment (Scheme 2:2). Plasma concentrations of diazepam 
predicted by the two-compartment model were generally in good agree-
ment with the observed values (Figures 4:1- 4:6). 
Analysis of variance of areas under the plasma concentration-time 
curves after administration of the 0.2 mg/kg dose showed that the areas 
under the curve for the baboon were significantly higher (P <0.05 non-
parametric version of Newman-Keuls multiple comparison procedure) than 
for the other two species. However, analysis of variance of areas 
under the concentration time curves after administration of the 1 mg/kg 
dose showed that at this dose level there were no statistically 
significant differences between these non-human primate species (P >0.05 
Newman-Keuls multiple comparison procedure). Areas increased approx-
imately in proportion to the administered dose in the rhesus monkey and 
the cynomolgus monkey, but there was only about a three-fold increase 
in the value of this pharmacokinetic parameter in the baboon. 
Analysis of variance showed that the volume of distribution was 
significantly lower in the rhesus monkey than that in the other two 
species (P <0.05 Newman-Keuls multiple comparison procedure) after the 
1 mg/kg dose and that there was a significant increase in the volume of 
distribution of diazepam in the cynomolgus monkey and the baboon after the 
larger dose (P <0.005 Newman-Keuls multiple comparison procedure) • 
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Analysis of variance of the systemic clearance of diazepam 
showed that the clearance of diazepam in thebaboon was significantly 
lower than that in the other two species {P< .. D.OS Newman-Keuls 
multiple comparison procedure) after the 0.2 mg/kg dose but that there 
were no significant dose related differences in the clearance of 
diazepam (P > 0.05 Newman-Keuls multiple comparison procedure). 
No other significant differences (P> 0.05) in the pharmacokinetics 
of diazepam in these non-human primates were observed at either dose 
level. The pharmacokinetics of diazepam were also found not to be 
greatly affected by an increase in the amount injected. 
Although diazepam is strongly bound to plasma proteins, the 
volume of distribution of diazepam was 50, 53 and 39% of the total 
bodyweight in the rhesus monkey, the cynomolgus monkey and the baboon, 
respectively, after the 0.2 mg/kg dose and 44, 81 and 63% respectively 
after the l mg/kg dose,suggesting that the tissues also have an affinity 
for this compound. These values are lower than those previously 
reported for man (70-200% of bodyweight, Van der Kleijn et al, 1971; 
Kaplan et al, 1973; Klotz et al,l976) and in other species {1277% 
in the dog, 714% in the rabbit, 395% in the guinea pig and 784% in the 
rat, Klotz et al, 1976). Thus there appears to be large interspecies 
variations in the degree of distribution of diazepam. These species 
related differences might result from differences in protein binding, 
but could also be an artefact resulting from differences in the method 
used to determine plasma concentrations {see page 66). 
The mean. volume of the central compartment was larger than that 
of the peripheral compartment in thase non-human primates. .The compart-
ment volume ratio ·(centtra~'..Peripheral) was 4.8, 3.8 and 2.1 in the rhesus 
monkey, the cynomolgus monkey and the baboon respectively, after the 
0.2 mg/kg dose and 1.9, 2.2 and 1.7 respectively after administration 
of the 1 mg/kg dose, suggesting that there was relatively free transfer 
of diazepam between the central and the peripheral compartment. At the 
higher dose level there was a general increase in the apparent volyme of 
distribution of both the central and peripheral compartments, with a 
slight increase in the proportion of distribution into the peripheral 
compartment. 
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The mean rate constant for the rapid distribution; phase, ~. 
corresponded to an apparent half-life 't~{a)' of 19 minutes, 12 minutes 
and 15 minutes for the rhesus monkey, the cynomolgus monkey and the 
baboon, respectively, after the 0.2 .mg/kg dose, and 11 minutes, 
14 minutes and 13 minutes respectively, after the 1 mg/kg dose. 
These values are similar to those in other commonly used laboratory 
animals such as the dog (t~(a) = 28 minutes), the rabbit (t~(a) = 
18 minutes) the guinea pig (t~(a)= 18 minutes) and the rat (t~(a) = 
17 minutes) (Klotz et al, 1976) but are shorter than that in man 
(t~(a) = 58 minutes, Kaplan, 1973; to t~(a) = 132 minutes, Klotz 
et al, 1976). The value of apparent half-life of the distribution 
phase following intraperitoneal injection of diazepam in the rhesus 
monkey has been reported to be 30 minutes (Curry et al, 1977). 
The ratio of S/Kel of 0.4 and 0.5 for the ~sus monkey and 
0.5 and 0.3 for the cynomolgus monkey and 0.6 and 0.4 for the baboon 
after the 0.2 mg/kg dose and the : 1 mg/kg dose respectively indicates 
that these fractions of the diazepam in the body were in the central 
compartment and available for elimination at any time during the a 
elimination phase (Gibaldi et al, 1969). 
Simulation of concentration of diazepam in the peripheral compart-
ment for a two-compartment open model with pharmacokinetic parameters 
shown in Tables 4:4 and 4:5 using equation 2:15, at both dose levels, 
showed that equilibrium was rapidly achieved. Peak levels of diazepam 
of 104 ng/ml, 127 ng/ml and 193 ng/ml in the rhesus monkey, the 
cynomolgus monkey and the baboon respectively, after the 0.2 mg/kg dose 
and 936·ng/ml, 556 ng/ml and 379 ng/ml respectively after the 1 mg/kg 
dose were reached 40 minutes after injection in these three non-human 
primate species after both administrations. Thereafter, concentrations 
of diazepam in the peripheral compartment were similar to · those in 
the central compartment, except in the rhesus monkey after both 
dose levels and in the cynomolgus monkey after the high dose level. 
(Tables 4:6, 4:7; Figures 4:1- 4:6). 
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TABLE 4:2 
Mean concentration~· (:!:. SD) of diazepam in the plasma of the rhesus 
monkey, the cynomolgus monkey and the baboon after a single bolus 
intravenous injection of diazepam at a level of 0.2 mg/kg. 
Results are expressed as ng/ml 
----------------
--------------------:::::::---------------------] 
Time 
--------------- ----------------- -------------
Rhesus monkey 'Cynomolgus monkey Baboon ~ 
--------------- --------------- ------------------ -------------
2 minute. 432 + 32 407 + 133 588 + 180 I I 
5 minute 386 + 31 325 + 60 556 + 151 ' 
10 minute 286 + 73 264 + 55 453 + 94 
-
20 minute 170 + 60 175 + 42 371 + 94 
-
40 lili.nute 81 + 31 90 + 25 221 + 63 
l-0 hour 37 + 13 44 + 7 142 + 40 
1.5 hour NS 21 + 6 94 + 31 
-
2 hour 10 + 6 13 + 6 68 + 31 
-
3 hour NS 4 + 3 33 + 26 
4 hour 2 + 3 ND 17 + 18 
5 hour ND ND 8 + ll 
7 hour. 3 + 4 
NS No sample taken at the time 
ND Less than the limit of detection (2ng/ml) 
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TABLE 4:3 
Mean concentrations (~ SD) of diazepam in the plasma of the rhesus 
. monkey, the cynomo1qus monkey and the baboon after a single bolus 
intravenous injection of diazepam at a level of 1.0 mg/kg. 
Results are expressed as ng/ml 
------------------ ------------------~----------------------------------
Time Species 
--------------- ------------------------------------
Rhesus monkey Cynomolgus monkey Baboon 
------------------ --------------- ------------------ -----------------
2 minute 2984 + 272 1841 + 718 2172 + 694 
-
5 minute· 2538 + 213 1692 + 514 2358 + 605 
10 minute. 1892 + 152 1360 + 373 1888 + 515 
20 minute 1243 + 166 887 + 274 1326 + 293 
40 minute 529 + 146 449 + 77 662 + 71 
1.o. hour 313 + 84 254 + so 388 + 105 
-
1.5 hour 147 + 39 131 + 20 230 + 52 
2 hour 89 + 28 72 + 9 163 + 47 
3 hour 35 + 21 35 + 9 89 + 26 
4 hour 14 + 11 13 + 4 45 + 13 
5 hour 3 + 4 5 + 3 23 + 8 
7 hour ND ND 7 + 4 
------------------ ---------------------------------- ------------------
ND Less than the limit of detection (2ng/ml) 
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TABLE 4:4 
Mean pharmacokinetic parameters (.:t_SD) determined for a two-compartment 
model after bolus intravenous injection of diazepam 0.2 mg/kg to the 
rhesus monkey, the cynomolgus monkey and the baboon. The data are 
presented as means of results from individual animals. 
------------------------- ----------------------------------------------
Parameter a 
Bodyweight (kg) 
Dose 
Dose 
A 
B 
Cl 
t~ 
v.l 
v2 
V (ss) 
vdWl 
A/ a. 
B/ a 
(mg) 
(mg/kg) 
(ng/ml) 
(ng/ml) 
-1 (hour ) 
-1 (hour ) 
-1 (minute ) 
(minute -l) 
-1 (minute ) 
(ng/ml/hour) 
(ml/minute) 
(minutes) 
(litres) 
(litres) 
(litres) 
(litres) 
(ng /ml/hour) 
(ng /ml/hour) 
----~E~~!~~--------------------
Rhesus monkey 
4.6 + l.O 
0.9 + 0.2 
0.2 + 0.0 
440 + 70 
40 + 20 
Cynomolgus 
monkey 
3.6 + 0.3 
0.7 + O.l 
0.2 + 0.0 
220 + llO 
160 + 150 
2.189 + 1.157 3.466 + 3.822 
0.770 + 0.640 1.260 + 0.768 
Baboon 
5.7 + o.8 
l.l + 0.2 
0.2 + o.o 
356 + 303 
280 + 90 
2.773 + 0.612 
o. 693 + o. 216 
0.003 + 0.001 0.008 + 0.061 0.009 + 0.003 
0.015 + 0.007 0.029 + 0.089 0.019 + 0.010 
0.031 + 0.012 0.042 + 0.008 0.021 + 0.006 
235 + 27 
66 + 3 
54 + 23 
1.9 + 0.6 
0.4 + 0.1 
2.3 + 0.5 
5.1 + 1.5 
91+ 54 
202 + 27 
193 + 35 
65 + 16 
43 + 17 
1.5 + 0.6 
0.4 + 0.6 
1.9 + l.l 
3.1 + 0.8 
63 + 93 
127 + 79 
525 + l76b 
43 + l4b 
60 + 12 
1.5 + l.O 
0.7 + 0.4 
2.2 + 1.3 
3.7 + 1.2 
130 + 109 
404 + 149 
a For details of abbreviations used, see Chapter 2. 
b Significance level (analysis of variance) baboons compared to the 
other two species (P < 0.05). 
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TABLE 4:5 
Mean pharmacokinetic parameters (::t_SD) determined for a t>~o-.compartment 
model after bolus intravenous injection of diazepam l.o mg/kg to the 
rhesus monkey, the cynomolgus monkey and the baboon. The data are 
presented as means of results from individual animals. 
------------------------- ----------------------------------------------
a Parameter 
Rhesus monkey 
---~2~=~~~---------------------
Cynomolgus 
monkey Baboon 
------------------------- -------------- ------------- -----------------
Bodyweight 
Dose 
Dose 
A 
B 
Cl 
Cl 
t., 
vl 
v2 
V (ss) 
vd(S) 
A/Cl 
B/S 
(kg) 
(mg) 
(mg/kg) 
(ng/ml) 
(ng/ml) 
(hour -l) 
-1 (hour ) 
(minute-l) 
(minute -l) 
-1 (minute ) 
(ng/ml/hr.) 
(ml/minute) 
(minute) 
(litres) 
(litres) 
(litres) 
(litres) 
(ng/ml/hr) 
(ng/ml/hr) 
4.5 + 1.0 
4.6 + 0.9 
1.0 ,+ 0.1 
2476 + 508 
885 + 812 
3.4 + 0.3 
3.6 .:!:. 0.2 
1.1 .:!:. 0.1 
1622 + 589 
466 + 329 
5.7 + 0.9 
5.7 + 0.9 
1.0 + 0.0 
2100 + 919 
620 + 115 
3.736 + 1.165 3.023 + 1.308 3.199 + 0.777 
0.986 + 0.716 0.832 + 0.512 0.650 + 0.096 
0.015 + 0.051 0.010 + 0.007 0.015 + 0.005 
0.029 + 0.089 0.020 + 0.016 0.021 + 0.003 
0.035 + 0.014 0.033 + 0.010 0.028 + 0.009 
1331 + 164 
59 + 14 
45 + 25 
1.3 + 0.2 
0.7 + 0.2 
- b 
2.0 + 0.4 
- b 
3.6 + 0.9 
669 +401 
661 + 336 
1035 + 191 
60 + 14 
50 + 22 
2.0 + 1.1 
0.9 + 0.3 
2.9 + 0.9 
4.3 + 1.0 
601 + 224 
433 + 242 
1653 + 174 
58 + 14 
64 + 7 
2.1 + 1.0 
1.5 + o. 7 
3.6 + 1.0 
5.4 + 1.3 
656 + 177 
954 + 193 
------------------------- -------------- ------------- -----------------
a For details of abbreviations used, see Chapter 2. 
b Significance level (analysis of variance) rhesus compared to the 
other two species (P <0.05) 
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TABLE 4;6 
Calculated concentrations of diazepam.in the peripheral compartment 
after administration of diazepam 0.2 mg/kg to the rhesus monkey, the 
cynomolgus monkey and the baboon. Results calculated from mean plasma 
data (Table 4.4) and expressed in ng/ml 
----~~~~~==-------------------------Time 
Baboon 
2 minute 13 26 27 
5 minute 30 58 61 
10 minute 53 95 107 
20 minute 83 126 162 
40. minute 105 127 193 
1 hour lOO 96 179 
1.5 hour 79 55 138 
2 hour 57 30 lOO 
3 hour 28 9 51 
4 hour 13 2 26 
5 hour 6 1 13 
7 hour 1 3 
--------------
----------------- ------------------ ------------------
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I 
TABLE 4:7 
Calculated concentrations of diazepam.in the peripheral compartment 
after administration of diazepam 1.0 mg/kg to the rhesus monkey, the 
cynomolgus monkey and the baboon. Results calculated from mean 
plasma data (Table 4.5) and expressed in ng/ml. 
-----------------------------------------------------l 
Time 
-~~~'::~-'.!!~!!~~L -~~~~1.!!~!2'::~-'.!!~~~~- Baboon 
--------------- ------------------
2 minute 183 75 57 
5 minute 407 182 130 
10 minute 669 327 222 
20 minute 930 472 330 
40 minute 936 533 379 
1 hour 751 466 344 
1.5 hour 482 333 264 
2 hour 297 225 194 
3 hour 112 99 102 
4 hour 42 43 53 
5 hour 15 19 l " 7 hour 2 4 8 
------------------------------- ------------------- ------------------
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Plasma concentrations of desmethyldiazepam. Desmethyldiazepam was 
detectable in the plasma at 5 minutes (the second time of blood 
withdrawal) and 2 minutes (the first time of blood withdrawal) after 
dosing with diazepam at levels of 0.2 mg/kg and 1 mg/kg respectively. 
Peak plasma concentrations of desmethyldiazepam of 118 ng/ml ~ 39 SD, 
107 ng/ml ~ 19 SD and 112 ng/ml ~ 13 SD in the rhesus monkey, the 
cynomolgus monkey and the baboon were reached 1-2 hours after admin-
istration of the 0.2 mg/kg dose. These values were similar to those in 
man after injection of diazepam at the same dose level (Korttila et al, 
1975). After administration of diazepam at a level of 1 mg/kg peak 
concentrations of 813 ng/ml ~ 232 SD, 551 ng/ml ~ 117 SD and 516 ng/ml 
+ 218 SD in the rhesus monkey the cynomolgus monkey and the baboon 
occurred 1-2 hours after dosing. The increase in plasma concentration 
of the metabolite was approximately five-fold and, therefore, in 
proportion to the increased dose, suggesting that there is a linear 
relationship between the plasma concentrations of desmethyldiazepam 
formed after administration of different amounts of the parent drug, at 
least over this concentration range. After reaching peak levels, plasma 
concentration declined with an apparent half-life of elimination of 
3-12 hours, to almost the limit of detection (2.0 ng/ml) 24-48 hours 
after administration of the 0.2 mg/kg dose. After administration of 
the 1 mg/kg dose, terminal half-lives varied from 4-18 hours and des-
methyldiazepam was detectable for 72 hours after administration in all 
three non-human primate species (Tables 4:8, 4:9, Figures 4:1- 4:6). 
Pharmacokinetic parameters for desmethyldiazepam. A plot of the 
observed plasma concentrations of desmethyldiazepam against time was 
fitted by a biexponential curve, described by equation 2:18. The 
pharmacokinetic parameters shown in Tables 4:10 and 4:11 were therefore 
calculated for a one-compartment open model with first order input and 
output (Scheme 2:3). Plasma concentration of desmethyldiazepam predicted 
by the one-compartment model were generally in good agreement with the 
observed values (Figures 4:1 - 4:6). 
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Analysis of variance showed that the areas under the plasma 
concentration time curve in the baboon were significantly lower than 
in the other two species (P<O.OS non-parametric version of Newman-
Keuls multiple comparison procedure) after the 0.2 mg/kg dose, and that 
the areas under the curve in the rhesus monkey were significantly lower 
(P<O.OS non-parametric version of Newman-Keuls multiple comparison 
procedure) after l mg/kg dose, The increased areas after the 
higher dose represented a four-, six- and twelve-fold increase over that 
after the lower dose in the rhesus monkey, the cynomolgus monkey and the 
baboon respectively, and were therefore approximately in proportion 
to the increased dose except in the baboon. The lower values obtained 
after the 0,2 mg/kg dose to the baboon and l mg/kg dose to the rhesus 
monkey were associated with shorter elimination half-lives of desmethyl-
diazepam in these species at those dose levels. 
The rate constant for formation of desmethyldiazepam 'K' was 
estimated by the method of residuals (Gibaldi and Perrier, 1975). 
Mean values were similar in all three species, corresponding to an 
apparent half-life of formation of about 20 minutes. After the higher 
dose, the rate of formation of the metabolite decreased slightly and 
was slowest in the baboon in which the mean apparent half-life of 
formation was estimated to be 33 minutes. Generally, the values of 
Kf were similar to those for the rate constant for elimination of 
diazepam from the central compartment 'Kel' for diazepam (Tables 4:4 
and 4:5). This similarity and also that no other metabolite of 
diazepam were detectable in the plasma of these species suggests that 
diazepam is eliminated by metabolism principally via the desmethyl 
metabolite pathway. 
Assuming that demethylation of diazepam is the primary stage in the 
elimiantion of diazepam from the body, the volume of distribution and 
total systemic clearance of desmethyldiazepam can be estimated using 
equations 1:1 and 2:4. Volumes of distribution in the baboon after 
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the 1 mg/kg dose were higher than those in the other two species, but 
this data was variable and there were no significant differences between 
the species with respect to this parameter after either dose of diazepam. 
Analysis of variance of estimated clearances (Tables 4:10 and 4:11) shows 
that the total systemic clearance of desmethyldiazepam is significantly 
higher (P<O.Ol, Newman-Keuls multiple comparison procedure) in the 
baboon than in the cynomolgus monkey after administration of the 0.2 mg/kg 
dose. Clearances were lower in the rhesus monkey than in the baboon, but 
this difference was not significant (P70.05) • After administration 
of diazepam at a level of 1 mg/kg the systemic clearance was again lower 
in the cynomolgus monkey than in the other two species but this 
difference was not statistically significant (P,..0.05). When adjusted, 
for bodyweight differences the adjusted clearance in the baboon (3.8 ml/ 
minute/kg) remained significantly higher than that in the rhesus 
monkey (2.4 ml/kinute/kg) and that in the cynomolgus monkey (2.4 ml/ 
minute/kg) (P<O.OS, Newman-Keuls multiple comparison procedure) after 
the 0.2 mg/kg dose. After the 1 mg/kg dose the adjusted clearance of 
desmethyldiazepam 2.8 ml/minute/kg, 2.0 ml/minute/kg and 2.6 ml/minute/ 
kg in the rhesus monkey, the cynomolgus monkey and the baboon 
respectively, remained not significantly different in these non-human 
primate species (P70.05, Newman-Keuls multiple comparison procedure). 
The volume of distribution of diazepam in non-human primates was 
171, 183 and 128% of bodyweight in the rhesus monkey, the cynomolgus 
monkey and the baboon respectively, after the 0.2 mg/kg dose and 
142, 182 and 288% of bodyweight in these species respectively after 
the l mg/kg dose. These values are higher than that in man, 64% of 
bodyweight (Klotz et a1, 1976) and in the dog approximately lOO% of 
bodyweight (estimated from published data, Kaplan and Jack, 1980). 
Desmethyldiazepam clearance in the non-human primate is greater than that in 
man (0.2 ml/minute/kg, Klotz et al, 1977; Brodie et a1, 1981; I 
Chasseaud et al, l980b), but much lower than that in the dog (33.4 ml/ 
minute/kg, estimated from published data, Kaplan and Jack, 1980). 
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TABLE 4:8 
Mean plasma concentrations (~ SD) of.desmethyldiazepam after bolus 
intravenous injection of diazepam 0.2 ,mg/kg to the rhesus monkey, 
the cynomolgus monkey and the baboon. Results are expressed as ng/ml. 
Time 
Baboon 
------------------
2 minute ND ND ND· 
5 minute 11+ 8 14 + 18 12 + 20 
10 minute 34 + 24 35 + 24 29 + 37 
20 minute 69 + 20 59 + 7 60 + 31 
40 minute 99 + 20 86 + 15 87 .:t 21 
1 hour 114 + 24 107 + 19 102 + 10 
1.5 hour NS 106 + 24 112 + 13 
2 hour 118,:t 39 101 + 19 103 + 14 
3 hour NS 92 + 18 96 + 15 
4 hour 99 + 33 85 + 18 82 + 14 
5 hour NS 79 + 16 69 + 14 
7 hour 77 + 23a 65 + 16 46 + 15 
24 hour 20 + 7 23 + 9 4 + 1 
30 hour 13 + 5 15 + 7 ND 
48 hour 2 + 1 4 + 3 
------------- ------------------ ------------------ -------------------
NS lndicating that no sample was taken at this time. 
a Result refers to sample taken at 6 hours post-dose. 
ND Less than the limit of detection (2ng/ml). 
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TABLE 4:9 
Mean plasma concentrations (.:!:_ SD) of desmethyldiazepam after bolus 
intravenous injection of diazepam 1.0 mg/kg to the rhesus monkey, the 
cynomolgus monkey and the baboon. Results are expressed as ng/ml. 
-------------- -------------------------------------------------------
Time 
2 minute 
5 minute 
10 minute" 
20 minute 
40 minute. 
1 hour 
1.5 hour 
2 hour 
3 hour 
4 hour 
5 hour 
7 
24 
hour 
hour 
30 hour 
48 hour 
72 hour 
-----------------------~2~~~~~------
4 +-
138 + 111 
335 .:!:. 120 
567 + 122 
813 .:!:. 232 
789 .:!:. 238 
742 + 202 
684 .:!:. l!77 
614 + 99 
523 + 96 
449 + 86 
363 .:!:. 75a 
66 + 56 
45 + 51 
10 + 19 
2 + 
3 + -
29 + 49 
145 + 59 
275 + 173 
466 + 129 
526 + 106 
551 + 117 
549 + 99 
517 + 87 
480 + 36 
467 + 51 
404 + 72 
153 + 67 
120 + 61 
39 + 29 
12 + 11 
Baboon 
------------------
ND 
28 + 31 
82 + 42 
225 + 42 
417 + 122 
490 + 212 
516 + 218 
514 + 181 
SOl + 172 
480 + 224 
434 + 245 
383 + 255 
180 + 106 
112 + 82 
47 + 36 
14 + 12 
-------~------ ---------------- ------------------- -------------------
a Result refers to sample taken at 6 hour post-dose. 
ND Less than the limit of detection (2ng/ml). 
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TABLE 4:10 
Mean pharmacokinetic parameters (~ SD} determined for desmethyldiazepam 
after bolus intravenous injection of diazepam (0.2 mg/ml} into rhesus 
monkeys, cynomolgus monkeys and baboons. The data are presented as 
means of results from individual animals. 
Parameter a ---~£~~!~~--------------------
Rhesus monkey Cynomolgus Baboon 
------------------------------- -----------------
---~£~~L-----
--------------
Lag time (minutes} !.2 + !.6 2.9 + 1.0 5.1 + 4.5 
Peak concentration (ng/ml} 112 + 22 104 + 17 111 + 10.5 
Time to peak 
concentration (minutes} 102 ~56 82 + 28 83 + 33 
t .. (hours) 8.5 ~ 0.6 9.9 + 2.5 4.2 + 0.9 
AUC (ng/ml/IDur} 1632 + 766 1527 + 459 887 + 199b 
Cld (ml/minute} 10.6 ~ 6,0 8.1 + 2.8 c 20.8 + 5.6 
d 
vd (litres} 7.9 ~ 4.4 6.6 + 2.3 7.3 + 2.0 
-1 2. 747 ~ !.822 2.067 + 0.033 2.0586 + 0.769 Kf (hour } 
Km 
-1 0.081 ~ 0,007 0.074 + 0.021 0.1728 + 0.049 (hour } 
-------------------------------~--------------------------------- ---------------
a 
b 
c 
d 
For details of abbreviations see Chapter 2. 
Significance 1evel(analysis of variance} baboon compared to the other two 
species (P, <. 0. 05} 
Significance level (analysis of variance} baboon compared to the cynomolgus 
monkey (P < 0.01}. 
Estimated assuming that all administered diazepam is primarily metabolised 
to desmethyldiazepam before elimination. 
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TABLE 4:11 
Mean pharmacokinetic parameters (.:t_ SD) determined for desmethyldiazepam 
after bolus intravenous injection of diazepam (1.0 mg/kg) into rhesus 
monkeys, cynomolgus monkeys and baboons. The data are presented as means 
of results from individual animals. 
Parameter a 
Rhesus monkey Cynomolgus Baboon 
----------------------------- --------------
-----~~~~x ______ 
---------------
Lag time (minutes} 2.4 + o. 7 3.5 + 2.0 3.1 + 2.0 
Peak concentration (ng/ml) 800 + 218 562 + 88 546 + 223 
Time to peak 
concentration (minutes} 55 + 16 99 + 26 125 + 47 
s. (hour.;;) 6.8 + 3.4 11.9 + 4.1 14.7 + 2.5 
AUC (n<y'ml/hour} 6636 + 259lb 9318 + 3261 10171 + 6674 
Clc (ml/minute) 12.6 + 4.3 6.7 + 2.4 13.1 + 9.3 
V c (litres) 6.4 + 2.2 6.2 + 2.2 16.4 + 11.6 d 
-1 
Kf (hour ) 4.304 + 1.311 2.259 + 0.910 1.949 + 0.983 
-1 K (hour ) 0.119 .:t. 0.042 0.065 + 0.025: 0.048 + 0.009 
m 
------------------------------ -------------- ----------------- ----------------
a For details of abbreviations see. Chapter 2. 
b Significance level (analysis of variance} rhesus monkey compared with 
the other two species (P< 0.05). 
c Estimated assuming that all administered diazepam is primarily metabolised 
to desmethyldiazepam before elimination. 
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Discussion 
The plasma concentration-time course for diazepam has been, 
described for many species, including man, in terms of a two-
compartment open model (Klotz et al, 1976, Van den Kleijn et al, 
1971; Vree et al, 1979; Kaplan et al, 1973; Mandelli et al, 1978; 
Curry et al, 1977). In these non-human primates also, the 
pharmacokinetic profile of diazepam appears to fit the two-compart-
ment model after intravenous injection at a therapeutic dose level 
(0.2 mg/kg) and at a level that might be selected for administration 
during a chronic toxicity study of diazepam (1 mg/kg). The 
distribution phase, A)l(, contributed 39, 33 and 25% to the total 
area under the curve in the rhesus monkey, the cynomolgus monkey and 
the baboon respectively after the 0.2 mg/kg dose and So, 58 and 40% 
respectively after the 1 mg/kg dose, increased after the higher: 
dose. 
As diazepam is eliminated almost exclusively by metabolism, 
the total systemic clearance reflects the metabolic clearance. 
The values for the clearance of diazepam in these non-human primates 
was about four-fold lower than the hepatic blood flow and, therefore, 
if diazepam metabolism occurs predominatly in the liver it is possible that 
an hepatic first pass effect coWd be a factor in diazepam disposition 
in the non-human primate after oral administration of this compound. 
When adjusted for bodyweight differences, the adjusted systemic 
clearance of diazepam 14.3 ml/minute/kg (13.1 ml/minute/kg), 
18.1 ml/minute/kg (17.6 ml/minute/kg) and 7.5 ml/minute/kg (10.2 ml/ 
minute/kg) in the rhesus monkey, the cynomolgus monkey and the baboon 
respectively after the lower dose (and higher dose) respectively, were 
similar to or less than those values found in the dog (18.9 ml/minute/kg) , the 
rabbit (30.5 ml/minute/kg), the guinea pig (18.9 ml/minute/kg) and the 
rat (81.6 ml/minute/kg) but higher than that in man (0.35 ml/minute/kg) 
(Klotz et al, 1976, 1977; Kaplan et al, 1973). 
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The values of the apparent half-life of elimination of diazepam 
observed in this study with non-human primates are similar to those 
values previously reported· for the rat.(60 minutes, Klotz et al, 1976) 
and for the dog (80 minutes, Vree et al, 1979) but shorter than those 
in the guinea pig (144 minutes, Klotz et.al, 1976), the dog (456 minutes 
Klotz et al, 1976) and for man (24-48 hours, Klotz et al, 1976, 1977; 
Kaplan et al, 1973; Van der Kleijn et al, 1971, Vree et al, 1979; 
Mandelli et al, 1978) 
Curry et al (1977) reported a biexponential decline of plasma 
concentrations in the rhesus monkey following an intraperitoneal 
injection of diazepam with ana-phase corresponding to an apparent half-
life of 30 minutes and a terminal half-life of 9.7 hours. However, 
these workers used a gas chromatographic procedure (De Silva and Puglisi, 
1970) and the terminal half-life was not observed until plasma con-
centrations were very low (< 40 ng/ml). No such terminal phase was 
observed in this study in which a high pressure liquid chromatographic 
method was employed. It is possible, therefore,that the longer half-
life reported by Curry et al was an artefact resulting from the gas 
chromatographic procedure. Another example of a considerable difference 
in the value of the biological half-life of diazepam using these two 
different analytical techniques can be found in the literature. Vree 
et al (1979) quote a value of 80 minutes for the biological half-
life of diazepam in the dog, using high pressure liquid chromatography 
to measure plasma concentrations, whereas Klotz et al (1976) found the 
biological half-life in the dog to be 7.6 hours using a gas chromato-
graphic method (Klotz et al,l975). 
It has been reported that diazepam is an inducer of its own 
metabolism (Kanto et al, 1974; Sellman et al, 1975) resulting in 
higher plasma concentrations of desmethyldiazepam after continuous 
therapy. Korttila et al (1975) explained the. increased· plasma con-
centrations of desmethyldiazepam after continuous therapy resulting 
from the saturation of tissues with this metabolite. In this study 
with non-human primates, plasma concentrations of ~oth the parent 
compound and the desmethyl metabolite increased approximately in 
proportion to the administered dose and the pharmacokinetic parameters 
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were similar at both dose levels. However, there was a two week 
interval between dosing sessions and it would, therefore, be 
unlikely that there was any induction effect resulting from the 
initial dose at 0.2 mg/kg influencing the kinetics after the 
l mg/kg dose. 
The values of the half-lives of elimination of desmethyl-
diazepam observed in these non-human primates were shorter than 
those reported for man (30 - 200 hours, Van der Kleijn, 1971; Klotz 
et al, 1977; Kanto et al, 1975; Carrigan and Bantenback, 1979; 
Brodie et al, 1980; Chasseaud et al, l980b) but similar to those 
previously reported for the rhesus monkey (8.2 hours, Curry et al, 1977) 
and for the dog (10 hours, Vree et al, 1979). Desmethyldiazepam is 
an unimportant metabolic product of diazepam in the rat. 
Inspection of the half-lives of elimination of diazepam and 
desmethyldiazepam in several species shows that during the once-
daily dosage regimen,. common to most chronic toxicity studies, 
diazepam would not accumulate in the body of the commonly used 
laboratory animals, since each dose would have been eliminated before 
the next is received. However, in humans receiving 30 mg diazepam once 
daily for the treatment of anxiety and tension, a plasma steady state 
concentration of diazepam of approximately 750 ng/ml would be achieved 
one to two weeks after commencement of therapy. To achieve this same 
steady state plasma concentration in non-human primates a possible 
dosing regimen would be to inject diazepam intravenously 1.9 mg every 
45 minutes, 2.5 mg every 50 minutes and 2.9 mg every 64 minutes into 
the rhesus monkey, the cynomolgus monkey and the baboon respectively. 
In practice, it would be more appropriate to monitor maximum and/or 
minimum diazepam plasma (blood) concentrations during a chronic dose 
study in which the drug would normally be administered orally. This is 
particularly relevant for diazepam, as this drug is thought to induce 
its own metabolism and therefore it would probably be necessary to adjust 
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the dosing regimen as described by Gibaldi and Perrier (1975) 
to obtain suitable steady state drug plasma (blood) concentration. 
There was no indication from this study at two dose levels in non-
human primates that diazepam pharmacokinetics were dose dependent. 
The accumulation of the desmethyl metabolite of diazepam in 
humans with the above dosing regimens can be estimated from published 
I pharmacokinetic parameters (Brodie et al, 198~; Chasseaud et al, l980b) 
if it is assumed that all diazepam is demethylated as the primary stage 
of elimination (see page 59) • In humans, therefore, a steady state 
plasma concentration of desmethyldiazepam of approximately 1.8 vg/ml 
would be achieved about 26 days after commencement of a dosing regimen 
of 30 mg of diazepam once daily. The steady state plasma concentrations 
of desmethyldiazepam in the rhesus monkey, the cynomolgus monkey and 
the baboon would be approximately 3.2 vg/ml, 7.1 vg/ml and 3.3 ~g/ml 
respectively, if diazepam was administered intravenously as described 
above. There is, therefore, relatively more accumulation of desmethyl-
diazepam in non-human primates than in humans with a dosing regimen 
designed to give the same steady state plasma concentration of diazepam. 
Using pharmacokinetic criteria, therefore, it can be concluded 
that the non-human primate is not a more suitable model for man than 
are the other commonly used laboratory animal species. More important 
factors in the choice of an animal model for man to study the fate of 
diazepam in vivo, would be species-related differences in metabolism, 
route of excretion, tissue distribution and protein binding. 
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C~Trn 5 
FRUSEMIDE 
Introduction 
Frusemide(4-chloro-N-furfuryl-5-sulphamoyl-anthranilic acid,pKa 3.9) 
is a potent, short acting diuretic (Kirkendall and Stein, 1968; Kim et al, 
1971). The mechanism of its effect is poorly understood, but frusemide 
has been shown to act at the lumen surface of the diluting segment of the 
loop of Henle, inhibiting active reabsorption of chloride and so prevent-
ing the reabsorption of sodium (for a review see Benet, 1979) . Although 
incompletely absorbed from oral preparations (approximately 60% bioavail-
ability in man, Benet, 1979, and in dogs Yakatan et al, 1976), the total 
diuretic response has been shown to be similar after both oral and intra-
venous administration of the same amount (80 mg) frusemide (Kelly et al, 
1974; Branch et al, 1976). 
After intravenous injection approximately 80% of the administered 
dose is excreted in the urine in the first 24 hours, apparently aided 
by active secretion (Gayer, 1965; Sorgel, 1978), and some is excreted 
in the faeces both in humans (Calesnick et al, 1966; Cutler et al, 1974; 
Beermann et al, 1975; Perez et al, 1979), and animals (Wallin et al, 1976; 
Yakatan et al, 1976; Sorgel et al, 1978). Of the excreted dose of up to 
loo mg/kg, approximately 80% is unchanged frusemide and its glucuronide 
(Haussler and Hajdu, 1964; Seno et al, 1969; Yakatan et al, 1976; Perez 
et al, 1979) but there have been conflicting reports about other 
metabolites. Some investigators have been unable to isolate any 
metabolites other than the glucuronide (Calesnick et al, 1966; Beermann 
et al, 1975; Branch et al, 1977) but others have indicated that some of 
the administered frusemide is metabolised to the defurfuryl metabolite, 
(4-chloro-5-sulphamoyl anthranilic acid; saluramine); for a review see 
Benet (1979). 
After administration of doses in excess of lOO mg/kg frusemide has 
been shown to produce hepatic and also possibly renal necrosis (see Mitchell 
and Jollow, 1975). The most likely cause of these toxic symptoms being 
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the possible formation of a metabolite by epoxidation of the furan 
ring. However, this possible route of metabolism has not been found 
at lower doses and therefore frusemide is thought· to be a safe drug 
at normal doses of less than 1 mg/kg. 
The apparent half-life of elimination of frusemide has been shown 
to be about 1 hour in normal humans (Benet, 1979) and in animals 
(Wallin et al, 1976; Data et al, 1978). In subjects with impaired 
renal function the half-life has been shown to increase and half-lives 
of up to 14 hours have been observed (Rupp et al, 1971; Tilstone and 
Fine, 1978). 
COOH COOH 
NHCH -01 I 2 o 
Cl Cl 
Frusemide Saluramine 
Blood sampling 
In addition to the normal blood sampling procedure, blood samples 
(1 ml) were withdrawn also from a femoral vein at predose 6.5 hours and 
24 hours and dispensed into non-heparinised tubes. These samples were 
assayed for sodium and potassium levels by flame photometry. 
Measurement of concentrations of frusemide in plasma 
Plasma concentrations of frusemide were assayed by the spectrophoto-
fluorimetric method of Hajdu and Haussler (1964) • Plasma (1 m1) was 
acidified with concentrated hydrochloric acid (lOO ~1) and shaken with 
redistilled diethyl ether (6 ml) for 5 minutes using a mechanical 
shaker (Griffin and George, London, UK). After centrifugation, the 
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ether phase (4 ml) was transferred to a pointed centrifuge tube and 
evaporated to dryness under a stream of nitrogen at 35°c. The residue 
was redissolved in hydrochloric acid (2 ml, 0.02M) and the fluorescence 
of the acid solution was measured in an Aminco Bowman spectrophoto-
fluorimeter at excitation and emission wave-lengths of 275 nm and 
415 nm respectively. The fluorimeter was calibrated using a standard 
solution of frusemide 40 lJg/ml in 0.02M hydrochloric'acid and reference 
standards of frusemide in control non-human primate plasma in the 
range 2-60 lJg/ml were taken through the analysis procedure with each 
group of 'test' plasma samples. Quantitation of plasma levels of 
frusemide was achieved by comparison of 'test' plasma samples to a 
calibration curve constructed from the reference plasma standards. 
TABLE 5:1 
Method parameters for the measurement of concentrations of frusemide 
in plasma. 
Linear range 2-60 \lg/ml 
Calibration linea Y = 1.5400X + 3.3204 
Accuracy ~ 6% at 60 \lg/ml and+ 52% at.5\lg/ml 
Precision + 8.8% at 20 lJg/ml 
+ 11.2% at 5 \lg/ml 
Recovery 95% + 2.7 SD 
Sensitivity 2.0 \lg/ml 
------------------------------- -------------------------------------------
a Least squares regression line where Y = % fluorescence and 
X = concentration of frusemide in plasma. 
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Measurement of concentrations of sodium and potassium in serum. 
Using an IL 343 Flame Photometer. Sertim concentrations of sodium and 
potassium in the rhesus monkeys were measured using an IL 343 flame 
photometer (Instrumentation Labs., Altrincham, Cheshire, UK). Serum 
was diluted automatically (1: 200 v/v) with distilled water containing 
lithium (150 mEq/litre) as internal standard. The aspiration rate of 
the diluted sample was 1.5 ml/minute and the instrument was calibrated 
using standard solutions containing 140 mEg/litre of sodium and 
5.0 mEg/litre of potassium. 
Using a Technicon SMA 12/60. Concentrations of sodium and potassium 
in serum of the cynomolgus monkey and the baboon were determined using 
a Technicon SMA 12/60 (Technicon Instruments Cc. Ltd., Basingstoke,UK). 
Serum was analysed on this instrument also by flame photometry using 
lithium (150 mEq/litre in water) as internal standard. The sample 
size was 350 ~l for a full profile of 10 tests, two of which were 
for sodium and potassium. The instrument was calibrated using serum 
(Wellcome Reagent Ltd., Beckenham, Kent) of known sodium and potassium 
concentrations. 
The author is grateful to the members of the department of 
Clinical Pathology for the use of their equipment and for analysing 
the serum sodium and potassium concentrations. 
Results 
Plasma concentrations. After a single intravenous injection of frusemide 
at a level of 3.0 mg/kg,peak mean plasma concentrations of frusemide 
(31.6 ~g/ml ~ 3.2 SD, 33.6 ~g/ml ~ l.l SD.and 43.6 ~g/ml ~ 5.5 SD in 
the rhesus monkey, the cynomolgus monkey and the baboon respectively) 
were reached at 2 minutes post administration (the first time of blood 
withdrawal). After an apparent rapid distribution phase, mean plasma 
concentrations declined with an apparent half-life of elimination of 
- 78 -
approximately 20 minutes, to almost the limit of detection (2~g/ml) at 
1-1.5 hours after administration (Table 5:3, Figures 5:1- 5:3). Results 
of sodium and potassium analysis (Table 5:2) at 6.5 hours and 24 hours 
post-administration.showed that with respect to these ions, serum levels 
were similar at those times after administration to those before dosing. 
Pharmacokinetic parameters. Observed plasma concentrations of frusemide 
following a single intravenous injection of frusemide at a level of 
3.0 mg/kg were fitted by a biexponential equation (Equation 2:2) but 
the distribution 'oc' phase was very short (<10 minutes) in all three 
species, and in the rhesus monkey only the first sample taken after 
dosing did not fit a log-linear regression of the data. However, the non-
linear least squares curve fitting programme BLUO does not allow the 
independent selection of a pharmacokinetic model and so the parameters 
shown in Table 5:4 were calculated using equations 2:3 - 2:12 for a 
two-compartment open model with elimination from the central compart-
ment (Scheme-2:2). Plasma concentrations of frusemide predicted by 
the two-compartment model were generally in good agreement with the 
observed values (Figures 5:1 - 5:3). However, the distribution phase, 
if any, was so rapid, pharmacokinetic parameters were also estimated 
assuming a one-compartment open model (Table 5:5). Nevertheless, data 
for the two-compartment open model are presented also, for comparison 
with that published in the literature for man and many animal species. 
Comparison of Tables 5:4 and 5:5 shows that there were no notable 
differences in the parameters calculated assuming either of the two 
models except perhaps in 'Kel' the elimination rate constant. 
The mean areas under the plasma concentration-time curves were 
13 ~g/ml/hour ~ 4 so, 18 ~g/ml/hour ~ 5 so and 14 ~g/ml/hour ~ 2 SD 
for the rhesus monkey, the cynomolgous monkey and the baboon respectively. 
Analysis of variance showed that the areas under the curves for the 
cynomolgous monkey were significantly higher than in the other two 
species (P<O.OS Newman Keuls multiple comparison procedure) .• There 
was no significant difference (P< 0.05) between the rhesus monkey 
and the baboon. 
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The mean total volume of distribution at steady state was 
similar for the rhesus monkey and the cynomolgus monkey accounting 
for 10.6% and 11.4% of the.total bodyweight respectively. However, 
although the mean total volume of distribution in the baboon (8.7% 
of the total bodyweight) was not significantly different from that 
for the rhesus monkey (P >o.os Newman-Keuls multiple comparison 
procedure) it was significantly different from that for the cyno-
molgus monkey (P <0.05). It is doubtful that this difference has 
any physiological importance as the volume difference is so small. 
The mean apparent volume of distribution of frusemide in these 
non-human primates is equivalent to 2-3 times the plasma volume 
and· is simtlar to data from man (6. 9-21% ·of bodyweight, Benet·, 
1979), the rat (16% of bodyweight, Wallin et al, 1977) and the dog 
(ll% of bodyweight, Data et al, 1978). This restricted distribution 
volume is probably related to a high degree of plasma-protein 
binding, 96-98% in man, Beerman and Groschinsky-Grind, 1980. 
Adopting a two-compartment model, the mean volume of the 
central compartment was of the same order of magnitude as that of 
the peripheral compartment in each species (Table 5:4). The 
compartment volume ratio (central:peripheral)was 1.5, 1.0 and 1.5 in 
the rhesus monkey, the cynomolgus monkey and the baboon respectively 
indicating that there was some, but not extensive distribution into 
the peripheral compartment. This is also implied by the similarity 
of the volume of distribution estimated after attainment of pseudo-
distribution equilibrium Vd~) to that of the volume of distribution 
at steady state Vd(ss) (Table 5:4). 
Analysis of variance showed that the clearance of frusemide in 
the cynomolgus monkey was significantly lower than that from the 
other two species (P <o.Ol Newman-Keuls multiple comparison procedure). 
When adjusted for differences in bodyweight the adjusted clearance of 
frusemide was 4.0 ml/minute/kg, 2.9 ml/minute/kg and 3.7 ml/minute/kg 
in the rhesus monkey, the cynomolgus monkey and the baboon, respectively. 
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Analysis of variance of adjusted clearances showed that the cynomolgus 
monkey remained significantly different from the rhesus monkey (P< 0.05 
Newman-Keuls multiple comparison procedure) but was not significantly 
different from that in the baboon (P> o.o5).with respect to this parameter. 
The mean rate constant for the rapid distributional phase 
(Table 5:4) for a two-compartment model corresponded to an apparent 
half-life of 1.5 minutes, 1.7 minutes and 3.0 minutes for the rhesus 
monkey, the cynomolgus monkey and the baboon, respectively. The mean 
biological half-life of frusemide in the baboon 15 minutes + 15 SD 
was significantly shorter(P < 0.01 Newman Keuls multiple comparison 
procedure) than in the cynomolgus monkey but not from that in the 
rhesus monkey (P. > 0.05). 
Adopting a two-compartment open model the mean ratio S/K of 
0.45,0.45 and 0.53 for the rhesus monkey, the cynomolgus monke¥1and 
thebaboon respectively, indicates that these fractions of frusemide 
in the body were in the central compartment and were available for 
elimination at any time after distribution equilibrium (Gibaldi et 
al, 1969). 
Simulation of the plasma concentration time profile of frusemide 
in the peripheral compartment for a two-compartment open model with 
pharmacokinetic parameters shown in Table 5:4, showed that following 
intravenous administration, equilibrium between the central and 
peripheral compartments was rapidly achieved, peak concentrations 
of 23.9 ~g/ml, 20 ~g/ml and 18.3 ~g/ml for the rhesus monkey, the 
cynomolgus monkey and the baboon occurring 5-10 minutes after injection 
(Table 5:5, Figures5:1- 5:3). Concentrations of frusemide in the 
central and peripheral compartments were similar at all times after 
distribution was complete. 
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Discussion 
For man the decline of plasma concentrations of frusemide has 
been described by a tri-exponential equation (Rupp and Hajdu, 1970) 
but more generally frusemide kinetics .appear· to be described in terms 
of two-compartment kinetics (Kelly et al, 1974: Beermann et al, 1975: 
Andreasen et al, 1978: Andreasen and Mikkelsen, 1977: Tilstone and 
Fine, 1978} and occasionally in terms of a single-compartment-open 
model (Cutler et al, 1976}. In animals also the disposition of 
frusemide has been described in terms of single and multicompartment 
models (Wallin et al, 1976; Data et al, 1978; Yakatan et al, 1979}. 
In non-human primates the distribution phase, if any, was 
short and pharmacokinetic parameters estimated for a one-compartment 
open model were not notably different from those estimated for a two-
compartment open model, except, .Perhaps in 'Kel'. Yak!\tan et al 
(1979} assumed one-compartment kinetics to describe the disposition 
of frusemide in the rhesus monkey after oral administration. In this 
study, the distributional phase A/a, contributed 15, 28 and 25% to 
the total area under the plasma concentration-time curve in the rhesus 
monkey, the cynomolgus monkey and the baboon respectively, indicating 
that distribution into the tissues is a feature of frusemide disposition. 
However, these values are possibly biased by rather high predictions 
of the zero time intercept of the a phase. 
Values of the systemic clearance of frusemide in animals reported 
in the literature are variable. Yakatan et al (1979} reported a value 
of 43 ml/minute for the dog and 38 ml/minute for the rhesus monkey, but 
Data et al (1978} reported a very high value of 246 ml/minute. The 
systemic clearance uf frusemide in the rat is quoted as 1.74 ml/minute 
(Wallin et al, 1976} and in man frusemide clearance has been reported 
to range from 112 ml/minute (Tilstone and Fine, 1978} to 268 ml/minute 
Homeida et al, 1977} with an average value of 165 ml/minute. With 
respect to the systemic clearance of frusemide, therefore, the non-
human primate is closer to man (Cl = 2.4 ml/minute/kg bodyweight} than 
are the other commonly used laboratory animal species. 
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In general, the apparent half-life of elimination of frusemide 
from plasma appears to be shorter when estimated by spectrofluori-
metric procedures than when assayed by procedures involving chroma-
tography. For man, average values are 44 minutes and 58 minutes when 
estimated by these procedures respectively, (Benet, 1979) and the range 
of values is represented by a half-life value of 26 minutes using a 
spectrofluorimetric assay (Kelly et al, 1974) and a half-life value 
of 72 minutes using a spectrofluorimetric method following a thin 
layer chromatographic separation (Andreason and Mikkelsen, 1977) • The 
half-life of frusemide in the dog and the rat, 22 minutes using 
high pressure liquid chromatography and 25 minutes using 35s-frusemide 
respectively (Data et al, 1978; Wallin et al, 1976) are closer to 
those in the non-human primate species than to that in humans. 
Yakatan et al (1979) using 35s-frusemide observed a slow 
elimination phase with a half-life of approximately 7 hours in the 
dog, but this value was obtained by fitting a three exponential 
equation to the plasma concentration time curve and the terminal 
phase was not observed until plasma concentrations were less than 
0.2 ~g/ml. The major portion of the disposition curve had a half-
life of approximately 30 minutes, similar to that found by Data et al, 
(1978). In the rhesus monkey, Yakatan et al (1979) reported a half-
life of ll hours for frusemide after an oral dose of 5 mg/kg ~f 
35
s-frusemide. However, this half-life value might not be typical 
as the data was obtained from a group of animals and a complete 
concentration-time profile was not obtained in any one animal. 
Distribution studies of 35s-frusemide in animals {Seno et al, 
1969; Yakatan et al, 1979) and in humans (Calesnick et al, 1966; Beer-
mann et al, 1975) indicate that frusemide might be sequestered 
somewhere in the body and accumulate during the once-daily dosing 
regime common to most chronic toxicity studies. However, the major 
portion of the dose has a short half-life in plasma and approximately 
80% of the administered dose is excreted in the first 24 hours. 
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There is no evidence, from this study, to suggest that frusemide 
would accumulate in the body of the non-human primate during a once-
daily dosing regimen. In man, also, receiving a normal daily dose of 
frusemide (80 mg once daily) for the treatment of oedema in congestive 
heart failure, for example, it is unlikely that frusemide would 
accumulate in the body. However, an average steady state plasma 
concentration of frusemide of approximately 0.4 ~g/ml would be maintained 
with such a regimen. To establish this same steady state plasma concen-
tration of frusemide in non-human primate species it would require the 
administration of frusemide 0.2 mg intravenously every 26 minutes to 
rhesus monkeys, 0.1 mg intravenously every 28 minutes to cynomolgus 
monkeys and O.l mg intravenously every 14 minutes to baboons, or 
alternatively, the intravenous administration of a total of 11.1 mg, 
5.1 mg and 10.3 mg daily to the respective species, given in equal 
amounts at intervals of approximately seven half-lives. 
Comparison of the relatively small extent of metabolism of 
frusemide in different animal species would not provide the best 
criteria for the selection of a suitable species for chronic toxicity 
studies of this drug, but rather a comparison of the drug's pharmaco-
kinetics would be more appropriate. However, when selecting a species 
for study, due allowance should be made for the reported hepatotoxicity 
and nephrotoxicity at high dose levels in rodents (Mitchell and Jollow, 
1975) • Using pharmacokinetic criteria therefore, the fate of frusemide 
in humans (Benet et al, 1979) is more closely reflected by that in the 
cynomolgus monkey after intravenous injection than by that in the 
rhesus monkey, the baboon or other laboratory animal species (Wallin et al, 
1976; Data et al, 1978), however, this might not be true after oral 
administration (Yakatan et al, 1979). As frusemide is known to be 
incompletely absorbed from the G. I. tract it would be advisable to 
monitor changes in frusemide pharmacokinetics that might be produced 
bY changes,in the rate and extent of absorption. 
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TABLE 5:2 
Mean serum sodium and potassium levels (~SD) in rhesus monkeys, 
cynomolgus monkeys and baboons before and after injection of frusemide 
3.0 mg/kg. 
a 
b 
Sodium 
Time 
a Rhesus monkey 
--~2~~!~~---------­
b Cynomolgus monkey b Baboon 
Predose 145 + 1.3 146 + 2.6 146 + 3.4 
6.5 hour 139 + 2.9 143 + 1.9 143 + 3.9 
24 hour 145 + 2.7 144 + 1.9 145 + 1.9 
Potassium 
Time 
Predose 
6.5 hour·· 
24 hour: 
Normal range 
4.0 + 0.3 
4.0 + 0.1 
4.0 + 0.3 
4.9 + 0.3 
5.0 + 0.9 
5.1 + 0.9 
sodium 136 - 159 mEq/litre 
potassium 3.4 - 5.4 mEq/litre 
Normal range sodium 137-155 mEq/litre 
potassium 3.7- 5.5 mEq/litre 
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5.4 + 0.6 
4.9 + 0.3 
5.2 + 0.2 
TABLE 5:3 
Mean concentrations (~ SD) of frusemide in the plasma of the rhesus monkey, 
the cynomolgus monkey and the baboon after a single bolus intravenous 
injection of frusemide at a level of 3.0 mg/kg. Results are expressed in 
\lg/ml. 
--------------------- --------------------------------------------------------
Time Rhesus monkey Cynomolgus monkey Baboon 
2 minute: 31.6 ~ 3.2 33.6 + 1.1 43.6 ~ 5.5 
5 minute. 21.8 ~ 5.3 26.4 + 3.0 29.6 + 1.2 
10 minute. 17.4 + 4.0 19.4 + 3.6 21.6 ~ 2.1 
20 minute. 11.4 + 3.0 16.2 + 2.8 13.4 + 2.1 
40 minute. 5.2 + 2.7 9.2 + 3.4 4.0 ~ 1.0 
1 hour 3.4 + 1.1 5.0 + 2.2 ND 
1.5 hour ND 2.6 + 0.9 ND 
2 hour ND ND 
-------------------- ----------------- --------------------------------------
ND Less than the limit of detection (2.0 IJg/ml) 
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TABLE 5:4 
Mean ph~rm~cokinetic p~rameters (~ SD) determined for ~ two-comp~rtment 
open model; ~fter bolus intravenous injection of frusemide 3.0 mg/kg in 
the rhesus monkey, the cynomolgus monkey ~nd the b~oon. The d~t~ are 
prEsented as means of results from individual animals. 
----------------------- -------------------------------------------------------
a Parameter ------------------------~2~~!~~------------------------Rhesus monkey Cynomolgus monkey B~oon 
----------------------- ---------------- ------------------- ------------------
Bodyweight(kg) 4.7 + 0.8 3.5 ~ 0.4 5.7 + 0.9 
Dose (mg) 14.0 + 2.7 10.4 + 0.9 17.1 + 2.7 
Dose (mg/kg) 3.0 + 0.1 3.0 + 0.1 3.0 + 0.0 
A (JJg/ml) 
B (JJg/ml) 
-1 
<X (hour ) 
-1 
~ (hour ) 
-1 
Kl2 (minute ) 
-1 
K2l (minute ) 
-1 
Kel (minute ) 
AUC (JJg/ml/hour) 
Cl (ml/minute) 
~ (minutes) 
vl (litres) 
v2 (litres) 
vd(ss) (litres) 
vd < l (litres) 
A,6< ~ (JJg/ml/hour) 
B/~ (JJg/ml/hour) 
-----------------------
35 + 14 
22 + 4 
26.978 + 18.701 
2.090 + 0.607 
0.213 + 0.187 
0.194 + 0.120 
0.078 + 0.028 
13 + 4 
19 + 4 
22 + 8 
0.3 + 0.1 
0.2 + 0.0 
0.5 + 0.1 
0.6 + 0.1 
2 + 2 
11 + 3 
31 + 17 
24 + 4 
24.320 + 20.953 
1. 436 + o. 642 
0.191 + 0.209 
o.l85 + o.l36 
0.053 + 0.034 
1s + 5b 
10 + 4b 
29 + 9C 
0.2 + 0.1 
0.2 + 0.1 
0.4 + 0.1 
0.4 + 0.2 
5 + 8 
16 + 3 
48 + 24 
31 + 6 
13.991 + 13.263 
2.753 + 0.565 
0.075 + 0.114 
0.110 + 0.100 
0.085 + 0.046 
14 + 2 
21 + 3 
15 + 4 
0.3 + 0.1 
0.2 + 0.2 
0.5 + 0.2 
0.5 + 0.1 
4 + 5 
11 + 2 
a For details of ~breviations, see Chapter 2. 
b Significance level (analysis of variance) cynomolgus monkey compared to the 
other two species (P <0.05). 
c Significance level (analysis of variance) cynomolgus monkey compared to the 
b~oon (P<O.Ol). 
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TABLE 5:5 
Pharmacokinetic parameters of frusemide in the rhesus monkey, the 
cynomolgus monkey and the baboon for a one-compartment open model 
compared to those for a two-compartment open model following a 
single intravenous injection of frusemide (3.0mg/kg). The data are 
presented as means of results from individual animals. 
Model and Species 
Parameter a One-compartment Two-compartment 
-------------------
------- ------
------------
------
Rhesus Cynomolgus Baboon Rhesus Cynomolgus Baboon 
monkey monkey monkey monkey 
------------------
-------
-----------
------- ------
------------
------
AUC()Jg/ml/hour) 14.1 l8b 12.4 l3 18b 14 
Cl (ml/minute) 18.5 lOb 23.5 19 lOb 21 
t~, (minutes) 26 28c 14 22 29° 15 
vd (litres) o. 7 0.4 0.5 o. 5 0.4 0.5 
-1 0.026 0.026 0.050 0.078 0.053 0.085 Kel (minute ) 
-------------------
-------
-----------
------- ------
------------
------
a For details of abbreviations, see Chapter 2. 
b Significance lecel (analysis of variance) cynomolgus monkey 
to the other two species (P< 0.05). 
compared 
c Significance level (analysis of variance) cynomolgus monkey compared 
to the baboon (P< 0.01). 
vd ~otal volume of distributes =Vd(ss) for the two-compartment model. 
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TABLE 5:6 
Calculated concentrations of frusemide in the peripheral compartment 
after bolus intravenous injection of frusemide 3.0 mg/kg to non-
human primates. Results calculated from mean data and expressed as 
\lg:/ml. 
------------------ --------------------------------------------------------
-~2~~~~~-----------------------------Time 
Rhesus monkey Cynomolgus monkey Baboon 
------------------ ----------------- ------------------- -----------------
2 minute· 16.2 12.4 9.0 
5 minute 23.9 16.9 16.3 
10 minute 22.6 20.0 18.3 
20 minute 16.4 16.2 13.6 
40 minute 8.1 10.1 5.5 
60 minute 4.0 6.2 2.3 
90 minute 1.4 3.0 
------------------ ----------------- ------------------- -----------------
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FIGURE 5:1 
liO 
40 
l 2 3 
Time {Hours) 
Mean concentration-time curves a,fter a single intravenous injection 
of frusemide (3.0 mg/kg) to rhesus monkeys. Observed concentrations 
in the central compartment • • ), estimated concentrations 
in the central compartment (solid line) and in the peripheral 
compartment ( 11 • ) . 
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FIGURE 5:2 
lOO. 
so 
40 
30 
• 
l 2 
Time (Hours) 
Mean concentration-time curves after a single intravenous injection of 
frusemide (3.0 mg/kg) to cynomolgus monkeys. Observed concentrations 
in the central compartment • • ), estimated concentrations 
in the central compartment (solid line) and in the peripheral corn-
partment ( 11 11 ) . 
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FIGURE 5:3 
1 
50 
40 
30 
20 
1 2 
Time {Hours) 
Mean concentration-time curves after a single_intravenous injection 
of frusemide (3.0 mg/kg) to baboons. Observed concentrations in the 
central compartment • • ), estimated concentrations in the 
central compartment (solid line) and in the peripheral compartment 
• • ) . 
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CHAPTER 6 
ISOSORBIDE DINITRATE 
Introduction 
Isosorbide dinitrate (1,4:3,6-dianhydrosorbitol-2,5-dinitrate) 
is an organic nitrate antianginal agent (for reviews see Needleman, 
1975; Rudolph and Siegenthaler, 1976; Rudolph and Schrey, 1980) with a 
high hepatic extraction ratio (Needleman et al, 1972). 
This lipophilic drug is almost completely eliminated by bio-
transformation being rapidly denitrated (Johnson et al, 1972; Needleman 
et al, 1972) by glutathione-S-transferases (Keen et al, 1976). The 
urinary metabolites of isosorbide dinitrate in animals (Dietz, 1967; 
Ree.d et al, 1971; Sisenwine and Ruelius, 1971; Rosseel and Bogeart, 
1973) and humans (Down et al, 1974; Down and Chasseaud, 1980) are 
the corresponding isomeric mononitrates (1,4:3,6-dianhydrosorbitol-
2-hydroxy-5-nitrate and 1, 4:3,6 - .dianhydrosorbitol-5-hydroxy-2-nitrate) 
and isosorbide which are excreted free and probably partly conjugated 
with glucuronic acid. Sorbitol has also been shown to be a urinary 
metabolite of isosorbide dinitrate in humans (Down et al, 1974). 
There has been little reported regarding the pharmacokinetics of 
the drug, probably due to the difficulty in measuring low concentrations 
in plasma, and most of the early data has been obtained using 14c-isosorbide 
dinitrate. The recent development of adequately sensitive analytical 
methods has now permitted studies of the pharmacokinetics of isosorbide 
dinitrate in humans (e.g. Assinder et al, 1977; Chasseaud and Taylor, 
1980; Taylor et al, 1980). 
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ONOz 
isosorbide dinitrate 
2-isosorbide mononitrate 
sorbitol OH 
0-gluc 
OH 
5-isosorbide mononitrate 
.., 
0-gluc 
isosorbide mononitrate 
glucuronide 
isosorbide glucuronide 
Scheme 6:1 Possible biotransformation of isosorbide dinitrate in 
humans (glue represents glucuronic acid). 
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Measurement of concentrations of isosorbide dinitrate in plasma 
Concentrations of isosorbide dinitrate in plasma were m7asured 
by means of a gas chromatographic method using electron capture 
detection (Doyle et al, 1980 } " Samples of plasma were assayed 
according to one of three different procedures depending on con-
centration of isosorbide dinitrateo These procedures covered the_ 
concentration ranges 1 - 10 ng/ml, 10-250 ng/ml and 100-1000 ng/mlo 
Range 1-10 ng/mlo Plasma (1 ml} was mixed with internal standard 
(glyceryl trinitrate 5 ng, 5 ~1 of a 1 ~g/ml solution in ethyl 
acetate} and extracted with freshly redistilled petroleum spirit (B.P. <48°C) 
(10 ml) by shaking the mixture using a mechanical shaker (Griffin and 
George, London U.Ko} for 15 minutes. After centrifugation, the 
organic phase (9 ml} was transferred to a pointed centrifuge tube and 
evaporated to a volume of approximately 50~1 under a stream of 
nitrogen at 35°c. Portions of the residual solution (1-2 ~1) were 
injected into the gas chromatograph. 
Range l0-250 ng/ml. Plasma (0.2 ml) was mixed with internal standard 
(glyceryl trinitrate 25 ng, 5~1 of a 5~g/ml solution in ethyl acetate) 
and extracted with petroleum spirit (5 ml} by shaking the mixture 
mechanically for 15 minutes. After centrifugation the organic phase 
(4 ml) was transferred to a pointed centrifuge tube and evaporated 
to an approximate volume of 200~1 under a stream of nitrogen, at 35°C. 
Portions of the residual solution (1-2 ~1} were injected into the gas 
chromatograph. 
Range 100-lOOOng/ml. Plasma (0.1 ml} was mixed with internal standard 
(glyceryl trinitrate, 50 ng, 10~1 of a S~g/ml solution in ethyl acetate) 
and extracted with petroleum spirit (2 ml) by shaking on ~ rotary 
shaker (Fisons Scientific Apparatus Ltd., Loughborough Leicestershire, 
U.K.) for 2 minutes. After centrifugation, the organic phase 1.5 ml 
was transferred to a pointed centrifuge tube and evaporated to an 
approximate volume of 0.4 ml. Portions of the residual solution 
(1-2 ~1) were injected into the gas chromatograph. 
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After extraction, all residues were kept at -20°C to avoid the 
formation of large unidentified peaks that interfered with the 
assay. 
The gas chromatographic column was glass 1.83 m x 2 mm i.d. 
packed in the 3.5% QFl on gas chrom Q 60-80 mesh (Phase Separations 
Limited, Queensferry, Clwyd, U.K.). The injection port temperature 
was 150°C, the detector temperature was 180°C and the oven temp-
o 
erature was 120 c. The carrier gas was oxygen free nitrogen at a 
flow rate of 60 ml/minute. 
TABLE 6:1 
Method parameters for the measurement concentrations of isosorbide 
dinitrate in plasma. 
------------------- ----------------- -------------------------------------
Parameter/Range 1-10 mg/ml 10-250 mg/ml 100-1000 mg/ml 
------------------ ----------------- ----------------- ------------------
Calibration linea Y~(0.0790~.00ll) Y=0.0031X-0.0275 
Accuracy ± lOO% at lng/ml + 6% at 25ong/ml 
± 10% at 10 ng/ml 
Precision ± 8% at 10 ng/ml + 5% at 250 !lg/ml 
Sensitivity 0.5 ng/ml 
Recovery of 
glyceryl tri- 90%+4 at Sng/ml 91%+3 at 125ng/ml 
nitrate (± SD) 
Recovery of 
isosorbide di- 90%+2 90%+4 
nitrate (± SD) 
Y=O.OC06X-0.0652 
+ 18% at lOocng/ml 
+2.4% at ·looong/ml 
91%+3 at 50Qngjml 
83%+4 
------------------ ----------------- ----------------- ------------------
a Least squares regression time where Y ~ 
( ak h . ght rat. isosorbide dinitrate) 
pe e~ ~0 glyceryl trinitrate· 
concentration of isosorbide dinitrate. 
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instrument response 
and X = plasma 
Results 
Plasma concentrations. After a single intravenous injection of 
isosorbide dinitrate at a level. of 1.0 mgjkg mean plasma concentrations 
at the first time of blood withdrawal (2 minutes after injection) were 
similar for the rhesus monkey and the cynomolgus monkey, 565 ng/ml 
+ 6650 and 586 ng/ml ~ 4350 respectively. In the baboon at the 
first time of blood withdrawal (2 minutes after injection) mean plasma 
concentrations of isosorbide dinitrate (1572 ng/ml ~ 25350) were 
approximately three-fold higher than in the other two species. In the 
cynomolgus monkey and the baboon, after an initial short distribution 
phase, mean plasma concentrations declined with an apparent half-life 
of elimination of about 25 minutes (Table 6:2, Figures 6:1 - 6:3) to 
almost the limit of detection ( < l.O ng/ml) at 4 hours after admin-
istration. In the rhesus monkey the distribution phase was slightly 
longer than in the other two species and the apparent half-life of 
elimination was also longer (about 60 minutes~. Isosorbide dinitrate 
was still detectable in the plasma of the rhesus monkey (lOng/ml) 
4.5 hours after injection (the last time of blood withdrawal). 
Pharmacokinetic parameters. Observed plasma concentrations of isosorbide 
dinitrate were adequately described by a biexponential equation (equation 
2:2). The pharmacokinetic parameters shown in Table 6:3 were, therefore, 
calculated using equations 2:3 - 2.12 for a two-compartment open model 
with elimination from the central compartment (scheme 2:2). Plasma 
concentrations of isosorbide dinitrate predicted by the two-compartment 
model were generally in good agreement with the observed values 
(Figures 6:1- 6:3). However, since the distribution phase was short1 
the pharmacokinetic parameters were also calculated usin9 a one-compartment 
open model (equation 2:1). There were no notable differences in para-
meters calculated assuming a one-compartment model (equations 1:1, 2:4, 
2:13, 2:14) from those for the two-compartment model except in Kel the 
elimination rate constant (Table 6:4). However, Kel obtained for a one-
compartment open model is almost identical to S calculated for a two-
compartment open model. 
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Analysis of variance of areas under the plasma concentration 
time curves showed that in respect of this parameter the cynomolgus 
monkey was significantly different from that for the other two species 
(P <0.01 Newman-Keuls multiple comparison procedure) and that the 
rhesus monkey was significantly different from that for the baboon 
(P < 0.05 Newman-Keuls multiple comparison procedure). 
Analysis of variance of volumes of distribution and of apparent 
half-lives of elimination showed, also, that the volume of distribution 
was significantly larger, and that the half-life was significantly 
longer in the rhesus monkey than in the other two species (P < 0.001 
Newman-Keuls multiple comparison procedure). However, analysis of 
variance of clearances of isosorbide dinitrate showed that in this 
respect these species of non-human primate were similar (P> 0.05 
Newman-Keuls multiple comparison procedure). 
The mean total volume of distribution varied between species 
and was equivalent to 273, 168 and 84% of the total bodyweight in the 
rhesus monkey, the cynomolgus monkey and the baboon respectively. The 
largervalues found in the rhesus monkey and the cynomolgus monkey are 
surprising as isosorbide dinitrate does not strongly bind to proteins. 
However, these observations could be explained by a rapid uptake of the 
drug into tissue. In the baboon the volume of distribution was not 
too dissimilar from the probable body water volume. Adopting the two-
compartment model, the mean volume of the central compartment was 
larger than that of the peripheral compartment. In these non-human 
primates the compartment volume ratio (central:peripheral) was 1.2, 
3.1 and 1.6 for the rhesus monkey, the cynomolgus monkey and the baboon 
respectively, indicating that there was relatively free transfer of 
isosorbide dinitrate between the two compartments. 
The total volume of distribution,estimated after attainment of a 
pseudo-distribution equilibrium multiplied by the plasma concentration, 
indicates that only 53, 41 and 59% of the administered drug remained in 
the body of the rhesus monkey, the cynomolgus monkey and the baboon 
respectively at 45 minutes, 30 minutes and 15 minutes respectively. 
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The mean ratio S/Kel of 0.43, 0.63 and 0.51 for the rhesus 
monkey, the cynomolgus monkey. and the baboon respectively, indicates 
that these fractions of isosorbide dinitrate in the body were in the 
central compartment and were available for elimination during the 
terminal linear phase of·the disposition curve (Gibaldi et al, 1969). 
Simulation of the plasma concentration-time profile of isosorbide 
dinitrate in the peripheral compartment of a two-compartment open model 
with pharmacokinetic parameters shown in Table 6:3 showed that equilibrium 
between the central and peripheral compartments was rapidly achieved. 
Peak concentrations of isosorbide dinitrate in the peripheral compart-
ment (258 ng/ml, 394 ng/ml and 727 ng/ml) in the rhesus monkey, the 
cynomolgus monkey and the baboon respectively, occurred 10-30 minutes 
after injection. Thereafter concentrations of isosorbide dinitrate 
were similar in both compartments (Table 6:5, Figures 6:1- 6:3). 
Discussion 
There has been little reported regarding the pharmacokinetics of 
isosorbide dinitrate in animals. This is probably due, in part, to 
the lack of a suitable analytical method for the assay of this drug. 
However, the decline of isosorbide dinitrate concentrations in the 
plasma of the dog (Sisenwine and Ruelius,l971) and man (Assinder et al, 
1977; Chasseaud and Taylor; l980a; Taylor et al, 1980) appears to fit 
a one-compartment open model but in the rat (Needleman et al,l972) a 
two-compartment model appears to be more appropriate. In the non-
human primate, although a two-compartment open model seemed suitable, 
a one-compartment model could also be applied without introducing any 
important differences in cthe parameter 'estimates, _exc_ept possibly in Ke1 • 
In each species there was at least three mean values (n = 5) describing 
the distribution phase and the contribution of this phase 'A/~' to 
the total area under the plasma concentration time curve was 14, 15 
and 18% in the rhesus monkey, the cynomolgus monkey and the baboon 
respectively. This indicates that the distribution phase of isosorbide 
dinitrate, albeit short, should be considered in a pharmacokinetic 
analysis of the drug. 
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Although clearance of isosorbide dinitrate by enzymes in the 
intestinal mucosa might take place after oral administration, after 
intravenous administration the total systemic clearance can probably be 
regarded as representing hepatic clearance. In rhesus monkeys, the 
systemic clearance of isosorbide dinitrate was similar to but less 
than that of the reported hepatic blood flow of 50 ml/minute/kg in 
this species (Branch et al, 1973) as might be expected for a drug of high 
hepatic extraction ratio such as isosorbidedinitrate (Needleman et al, 
1972). By contrast the systemic clearance of isosorbide dinitrate in 
humans appears to be about ten-fold lower than hepatic blood flow 
(Taylor et al, 1980). Despite this species difference in clearance, 
the drug is subjected to an extensive first-pass effect in both non-
human primates and man (unpublished data, cited in Doyle and Chasseaud, 
1981; Taylor et al, 1980) as it is in rats also (Needleman et al, 1972). 
Adopting a two-compartment model, the mean rate constant for 
the rapid distribution phase corresponded to an apparent half-life 
of 5.8 minutes, 4.1 minutes, and 3.2 minutes in the rhesus monkey, the 
cynomolgus monkey and the baboon respectively. These values are 
similar to those values previously reported for the elimination half-
life of isosorbide dinitrate in man (9 minutes; Taylor et al, 1980)1 in 
the dog (7 minutes; Sisenwine and Ruelius, 1971) and in the rat 
( <l minute; Needleman et al, 1972). The latter value for the rat 
has been disputed by Reed et al (1977) who claimed that it only rep-
resented a tissue distribution phase. The mean terminal phase of the 
log - linear plot of concentrations of isosorbide dinitrate in plasma 
e 
against time, for the rhesus monkey corresponded to an apparent half-life 
of elimination of 62 minutes and was longer than that for the other two 
species (23 minutes and 24 minutes in the cynomolgus monkey and the baboon 
respectively). These latter values are similar to the plasma terminal half-
life previously found after oral administration to man (Assinder et al, 
1\C. 0 1 • ,__. :t977a; 1977b; .. Chas.seaud_ et al,, l980c)... and now sp.owr~o be associated with \"\()<Cf<'.'~•mV.~"'J1(.'1N__ eWMI.,W~~vC.Ii~<tV.C.,. <\- !PG~'(,\, ;..\a et'\."'~""""- ~ ruoc~llb.\ b'<;\ 
the absorption of the arug. a "flip-flop"meeh~m" ( aylor et al, 1980). 
'('Vte - • 
The longer half-lives observed in these non-human primates might be 
explained by the deposition of some of the administered dose into a deep 
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(poorly perfused) compartment from which it is reabsorbed back into 
the central compartment. Indeed there have been previous reports of 
isosorbide dinitrate and a related compound, glyceryl trinitrate, 
apparently diffusing back into the blood from the peripheral 
compartment (Johnson et al, 1972; Bogeart et al, 1970). However, in 
humans receiving a four-times daily oral dose of 10 mg of isosorbide 
dinitrate for prophylactic treatment of angina, isosorbide dinitrate 
might accumulate due to a slow rate of absorption of the drug. To 
maintain a steady state plasma concentration of isosorbide dinitrate 
in non-human primate species of approximately 1 ng/ml it would be 
necessary to administer this drug intravenously 11.6 ~g every 
62 minutes to the rhesus monkey, 4.6 ~g every 23 minutes to the 
cynomolgus monkey and 4.1 ~g every 24 minutes to the baboon. 
These considerations apply to isosorbide dinitrate given intra-
venously. If given orally, it would be necessary to compensate for 
losses due to first pass metabolism (approximately 2% bioavailability; 
Doyle and Chasseaud, 1981; Taylor et al, 1980). In addition, since the 
drug plasma terminal half-life is associated with absorption (see page 
lOO) this factor would also have to be considered when designing a 
dosing regimen. 
Since similar metabolites of isosorbide dinitrate are produced by 
animals and humans, a comparison of the relatively straightforward bio-
transformation of isosorbide dinitrate in different animal species would 
probably not provide the best criteria for the selection of a suitable 
species for chronic toxicity studies of the drug, rather a comparison of 
the drug's pharmacokinetics would be more appropriate. Using pharmaco-
kinetic criteria therefore, the fate of isosorbide dinitrate in humans 
(Taylor et al, 1980) appears to be more closely reflected by that in 
baboons (Tables 6:3 and 6:4) than that in either of the other two non-
human primate species studied. 
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TABLE 6:2 
Mean concentrations (~ SD) of isosorbide dinitrate in the. plasma of 
the rhesus monkey, the cynomolgus. monkey and the baboon after a single 
bolus intravenous injection of isosorbide dinitrate at a level of 
1.0 mg/kg. Results are expressed as ng/ml 
--------------- ------------------------------------------------------
Time 
-----------------
-----~2~=!~~------
-----------------
Rhesus monkey Cynomolgus monkey Baboon 
-------------- ----------------- ------------------ -----------------
2 minute 565 + 66 586 + 43 1572 + 253 
5 minute 457 + 120 581 + 88 1178 + 258 
10 minute 394 + 70 447 + 71. 750 + 34 
15 minute 305 + 26 374 + 67 599 + 50 
30 minute 206 + 28 209 + 32 364 + 14 
45 minute 153 + 6 109 + 28 214 + 44 
1 hour 110 + 14 65 + 16 145 + 19 
1.5 hour 82 + 15 28 + 8 63 + 5 
2 hour 51 + 7 11 + 4 27 + 3 
3 hour 28 + 8 3 + 1 6 + 2 
4 hour 10 + s+ l 1 
+Indicates that this sample was taken at 4.5 hours. 
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TABLE 6:3 
Mean pharmacokinetic parameters (~ SD) determined for a two-compartment 
open model in the rhesus monkey, the cynomolgus monkey and the baboon 
after a single intravenous injection of isosorbide dinitrate at a level 
of 1.0 mg/kg. The data are presented as means of the results from 
individual animals. 
---------------------------------------------------------------------------------
a Parameter 
Baboon 
-----------------
Bodyweight (kg) 4.8 + 0.8 
4.6 ~ 0.9 
1.0 ~ o.o 
435 + 113 
220 + 74 
3.4 + 0.4 
3.4 + 0.4 
1.0 ~ o.o 
384 ~ 222 
427 ~ 120 
5.8 + 0.9 
5.8 + 0.9 
1.0 + o.o 
Dose 
Dose 
A 
B 
8 
Kl2 
K21 
Kel 
AUC 
Cl 
t~, 
(mg) 
(mg/kg) 
(l.lg/ml 
(l.lg/ml) 
-1 (hour ) 
(hour -l) 
(minute -l) 
-1 (minute ) 
(minute) 
(l.lg/ml/hour) 
(ml/minute) 
(minutes) 
(litres) 
(litres) 
7.123 ~ 7.658 
o. 703 + 0.168 
0.051 + 0.066 
0.053 ~ 0.059 
0.027 ~ 0.006 
409 + 4lc 
188 + 29 
62 + l3d 
7.1 ~ 1.3 
10.061 ~ 7.430 
l. 788 ~ 0.157 
0.040 ~ 0.042 
0.110 ~ 0.084 
0.047 ~ 0.012 
292 ~ 47b 
200 ~ 37 
23 + 2 
4.3 ~ 0.8 
1.4 ~ 0.7 
1139 + 557 
843 + 183 
12.933 + 4.500 
1. 772 + o. 256 
0.071 + 0.029 
0.117 + 0.055 
0.058 + 0.011 
575 + 37 
169 + 30 
24 + 3 
3.0 + o. 7 
l. 9 + 0. 3 6.0 ~ 2.4 
d 
vd(ss) (litres) 13.2 + 2.9 
d 
5.7 ~ 0.8 4.9 + 0.8 
vd(8) (litres) 16.0 ~ 2.5 6.7 ~ 1.2 5.7 + 1.0 
A/ a. ()Jg/ml/hour) 61 + 51 56 ~ 40 101 + 71 
B/8 (l.lg/ml/hour) 318 + 39 237 + 61 474 + 74 
- - I -
~----------------------------------------------------------------------------------
a 
c 
d 
For details of abbreviations see ··Chapter 2. 
Significance level (analysis of variance) cynomolgus monkey 
compared with the other two species (P< 0.01). 
Significance level (analysis of variance) rhesus monkey compared 
with the baboon (P<o.05). 
Significance level (analysis of variance) rhesus monkey compared 
with the other two species (P<O.Ol). 
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.TABLE 6:4 
Mean pharmacokinetic parameters of isosorbide dinitrate in the rhesus 
monkey, the cynomolgus monkey. and the baboon for a one-compartment open 
model compared to those for a two-compartment open model following a 
single intravenous injection of isosorbide dinitrate (l mg/kg). The 
data are presented as means of results from individual animals. 
------------------- -------------------------------------------------------
Model and Species 
-------------------------- ----------------------------
Parameter a 
Rhesus Cynomolgus Baboon Rhesus Cynomolgus Baboon 
-------------------
~~!:~~l __ !,!!~!:~~L--
------
_t.!!~~~L- --I.!!~!:~~L-
-------
AUC(\lg/ml/hour) 404c 28lb 538 409c 292b 575 
Cl (ml/minute) 189 203 173 188 200 169 
t~ (minutes) 47d 29 29 62d 23 24 
vde(litres) 12. 2d 8.5 7.2 l3.2d 5.7 4.9 
-1 Ke1 (minute ) 0.015 0.024 0.024 0.027 0.047 0.058 
-------------------
------
------------
------
--------- ----------
-------
a 
b 
c 
d 
e 
For details of abbreviations, see Chapter 2. 
Significance level (analysis of variance) cynomolgus monkey 
compared to the other two species (P < o. Ol) • 
Significance level (analysis of variance) rhesus monkey, compared 
to the baboon (P< 0.05). 
Significance level (analysis of variance) rhesus monkey, compared 
to the other two species (P< 0.01). 
Vd = Total volume of distribution = V for the two-compartment d (ss) 
open model. 
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TABLE 6:5 
Calculated concentrations of isosorbide dinitrate in the peripheral 
compartment after bolus intravenous injection of isosorbide dinitrate 
1.0 mg/kg to non-human primates. Results calculated from mean data and 
expressed as ng/ml. 
-----------------------------------------------------------------------
Species 
Time 
--------------- ------------------- -----------------
Rhesus monkey Cynomolgus monkey Baboon 
--------------- --------------- ------------------- -----------------
2 Minute 72 160 339 
5 minute 149 304 605 
10 minute 223 392 727 
15 minute 256 394 698 
30 minute 258 284 474 
45 minute 223 184 307 
1 hour 188 118 197 
1.5 hour 133 48 81 
2 hour 93 20 33 
3 hour 46 3 6 
4 hour 23 
5 hour 11 
7 hour 3 
--------------- --------------- -------------------------------------
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FIGURE 6:1 
1000 • 
500 
400 
300 
200 
lOO 
so 
1 2 3 4 5 6 7 
Time (Hours) 
Mean concentration-time curves after a single intravenous injection 
of isosorbide dinitrate (1.0 mg/kg) to rhesus monkeys. Observed 
concentrations in the central compartment 
concentrations in the central compartment 
peripheral compartment ( • . ) . 
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Mean concentration-time curves after a single intravenous injection 
of isosorbide dinitrate (1.0 mg/kg) to cynomolgus monkeys. Observed 
concentrations in the central compartment 
coricentrations in the central compartment 
peripheral compartment ( • • ) . 
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FIGURE 6:3 
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Time (Hours} 
Mean concentration-time curves after single intravenous injection 
of isosorbide dinitrate (1.0 mg/kg) to baboons. Observed concentrations 
in the central compartment e e ). Predicted concentrations 
in the central compartment ( solid line ) and in the peripheral compart-
ment ( • • ) • 
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CHAPTER 7 
PARACETAMOL 
Introduction 
Paracetamol (N-acetyl-p-aminophenol) is a commonly used analgesic 
with antipyretic effect (Flinn and Brodie, 1948). It is a weak base 
(pKa 9.5), mainly undissociated at physiological pH and only slightly 
bound to plasma proteins (about 10% bound, Duggin and Mudge, 1975; 
Laventhal et al, 1976). 
The pattern of metabolism of paracetamol is similar in man 
(Greenberg and Lester, 1946; Brodie and Axelrod, 1948a, 1949; 
Jagenberg and Toczko, 1964; Cummings et al, 1967; Jagenberg et al, 
1968; Levy and Yamanda, 1971; Mitchell et al, 1974; Mrochek et al, 
1974; Andrews et al, 1976) and in laboratory animal species (Shibusaki 
et al, 1968, 1971; Focella et al, 1972; Wong et al, 1976). Approx-
imately 80% of the administered dose is excreted as the glucuronic acid 
and sulphate conjugates, the remaining fraction consists of unchanged 
paracetamol (less than 5%) and products of oxidative metabolism, i.e. 
catechol derivatives and sulphur containing conjugates (Scheme 7:1). 
The hepatotoxicity of paracetamol in man following overdose was 
first reported by Davidson and Eastham (1966) and Thomson and Prescott 
(1966) and has since been confirmed in laboratory animals (Boyd and 
Bereczky, 1966; Dixon et al, 1971, 1975; Jollow et al, 1973). Paracetamol 
is partly converted by microsomal cytochrome P-450 mixed function oxidase 
to a reactive metabolite which may be a quinone (Scheme 7:1), although its 
exact structure is still uncertain (Hinson et al, 1980). This reactive 
metabolite is detoxified by conjugation with glutathione within hepato-
cytes and probably other tissue cells (Boyland and Chasseaud, 1969; 
Jollow et al, 1974). At high doses of paracetamol, the supply of gluta-
thione is insufficient to prevent covalent binding of notable amounts 
of the reactive metabolite with hepatocyte proteins, resulting 
in liver damage (Mitchell et al, 1973; Davis et al, 1975). 
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Scheme 7:1 Metabolic pathways of paracetamol. 
(GSH represents glutathione; Glu .represents_ glutamate; 
Gly represents glycine). Although 3-hydroxy-paracetamol has 
been isolated and identified as a metabolite of paracetamol 
(Hinson et al, 1980) its mechanism of formation is unclear. 
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In man, the normal half-life of elimination of paracetamol is 
about 2 hours but this value increases to more than 4 hours in cases 
of liver damage produced by paracetamol over-dosage (Prescott et al, 
1971; Prescott and Wright, 1973; Peterson and Rumack, 1977). The 
half-life of elimination or paracetamol also increases in the rat and 
the mouse after high dose levels, but this increase is not thought to 
result from liver damage (Siegers et al, 1978). A sensitive test for 
the degree of damage to the liver is provided by serum alanine and 
aspartate transaminase (SGPT and SGOT) and hydroxybutyrate and lactate 
dehydrogenase (HBD and LDH) levels (Prescott et al, 1971). 
Measurement of concentrations of paracetamol in plasma 
Paracetamol was measured in plasma by means of the colorimetric 
method of Brodie and Axelrod (1948b). 
Plasma (1 ml) was saturated with sodium chloride (approximately 
2.5 g) and distilled water (4 ml) was added. The diluted plasma 
sample was extracted with purified* organic solvent LSO ml of a 
mixture of washed, redistilled diethyl ether (100 ml) and isoamyl 
alcohol (1.5 ml)_/ by shaking the mixture mechanically for 15 minutes. 
After cetrifugation, the organic phase (40 ml) was transferred to a 
50 ml centrifuge tube containing sodium hydroxide (5 ml O.lM) and the 
mixture was shaken mechanically for 5 minutes. After centrifugation 
the organic phase was discarded and the alkaline solution (4 ml) was 
transferred to another tube containing concentrated hydrochloric 
acid (1 ml). This tube was loosely stoppered and the mixture was 
incubated at l00°C for 30 minutes in an oven, occasionally checking that 
the stoppers had not blown out of the tube. The acid solution was 
cooled and 4 ml was transferred to another tube. Sodium nitrite 
* Footnote to method: 
The ether was washed with sodium hydroxide (200 ml/litre, lM) and with 
hydrochloric acid (200 ml/litre, lM) followed by 3 successive washes 
with distilled water (200 ml/litre) before distillation. 
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(0.5 ml of a 0.2% solution in water) was added and the solution was 
left for 20 minutes. After 20 minutes, ammonium sulphamate (0.5 ml 
of a l% solution in water) was added and the solution was left for 
a further 3 minutes. After 3 minutes, a-naphthol (0.1 ml of a 12% 
solution of resublimed a-naphthol in ethanol) and sodium hydroxide 
(2ml, 5.5M)were added. This solution was immersed immediately in 
iced water and left for 5 minutes. After 5 minutes the optical 
density of the solution of diazo dye was measured at a wavelength 
of 510 nm. A reagent blank was run through the above procedure 
and was used for the zero setting. 
Measurement of concentrations of serum enzymes using the Union Carbide 
Centrifichem 
Serum alanine and aspartate transaminate (SGPT and SGOT) and 
hydroxybutyrate and lactate dehydrogenase (HBDB and LDH) levels were 
determined using a Union Carbide Centrifichem using Roche Diagnostic 
test kits (both obtained from Roche Products Ltd., Welwyn Garden City, 
U.K.). The author is grateful to the members of the Department of 
Clinical Pathology for the use of their equipment and for analysing the 
serum enzyme concentrations. 
Results 
Plasma concentrations After a single intravenous injection of para-
cetamol at a level of 70 mg/kg, the peak of mean plasma concentrations 
of the unchanged drug, 105 ~g/ml ~ SSD and 87 ~g/ml ~ 15 SD occurred 
2 minutes after injection (the first time of blood withdrawal) in the 
rhesus monkey and baboon respectively. In the cynomolgus monkey, a peak 
of mean concentrations (91 ~g/ml ~ 30 SD) was not reached until 5 minutes 
after dosing (the second time of blood withdrawal). The apparent delay 
in reaching peak mean concentrations in the species was contributed by the 
data from two animals in which this effect was observed. Plasma con-
centrations of paracetamol declined from peak levels in a biexponential 
manner with an apparent half-life of elimination of about 1.2 hours, to 
almost the limit of detection (1 ~g/ml) at 7 hours after administration 
(Table 7:3; Figures 7:1- 7:3). 
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TABLE 7:1 
Method parameters for the measurement of concentrations of paracetamol 
in plasma. 
---------------------------------- ----------------------------------------· 
Linear range 
a Calibration line 
Accuracy 
Precision 
l-100 !Jg/ml 
Y = (0.0192 ~ O.OOOS)X 
~ 138% at S!Jg/ml, ~ 35% at 20 !Jg/ml 
and ~ 15% at SO !Jg/ml 
~ 13% at Sllg/ml, ~ 10% at 25 !Jg/ml 
and + 7% at 50 !lg/ml 
Sensitivity 1 )lg/ml 
Recovery of paracetamol 77% + 4.1 SD 
---------------------------------- ----------------------------------------
a Least squares regression line where Y = absorbance and 
X = paracetamol concentration in plasma. 
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Analysis of serum enzymes one week after dosing showed that the 
administered paracetamol had no prolonged adverse effects on these 
animals (Table 7:2). The cynomolgus monkey was affected more than 
the other two species and one animal of this species had a high SGPT 
level, but this enzyme level returned to normal before the next 
dosing session. 
Pharmacokinetic parameters. Observed plasma concentrations of para-
cetamol following a single intravenous injection of paracetamol 
70 mg/kg, were described by a biexponential equation (equation 2:2). 
The pharmacokinetic parameters shown in Table 7:4 were, therefore, 
calculated using equations 2:3 - 2:12 for a two-compartment open 
model with elimination from the central compartment (Scheme 2:2). 
Concentrations of paracetamol in plasma predicted by the two-compartment 
model were generally in good agreement with the observed values 
·(Figures 7:1- 7:3) 
Analysis of variance of pharmacokinetic parameters showed that there 
was only a statistically significant difference in paracetamol clearance 
when these parameters were adjusted for bodyweight; clearance was higher 
in the cynomolgus monkey than in the other two species (P<0.05) , Newman-
Keuls multiple comparison procedure. However, mean areas under the plasma 
concentration time curves and volumes of distribution were lower and half-
lives of elimination were shorter in the cynomolgus monkey than in the 
other two species, but the differences were not statistically significant. 
The mean volume of distribution was equivalent to 82, 106 and 
98% of the total bodyweight in the rhesus moneky, the cynomolgus monkey 
and the baboon respectively. These values are of the same order of 
magnitude as those previously reported for man (85%, unpublished results, in 
Prescott and Wright, 1973; 95%, Rawlins et al, 1977) but higher than 
those values calculated from data published for the rat (35%, Pang 
and Gillette, 1978) and dog (60% Kampffmayer, 1974). 
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The mean volume of the central compartment was larger than 
that of the peripheral compartment. The compartment volume ratio 
(central: peripheral) was 3:4, 2,1 and 4;4 in the rhesus monkey, 
the cynomolgus monkey and baboon respectively. These values indicate 
that there is relatively free transfer of paracetamol between the 
two compartments and that in this respect the non-human primate is 
similar to man (Rawlins et al, 1977). 
The total volume of distribution Vd(~)' estimated after attain-
ment of pseudo-distribution equilibrium multiplied by the plasma 
concentration at 1 hour indicates that 49, 46 and 59% of the administered 
drug remained in the body at 1 hour after dosing in the rhesus monkey, 
the cynomolgus monkey and the baboon respectively. 
The mean ratio. ~/Kel of 0.64, 0.59 and 0.77 for the rhesus 
moneky, the cynomolgus monkey and the baboon respectively indicates 
that these fractions of paracetamol in the body were in the central 
compartment and were available for elimination at any time during the 
terminal linear phase of the disposition curve (Gibaldi et a!, 1969). 
Simulation of the plasma concentration-time profile of para-
cetamol in the peripheral compartment for a two-compartment open 
model with pharmacokinetic parameters shown in Table 7:4, showed that 
equilibirium between the central and peripheral compartments was 
achieved 1-2 hours after administration. Peak concentrations of para-
cetamol in the peripheral compartment (52.8 ~g/ml, 34.4 ~g/ml and 
47.8 ~g/ml in the rhesus monkey, the cynomolgus monkey and the baboon 
respectively) occurred at 40 minutes after injection (Table 7:5, 
Figures 7~1- 7:3). Concentrations of paracetamol in the central and 
peripheral compartments were similar at all times after the distribution 
phase was complete, reflecting the ease of transfer between the two 
compartments. These results agree with findings in the dog, for 
which concentrations of paracetamol in the liver, kidney, heart, 
spleen, lungs, brain and muscle were similar to those in the plasma, 
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although concentrations of paracetamol in the fat were lower (Gwilt 
et al, 1963). 
The mean total systemic clearance of paracetamol of 46 ml/minute, 
49 ml/minute and 51 ml /minute in the rhesus monkey, the cynomolgus 
monkey and the baboon respectively, shows a remarkably similar 
capability of elimination of paracetamol in these non-human primate 
species. When adjusted for differences in bodyweight the clearance 
of paracetamol 9.2 ml/minute/kg, 14.0 ml/minute/kg and 8.5 ml/ 
minute/kg in the rhesus monkey, the cynomolgus monkey and the baboon 
respectively was higher than that in man (5 ml/minute/kg, Rawlins 
et al, 1977) but lower than that in the rat (34 ml/minute/kg, Pang and 
Gillette, 1978) and than that estimated from data published for the 
dog (18 ml/minute/kg, Kampffmayer, 1974). 
The mean rate constants for the rapid distribution ·~· phase 
(Table. 7:3) correspond to an apparent half-life of 16 minutes, 
12 minutes and 14 minutes for the rhesus monkey, the cynomolgus 
monkey and the baboon respectively and are similar to those values 
found previously for man 16 minutes - 44 minutes (Rawlins et al, 1977; 
Albert et al, 1974). The mean biological half-lives of 72 minutes, 
59 minutes and 75 minutes for the rhesus monkey, the cynomolgus 
monkey and the baboon respectivel~ are shorter than that in man 
(about 2 hours) after therapeutic administration (Nelson and Morioka, 
1963: Prescott et al, 1971; Prescott and Wright, 1973; Albert et 
a1 19741 Rawlins et al, 1974; Laventha1 et al, 1976). The half-
life of elimination of paracetamol after intravenous injection to the 
rat (37 minutes, Pang and Gillette, 1978) and to the dog (32 minutes, 
Kampffmayer, 1973) are shorter than that in the non-human primates. 
However, the half-life of paracetamol has been shown to be dose 
dependent, increasing from 1.8 hours after an intravenous injection 
at a level of lOO mg/kg to 3 hours after injection of 400 mg/kg in 
the rat, and in the mouse also after oral dosage (0.5 hours after a 
dose of 200 mg/kg and 0,9 hours after a dose of lg/kg. The increased 
half-life of elimination is thought to be due to saturation of the 
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of the metabolic pathways as no associated liver damage occurred 
(Siegers et al, 1978). 
Discussion 
Plasma concentrations of paracetamol decline in a biexponential 
manner in man after both oral and intravenous administration of the 
drug (Levy and Yamada, 1971; Albert et al, 1974; Rawlins et al, 1977) 
and after intravenous administration to the rat (Pang and Gillette, 1978) 
but paracetamol elimination appears to obey one-compartment kinetics after 
intravenous administration to the dog (Kampffmeyer, 1973). 
In non-human primates, plasma concentrations of paracetamol after 
intravenous administration of the drug decline in a biphasic manner. The 
contribution of the distribution phase 'A/a' to the total area under the 
plasma concentration time curve was 16 and 19.6% in the rhesus monkey and 
cynomolgus monkey respectively but the rapid distribution phase contributed 
only 12% to the total area under the plasma concentration time curve in the 
baboon. Nevertheless, the distribution phase was clearly defined in all 
three species and distribution into the peripheral compartment does appear 
to be a feature of paracetamol disposition in the non-human primate. 
Paracetamol is eliminated almost exclusively by biotransformation, 
so much so that it has been used as a model substrate for examining 
conjugation mechanisms (Shively and Vesell, 1975; Triggs et al, 1975). 
The total systemic clearance, therefore, approximates to the metabolic 
clearance which after intravenous administration presumably occurs 
predominantly in the liver. In the non-human primate clearance values 
were about fourfold lower than the hepatic blood flow, suggesting that 
the clearance of paracetamol might be dependent on both hepatic blood 
flow and on the hepatic extraction ratio. The dependence of paracetamol 
clearance on the hepatic blood flow suggests that first-pass metabolism 
would be an important factor in paracetamol disposition after oral adminis-
tration to non-human primates. Paracetamol has already been shown to 
exhibit a significant first pass effect in man due to biotransformation 
in the liver and gut wall (Rawlins et al, 1977). 
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Inspection of the half-lives of elimination of paracetamol 
shows that during the once-daily dosage regimen common to most chronic 
toxicity studies paracetamol would be unlikely to accumulate in the 
body of the commonly used laboratory animal species since each dose 
would have been eliminated before the next was received. In man, 
the half-life was longer, approximately 2 hours, but paracetamol 
would still not accumulate during a once-daily dosage regimen. 
HOwever, when administered three times daily to patients in pain, a 
dose of 1 g of paracetamol would accumulate in the body particularly 
if the elimination half-life of the drug increased as a result of 
liver damage caused by this treatment. In normal subjects with an 
elimination half-life of 2 hours a plasma steady state concentration 
of 6 ~g/ml would be achieved after the first day with a l g three 
times daily dosing regimen. To achieve this same steady state plasma 
concentration in non-human primates, paracetamol would have to be 
injected intravenously at a level of about 19.9 mg, 17.3 mg and 
23.0 mg at intervals of 72 minutes, 59 minutes and 75 minutes to the 
rhesus monkey, the cynomolgus monkey and the baboon respectively, or 
a similar dosing regimen adopted. These considerations apply to 
paracetamol administered intravenously. If administered orally, and 
particularly at much higher dosages, other factors (such as release 
from the dosage form) have to be assessed. 
Although the half-life might increase at higher dose levels due 
to saturation of metabolic pathways with or without liver damage, it 
appears that the non-human primate is closer to man than are the other 
commonly used laboratory animals. Using pharmacokinetic criteria, 
the~efore, the fate of paracetamol in humans (Albert et al, 1974; 
Rawlins et al, 1977) appears to be more closely reflected by that in 
the non-human primate, except perhaps the cynomolgus monkey, than in 
the other commonly used laboratory animals. 
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TABLE 7:2 
Mean serum alanine and aspartate transaminase and hydroxybutyrate and 
lactate dehydrogenase levels (± SD) in the rhesus monkey, cynomolgus 
monkey and baboon after injection of paracetamol 70 mg/kg. 
Species 
Enzyme 
Babcon 
------------- ~=~~~-~~~=~---- ~~~~~!~~~-~~~~=Y- ----------------
SGPTa 41.8 + 16.8 84.4 + 76.9e 31.2 + 5.6 
SGOTb 35.8 + 7.8 39.6 + 20.2 32.2 + 4.8 
HBDC 
LDHd 
a 
b 
c 
d 
e 
210.8 + 43.9 422.0 + 40.9 205.2 + 37.9 
428.2 + 84.0 215.6 + 14.8 474.4 + 86.1 
Alanine transaminase, upper limit of normal 50 mu/ml. 
Aspartate transaminase, upper limit of normal 60 mu/ml. 
Hydroxybutyrate dehydrogenase, upper limit of normal 1000 mu/ml. 
Lactate dehydrogenase, upper limit of normal 1000 mu/ml. 
High value in one animal was observed one week after dosing 
but the serum enzyme level returned to normal before the next 
dosing sessiona 
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TABLE 7:3 
Mean observed concentrations of paracetamol (+ SD} in the plasma of 
- ' 
the rhesus monkey, the cynomolgus monkey and the baboon after a single 
bolus intravenous injection of paracetamol .. at a level of 70 mg/kg. 
Results are expressed as ~g/ml. 
------------------------------------------------------
Time -----------------------~£~=~~=-----------------------
Rhesus monkey Cynomolgus monkey Baboon 
----------------- ----------------- ------------------ ----------------
2 minute 105 + 8 77 .±. 6 87 + 15 
5 minute 91 + 10 91 .±. 30 78 + 6 
10 minute 84 + 10 72 + 25 81 + 9 
20 minute 70 + 8 55 + 23 70 +' 8 
40 minute 53 + 8 39 + 12 54 + 3 
1 hour 36 + 5 29 + 10 40 + 8 
1.5 hour 26 + 3 17 + 4 31 + 8 
2 hour 17 + 3 12 + 7 25 + 8 
3 hour 11 + 1 . 6.+ 2 14 + 6 
4 hour 7 + 1 4 + 2 9 + 5 
5 hour 3 + 1 2 + 1 s.±.4 
7 hour ND 1 2 + 2 
-----------------
-----------------------------------------------------
ND ·Less than the limit of detection (1 ~g/ml}. 
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TABLE 7:4 
Mean pharmacokinetic parameters (~ SD) determined for a two-
compartment open model for the rhesus monkey, the cynomolgus 
monkey and the baboon after single intravenous injection of 
paracetamol at a level of 70 mg/kg. The data are presented as 
means of results from individual animals. 
----------------------- ---------------------------------------------------
Parameter a 
-----------------------
~~~~~-~~~~x ___ 
Bodyweight. (kg) 5.0 + 0.7 
Dose (mg) 350 + 55 
Dose (mg/kg) 70 + 2 
A ()lg/ml) 48 + 33 
B ()lg/ml) 64 + 31 
-1 2.601 + 1.175 CL (hour ) 
a 
-1 (hour ) 0.578 + 0.270 
Kl2 (minute -1) 0.009 + 0.003 
K21 
-1 (minute ) 0.029 ~ 0.045 
Kel 
-1 (minute ) 0.015 ~0.004 
AUC ()lg/ml/hour) 129 + 25 
Cl (ml/minute) 46 + 12 
~ (minutes) 72 + 24 
vl (litres) 3.1 + 0.4 
vz (litres) o. 9 + o. 7 
V d (ss) (litres) 4.1 + 0.7 
vdtal (litres) 4.8 + 1.3 
A/a ()lg/ml/hour) 20 + 25 
B/a ()lg/ml/hour) 109 + 13 
______ §2~~!~~----­
~~~~~!2~~-~~~~X-
3.5 + 0.3 
245 ~ 25 
70 + 3 
55 + 12 
51 + 8 
3.464 + 2.423 
o. 747 ~ 0.180 
0.015 + 0.013 
0.034 + 0.013 
0.021 ~ 0.006 
90 + 27 
49 + 15 
59 + 15 
2.5 ~ 0.2 
1.2 + 1.3 
3.7 ~ 1.3 
3.9 + 1.2 
28 + 27 
71 + 28 
Baboon 
6.0 + 0.9 
410 + 63 
69 + 1 
28 + 91 
65 + 12 
2.881 + 0.908 
0.507 + 0.098 
0.009 + 0.009 
0.032 + 0.041 
0.011 + 0.007 
141 + 34 
51 + 18 
75 + 30 
4.8 + 2.3 
1.1 + 1.6 
5.9 + 1.3 
6.0 + 2.1 
17 ,+ 36 
129 ~ 12 
------------------------ ----------------------------------------------------
a 
For details of abbreviations used see Chapter 2. 
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TJIBLE 7:5 
Calculated concentrations of paracetamol in the peripheral compartment 
after bolus intravenous injection of paracetamol 70 mg/kg to non-human 
primates. Results calculated from mean data and expressed as ~g/ml. 
Species 
----------------~------------------ ---------------
Time 
~~~~~-~~~~~--- ~~~~~~2~~-~~~~~~- Baboon 
----------------- ---------------
2 minute 6.0 5.2 6.3 
5 minute 14.9 12.4 23.0 
lO minute 37.7 22.0 25.3 
20 minute 41.8 31.3 39.0 
40 minute 52.8 34.4 47.8 
l hour 50.6 30.0 46.1 
1.5 hour 41.5 21.6 38.3 
2 hour 32.1 15.1 30.6 
3 hour 18.4 7.2 18.4 
4 hour 10.3 3.4 11.1 
5 hour 5.8 1.6 6.7 
7 hour 1.8 ND 2.4 
----------------------------------- -----------------------------------
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CHAPTER 8 
IBUPROFEN 
Introduction 
Ibuprofen 2-[4-isobutylphenyl] propionic acid is a non-steroid 
with proven anti-inflammatory properties in animals (Adams et al, 1967, 
1969a, 1969b, 1970; Masumato et al, 1972) and in man (Brooks et al 
1970, 1973; Davies and Avery, 1971). It is administered as a racemic 
mixture, is a weak acid (pK 5.2), only slightly soluble in water and 
a 
strongly bound to plasma proteins. 
In man and the commonly used laboratory animal species there are 
four metabolites of ibuprofen that are excreted into urine. These are 
formed by oxidation'and hydroxylation of the isobutyl side chain (Scheme 
8:1). In addition'a fifth metabolite, 2-(4-carboxyphenyl) propionic acid 
has been isolated from dialysis fluid samples taken from nephrectomized 
patients (Pettersen et al, 1978). The major urinary metabolites are the 
clextrorotatory isomers of 2- [4-(2-hydroxymethyl-2-methylpropyl) phenyl] 
propionic acid and 2-[4-(2-hydroxy-2-methylpropyl)phenyl] propionic acid and 
these are excreted both unchanged and conjugated (Adams et al, 1967, 
l969a; Brooks and Gilbert, 1974) but there are marked species variations 
in the proportions of these metabolites and the extent of conjugation 
(Mills et al, 1973). The conjugates of ibuprofen and its metabolites 
have not been identified. 
The observation that only the clextrorotatory isomers are excreted 
into urine has been explained by Wechter et al (1974a) and Kaiser et al 
(1976) • These workers demonstrated that ibuprofen undergoes a facile 
epimerization of the laevorotatory isomer prior to metabolism. 
Biliary excretion has been shown to be an important route of 
elimination of ibuprofen for the rat and dog. Approximately 25% of 
the administered dose of l 4c-ibuprofen was eliminated into bile (both 
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free and conjugated) of these species in 3 hours (Mills et al, 1973). 
These same workers also demonstrated that there was negligible 
enterohepatic circulation of ibuprofen in the rat and dog (Mills et al, 
1973). 
After oral administration, ibuprofen appears mainly unchanged 
in the plasma of humans and the common laboratory animal species, 
although the two major metabolites are detectable in plasma,except in 
the dog (Adams et al, 1969; Mills et al, 1973). The half-life of 
elimination of ibuprofen in man (about 2 hours, Kaiser and Van 
Giessen, 1974; Kaiser and Martin, 1977) is similar to that in the rat 
(~ = 1.4 hours, Kaiser and Glenn, 1974) and other laboratory animal 
species (t~ =about 3 hours, Adams et al, 1969a; Mills et al, 1973). 
Measurement of concentrations of ibuprofen in plasma 
Concentrations of ibuprofen in plasma were measured by a gas 
chromatographic procedure developed and supplied by the Boots Company 
Limited (Glass and Hind, 1974). 
Plasma (0.5 ml) was mixed with internal standard (4-n-butyl 
phenylacetic acid, 1 ml of a 10 ~g/ml solution in water containing 
sufficient lM sodium hydroxide solution to dissolve the acid) and 
hydrochloric acid (250 ~1, lM) in a 10 ml graduated tube. The 
mixture was transferred to a glass column lO.Ocm x 4 mm i.d. containing 
washed Amberlite XAD-2 resin (25-30 mesh, approximately 7.0 cm, obtained 
from British Drug Houses Chemicals Ltd., Poole, U.K.). The tube was 
rinsed with distilled water (2 x 2 ml) and the washings were added 
to the column. The aqueous eluate was discarded. The test-tube was 
rinsed with methanol (Distol, 4 ml, obtained from Fisons Scientific 
Apparatus Ltd., Loughborough, U.K.), and the washings were transferred 
to the column. The eluate, a mixture of water and methanol, was 
collected in a conical centrifuge tube and concentrated by evaporating 
the methanol at 40°C under a strong current of nitrogen. The remaining 
solution was extracted'byvigororn mixing with dichloromethane (5 ml). 
After centrifugation, the bottom organic layer was transferred to a 
pointed centrifuge tube and evaporated to dryness at 40°C under a 
stream of nitrogen. The residue was redissolved in hexane (200 ~1) and 
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Scheme 8:1 Metabolic pathways of ibuprofen. 
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methylated by bubbling diazomethare through the solution until the 
solution was permanently coloured yellow. The solution was allowed 
to stand for 5 minutes and then carefully evaporated to dryness at 
room temperature, under nitrogen. The residues were dissolved in 
methyl acetate (20 ~1) and an aliquot (1-3 ~1) injected onto the 
gas chromatographic column. Quantitation was by peak height ratio using 
the internal standard technique. 
A Hewlett-Packard Model 5750G gas chromatograph fitted with a flame 
;(c;>nisation· .. detector·.was used to measure ibuprofen in the extracts of 
plasma. The column was b ft. long x l/8th inch i.d. stainless steel 
silanised and packed with 5% carbowax 20M on 100/120 mesh Gas Chrom 
Q support (Phase Separations Limited, Queensferry, Clwyd, U.K.) 
conditioned for 16 hours at 210°C. The carrier was nitrogen 
(oxygen free and dried) at a flow rate of 40 ml/minute. The column 
temperature was 1S0°C increased at a rate of 4°C/minute until the 
internal standard had eluted (at about 172°C), and then increased 
to 210°C and kept at this temperature for 4 minutes. The detector 
temperature was 295°C and the injector temperature was 255°C. Gas 
supply to the flame-ionization detector was optimized to give maximum 
sensitivity (hydrogen about 25 ml/minute and air about 3.00 ml/minute). 
Under these conditions the retention times of ibuprofen and the internal 
standard were 4.2 and 5.6 minutes respectively. 
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TABLE S:l 
Method parameters for the measurement of concentrations of ibuprofen 
in plasma. 
a 
b 
------------------------------ -----------------------------------
Linear rangea o.4-SO ~g/ml 
b Calibration line Y=(0.0554 ~ 0.0013)X 
Accuracy 
Precision 
Sensitivity 
Recovery of ibuprofen 
Recovery of internal 
standard 
+ 14.4% at SO~g/ml, 
+ 26.4% at 41.5 ~g/ml and 
~ 109% at 10 ~g/ml 
+ 9% at SO ~g/ml, 
+ 10% at SO ~g/ml and 
~ 9% at 10 ~g/ml 
0.4 ~g/ml 
46% + 10 SD 
46% 
Samples containing ibuprofen at levels greater than SO ~g/ml 
were assayed using a smaller volume of plasma (0.25ml) diluted 
with control plasma to a volume of 0.5 ml. 
Least squares regressions where Y= instrument response(peak height 
ratio, ibuprofen to internal standard) and X = plama concentration 
of ibuprofen. 
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Results 
Plasma concentrations. After a single bolus intravenous injection 
of ibuprofen at a level of 15 mg/kg, the peak of mean plasma 
concentrations in the rhesus monkey and baboon of 171 ~g/ml ~ 43SD 
and 179 ~g/ml ~ 23 SD respectively, were reached at 2 minutes 
after injection (the first time of blood withdrawal). However, the 
peak of mean plasma concentrations of ibuprofen in the cynomolgus 
monkey (235 ~g/ml ~ 62 SD) was not reached until 5 minutes post-
administration (the second time of blood withdrawal). The delayed 
time to peak concentrations in the cynomolgus monkey was due to 
data from two animals in which this effect was observed. In all 
three species, plasma concentrations declined in a biphasic manner, 
with an apparent half-life of elimination of about 1 hour and were 
at or near the limit of detection (0.4 ~g/ml) at 7 hours post-
administration (Table 8:2, Figures 8:1; 8:3). 
Pharmacokinetic parameters. Observed plasma concentrations of ibuprofen 
following a single intravenous injection of ibuprofen at a level of 
15 mg/kg were described by a biexponential equation (Equation 2:2). 
The pharmacokinetic parameters shown in Table 8:3 were, therefore, 
calculated using equations 2:3- 2:12 for a two. compartment open model 
with elimination from the central compartment (Scheme 2:2). Plasma 
concentrations of ibuprofen predicted by the two-compartment model 
were generally in good agreement with the observed values. That a 
two-compartment model is appropriate to describe ibuprofen kinetics 
is also indicated by the contribution of the distribution phase (~«) 
to the total area under the plasma concentration-time curve which was 
59, 62 and 28% for the rhesus monkey, cynomolgus monkey and baboon 
respectively. 
Analysis of variance showed that the areas under the plasma 
concentration-time curve for the rhesus monkey was significantly 
lower than that for the other two species (P(O.Ol Newman-Keuls 
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multiple comparison procedure) and that the total volume of 
distribution and the total systemic clearance in the cynomolgus 
monkey were significantly lower than in the other two species 
(P< 0.01). When adjusted for differences in bodyweight,there 
were no significant differences in the adjusted volumes of 
distribution (P>O.OS) but the clearance in the rhesus monkey 
(mean 3.1 ~g/ml/kg) was significantly higher (P<O.OS Newman-
Keuls multiple comparison procedure) than in the cynomolgus monkey 
(mean 2.0 ~g/ml/kg) and the baboon (mean 2.1 ~g/ml/kg). 
In common with other anti-inflammatories (for review see Hucher 
et al, 1980), the mean total volume of distribution Vd(ss) of ibuprofen 
was small, accounting for 14, 8 and 10% of the total bodyweight in the 
rhesus monkey, the cynomolgus monkey and the baboon respectively, presumably 
reflecting the high degree of plasma protein binding of this compound. 
The mean compartment volume ratio (central:peripheral) 0.8, 2.0 and 2.0 
for the rhesus monkey, the cynomolgus monkey and the baboon respectively, 
indicates that ibuprofen is able to transfer freely between the two 
compartments in the cynomolgus monkey and the baboon but may be released 
more slowly from the peripheral compartment in the rhesus monkey. In 
these non-human primate species, the volume of the central compartment 
is approximately 7% of the total bodyweight and therefore approximates 
to the blood volume. 
The mean rate constants for the rapid distribution phase, 
calculated for the rhesus monkey, the cynomolgus monkey and the 
baboon corresponds to an apparent half-life for theaphase of 
12 minutes, 16 minutes and 12 minutes respectively. 
The mean terminal half-lives of ibuprofen in these non-human 
primates, 91 minutes ~ 57 SD, 70 minutes ~ 40 SD and 49 minutes 
+ 129 SD for the rhesus monkey, the cynomolgus monkey and the baboon 
respectively showed large inter-animal variations in the value of this 
parameter. These mean values are shorter than those in man (about 
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2 hours, unpublished data Davies and Avery, 1971; Kaiser and 
Van Giesson, 1974; Collier et al, 1978) and that estimated for 
the dog (2.9 hours, calculated from data published by Mills et al, 
1973) but are similar to those reported for the rat (1.4 hours 
Kaiser and Glenn, 1974). 
The total ·volume of distribution Vd(S) estimated after 
attainment of pseudo-distribution equilibrium multiplied by the 
plasma concentration at 1.5, 2 and 1.5 hours after dosing in the 
rhesus monkey, cynomolgus monkey and the baboon respectively, 
indicates that 25, 15 and 21% respectively of the administered dose 
remained in the body at these times. 
The mean ratio S/kel of 0.2, 0.3 and 0.5 indicates that these 
fractions of the drug in the body were in the central compartment and 
available for elimination at any time during the S elimination phase. 
Simulation of the plasma concentration-time profile of ibuprofen 
in the peripheral compartment for a two-compartment open model with 
pharmacokinetic parameters shown in Table 8:3, showed that following 
intravenous injection, equilibrium was rapidly achieved. Peak 
concentrations of 39 ~g/ml, 81 ~g/ml and 112 ~g/ml in the rhesus 
monkey, the cynomolgus monkey and the baboon respectively, were 
reached at 40 minutes post administration (Table 8:4, Figures 8:1 -
8:3). Estimated concentrations of ibuprofen in the peripheral 
compartment of these species were higher than those in the central 
compartment. In dogs, total radioactivity measured in most tissues 
after administration of 14c-ibuprofen were lower than that in plasma, 
although total radioactivity in the bile was twenty to forty five-fold 
greater than that in plasma (Adams et al, 1969a). In rats, however, 
these same workers found that total radioactivity measured in several 
tissues, including well perfused tissues such as the liver and kidney, 
were higher than that in plasma. 
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Discussion 
Ibuprofen is normally administered orally and only limited 
information concerning the pharmacokinetics of this compound 
following intravenous administration has been reported in the 
literature. Mills et al (1973) have, however, published total 
radioactivity measurements of 14c in plasma after intravenous 
administration of 14c ibuprofen to dogs and these data can be 
used to estimate the half-life of ibuprofen because no metabolites 
are detectable in the plasma of this species. There is not 
sufficient information in the report by Mills et al. to estimate 
other pharmacokinetic parameters for ibuprofen in the dog. 
In the dog after intravenous dosing, (Mills et al, 1973) and 
in man after oral doses (Collier et al, 1978) , ibuprofen obeys two 
compartment kinetics, although a mono-exponential decline to the 
concentration-time curve was observed for some arthritic human 
volunteers (Collier et al, 1978) • Using the computerised non-linear 
least squares curve fitting programme BLUD, the plasma concentration-
time curve for ibuprofen following intravenous injection of this 
compound to non-human primates was described by a biexponential 
equation. 
Although concentrations of ibuprofen in the tissue compartment 
in the rat and the non-human primates are higher than those in the 
central compartment, the reverse is true in the dog. Nevertheless, 
there is no evidence to suggest that the fraction of administered 
ibuprofen that diffuses into the tissue compartment is not free to 
diffuse back into the plasma of these species after an intravenous 
injection. 
Inspection of the values for the apparent half-life of 
elimination of ibuprofen in the non-human primate (reported in 
Table 8:3), other laboratory animal species and inan following oral 
administration (Mills et al, 1973; Collier et al, 1978), shows that 
ibuprofen would not accumulate during the once-daily dosing regimen 
common to most chronic toxicity studies. However, ibuprofen would 
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accumulate in man if given 400 mg three times daily, for the 
treatment of osteo-arthrosis, for example. To maintain steady 
state concentrations of ibuprofen in the plasma of non-human 
primates, equal to the limit of detection of the analytical method 
(0.4 ug/ml) 1 a possible dosing regimen would be the injection of 
doses of 0.6 mg, 0.2 mg and 0.3 mg intravenously into the rhesus 
monkey, cynomolgus monkey and the baboon respectively at intervals 
of 91 minutes, 70 minutes and 49 minutes respectively. Such a 
dosing regimen would be impractical during a chronic toxicity study 
of this compound. An alternative dosing regimen would be the 
injection of doses of 9.5 mg, 4.1 mg and 10.5 mg of ibuprofen to the 
rhesus monkey, the cynomolgus monkey and the baboon respectively, 
once daily These doses would not harm the animals as they are 
similar to those given in this study, however, with such a dosing 
regimen ibuprofen would have been completely eliminated from the 
body after 7 to 12 hours in these non-human primate species. 
Ideally, a twice daily, or preferably a three times daily, oral 
dose designed to achieve a suitable steady state plasma drug level 
would be more suitable, as such a regimen would ensure that some 
ibuprofen remained in the body of the non-human primate during the 
whole day. 
Using pharmacokinetic criteria it can be concluded that the 
non-human primate would not be a more suitable model for man than 
other commonly used laboratory animals. Other factors that need 
to be considered in the choice of an animal model for man to study 
the fate of ibuprofen in vivo would be species-related differences 
in metabolism, routes of excretion, tissue distribution and protein 
binding. 
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TABLE 8:2 
Mean observed concentrations of ibuprofen (.±_ SD) in the plasma of 
the rhesus monkey, the cynomolgus monkey and the baboon after a 
single bolus intravenous injection of ibuprofen at a level of 
15 mg/kg. Results are expressed as ~g/m1. 
----------------- ----------------------------------------------------
Species 
---------------- -----------------------------------Time 
Rhesus monkey Cynomolgus monkey Baboon 
----------------- ---------------- ------------------ ----------------
2 minute 171 + 43 221 + 30 179 + 23 
5 minute 159 + 43 235 + 62 158 + 15 
10 minute 114 + 30 160 .±. 18 129 + 10 
-
20 minute 65 + 12 107 + 16 89 + 9 
40 minute 31 + 6 58 + 17 57 + 15 
1 hour 17 + 5 36 + 7 39 + 21 
-
1.5 hour 9 + 3 21 + 7 21 .±. 8 
2 hour 7 + 2 10 + 5 12 + 10 
3 hour 4 + 2 6 + 4 4 + 3 
4 hour 3 + 1 4 + 2 2 + 2 
5 hour 2 + 1 2 + 1 1 + 1 
7 hour 1 1 + 1 ND 
----------------------------------- ------------------------------------·· 
ND Less than the limit of detection (0.4 ~g/m1). 
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TABLE 8:3 
Mean pharmacokinetic parameters (~ SD) determined for a two-compart-
ment model in the rhesus monkey, the cynomolgus monkey and the baboon, 
after a single intravenous injection of ibuprofen at a level of 
15 mg/kg. The data are presented as means of results of individual 
animals. 
~------------------------ ---------------------------------------------------
Parameter a ----------------------~2~=!~~------
---------------
Rhesus monkey Cynomolgus monkey Baboon 
----------------------- ---------------- ------------------ ---------------
Bodyweight(kg) 4.8 ~0.8 3.5 + 0.3 6.1 + 0.9 
Dose (mg) 73.2 + 12.4 53.6 + 3.6 90.0 ~ 14.2 
Dose (mg/kg) 15.0 ~ 0.4 15.2 + 0.6 14.9 + 0.4 
A (l.lg/ml 174 + 83 205 + 82 114 + 73 
B . (1.1g/m1 17 + 9 33 + 22 70 + 39 
" 
(hour -ll 3.460 + 1.061 2.529 + 1.212 3.457 + 0.615 
~ -1 (hour ) 0.467 + 0.244 o. 555 + o. 224 o. 850 + o. 422 
-1 0.017 + 0.008 0.010 + 0.006 0.023 + 0.009 Kl2 (minute ) 
-1 
K2l (minute ) 0.012 + 0.004 0.014 + 0.006 0.066 + 0.042 
-1 
Kel (minute ) 0.036 + 0.006 0.029 + 0.003 o.o28 + o.oo8 
AUC . ().1g/m1/hour) 85 ~ 23b 127 + 6 123 + 23 
Cl (ml/minute) 15 + 3 7 + le 13 + 2 
t~, (minutes) 91 + 40 70 + 33 49 + 19 
vl (litres) 0.3 + 0.2 0.2 +0.1 o.4 + o.l 
v2 (litres) 0.4 + 0.3 0.1 + 0.1 0.2 + 0.5 
V d (ss) (litres) 0.7+0.4 o.3c+ o.l o.6 + o.l b vdl~ l (litres) 2.0 + 0.4 0.8 + O.l 0.9 + 0.2 
A/" ().1g/ml/hour) so + 18 79 + 3.1 34 + 23 
B/~ . ().1g/ml/hour) 38 + 14 63 + 47 74 + 32 
----------~-------------_; ___________________________________________________ _ 
a 
b 
c 
For details of abbreviations used see Chapter 2. 
Significance level (analysis of variance) rhesus monkeys 
compared with the .other two species (P < 0.01). 
Significance level (analysis of variance), cynomolgus monkeys 
compared with the other two species (P < 0.01). 
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TABLE 8:4 
Calculated concentrations of ibuprofen in the peripheral compartment 
after bolus intravenous injection of ibuprofen 15 mg/kg to non-human 
primates. Results calculated from mean data and expressed as ~g/ml. 
Species 
----------------~------------------ ----------------Time 
Rhesus monkey Cynomolgus monkey Baboon 
2 minute 6 12 18 
5 minute 13 24 42 
10 minute 25 42 74 
20 minute 34 65 105 
40 minute 39 81 112 
1 hour 38 79 94 
1.5 hour 31 65 65 
2 hour 25 51 44 
3 hour 16 30 19 
4 hour 11 17 8 
5 hour 7 10 3 
7 hour 3 3 1 
--------------------------------------------------- ----------------
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FIGURE 8:1 
200. 
so 
40 
30 
• 
~----~----~----~----~----~----~~--· 
1 2 3 4 5 6 7 
Time (hours) 
Mean concentration-time curves after single intravenous injection of 
ibuprofen 15 mg/kg to rhesus monkeys. Observed concentrations in the 
central compartment • • ), estimated concentrations in the 
central compartment (solid line) and in the peripheral compartment 
• • ) . 
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FIGURE 8:2 
lOO . 
• 
1 2 l 4 5 6 7 
Time (hours) 
Mean concentration-time curves after single intravenous injection 
of ibuprofen 15 mg/kg to cynomolgus monkeys. Observed concentrations 
in the central compartment • .. ), estimated concentrations 
in the central compartment (solid line) and in the peripheral 
compartment ( • • ) . 
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FIGURE 8:3 
200. 
• 
• 
Time (hours) 
Mean concentration-time curves after single intravenous injection of 
ibuprofen 15 mg/kg to baboons. Observed concentratiorls in the central 
compartment • • ), estimated concentrations in the central 
compartment (solid line) and in the peripheral compartment ( 11 • 
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CHAPTER 9 
PENTOBARBITONE 
Introduction 
' Pentobarbitone (5-ethyl-5~1-methylbutyl) barbituric acid) is 
a short acting barbiturate with hypnotic and sedative properties 
(Goodman and Gilman, 1975). It is a weak acid (pK· 8.1), lipid 
a 
soluble and only slightly bound to plasma proteins (Brodie et al, 1953; 
Ehrnebo, 1974). 
Pentobarbitone is metabolized by hydroxylation and oxidation, 
presumably in the liver, in both humans and the commonly used 
laboratory animal species. Only trace amounts of the administered 
pentobarbitone are excreted unchanged (Brundage and Gruber, 1937; 
Herwick, 1933; Van Dyke et al, 1947);the major fraction (about 75%) 
is found in urine as the diastereoisomeric forms of 5-ethyl-5-
(3~hydroxy-t-methylbutyl) barbituric acid and their glucuronic acid 
conjugates (Maynert and Dawson, 1952; Brodie et al, 1953; Titus 
and Weiss, 1955; Tang et al, 1977). Approximately twice as much of 
the laevorotatory isomer appears in the urine unchanged as does the 
dextrorotarary isomer, and this has been explained by the prefer-
ential conversion of the dextrorotatory isomer to the glucuronide 
(Titus and Weiss, 1955). Of the remaining dose, Maynert and Van Dyke 
(1950) suggested that small amounts are converted to urea; Algeri and 
MCBay (1952) and Titus and Weiss (1955) isolated 5-ethyl-5-(i-methyl-
' 3-carboxypropyl) barbituric acid. 
Measurement of concentrations of pentobarbitone in plasma. 
Concentrations of pentobarbitone in plasma were measured by 
means of a modification of the gas chromatographic procedure of Inaba 
and Kalow (1972) . 
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CH -CH -CH -CH 
3 2 2 I 
CH3 
0 
\ ;= 
rr-N 
0 
5-ethyl-5-~l-methylbutyl)barbituric acid 
~ (pentobarbitone) 
' (+)5-ethyl-5-(-3-hydroxy-
l~methylbutyl) barbituric acid 
,_J 
acid 
conjugates 
' ' 5-ethyl-5-(-3-carboxy-1-methylpropyl) 
barbituric acid 
Scheme 9:1 Metabolic pathways of pentobarbitone. 
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Plasma (1 ml) was mixed with internal standard (0.5 ml of a 
solution of methyl stearate .l).Jg/ml in chloroform) and extracted 
with freshly redistilled diethyl ether by shaking on a rotary mixer 
(Fisons Scientific Apparatus Limited, Loughborough, Leicestershire, U.K.) 
for 30 seconds. After centrifugation the organic layer was transferred 
to a 50 ml centrifuge tube. The plasma was extracted twice again with 
a mixture of redistilled diethyl ether and redistilled chloroform 
(3 m~ 80:20 v/v) and the extracts were combined. The combined extracts 
were washed with hydrochloric acid (0.5 ml;M.l before the organic 
phase was transferred to a 10 ml pointed centrifuge tube and 
evaporated to dryness under a stream of nitrogen at 40°C. The residue 
was dissolved in 0.5 ml of the solvent mixture, washing the sides of 
the tube, and blown carefully to dryness once again. The concentrated 
sample was dissolved in chloroform (10 ml) and a fraction of the final 
solution (about 1 ).Jl) was injected into the. chromatograph. Quantitation 
was by peak height ratio using the internal standard technique. A 
Perkin-Elmer Fl1 gas chromatograph (Perkin-Elmer Limited, Beaconsfield, 
U.K.) fitted with a flame ionization detector was used. The column 
was glass, 5 ft. x 2 mm id packed with 3% SE-30 on 60-80 mesh, AW-DMCS 
Chromosorb· · 11, support (Phase Separations 
U.K.) conditioned for 16 hours at 280°. 
flow rate of 60 ml/minute. The column 
Limited, Queensferry, Clwyd, 
The carrier was helium at a 
temperature was 200°C and 
the detection and injection temperatures were maintained at about 
24o0c and ab~ut 2Bo0c respectively. The supply of air and hydrogen 
to the detector were optimized for maximum sensitivity at about 
25 ml/minute for hydrogen and 300 ml/minute for air. 
To avoid interference from high boiling materials extracted from 
plasma, the column temperature was increased to 2Bo0 c after every 
3 or 4 injections and maintained at the elevated temperature until 
the long running peaks had been eluted (about 20 minutes). Under 
these conditions pentobarbitone and the internal standard were 
eluted as symmetrical peaks with retention times of 1.2 minutes and 
4 minutes respectively. 
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TABLE 9:1 
Method parameters for the measurement of concentrations of 
pentobarbitone in plasma. 
a 
Linear range 
Calibration linea 
Accuracy 
Precision 
Sensitivity 
a; 3-2 .o pg/m1 
Y=(O.l434~ 0.0035)X 
+ 14.7% at 15 ~g/ml, ~ 24.0% at 8.8 ~g/ml 
and 68.9% at 3~g/m1. 
+ 5% at 15 ~g/ml, + 6% at 9~g/ml and 
S. 3% at 3 ~g/ml. 
o. 3 ~g/ml 
Recovery of pentobarbitone 97% + 2.3 SD 
Recovery of internal 
standard 
97% + 2.8 SD at a level of 2 ~g/ml 
Least squares regression line where Y = instrument response 
peak height ratio, pentobarbitone (to internal standard) and 
X = plasma concentrations of pentobarbitone. 
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Results 
Plasma concentrations. After a single intravenous injection of 
pentobarbitone at a level of 12 mg/kg, peak of mean concentrations 
of pentobarbitone in plasma occurred, as would be expected, at the 
first time of blood withdrawal (2 minutes after injection), in the 
cynomolgous monkey and the baboon. However, the peak of mean 
concentrations of pentobarbitone in the plasma of the rhesus monkey 
was not reached until 5 minutes after injection (the second time of 
blood withdrawal). After an initial rapid distribution phase, mean 
plasma concentrations declined with an apparent half-life of 
elimination about 2 hours and were still detectable at 7 hours post-
administration (Table 9:2; Figures 9:1 - 9:3) 
Pharmacokinetic parameters. Observed plasma concentrations of 
pentobarbitone following a single intravenous injection of pento-
barbitone at a level of 12 mg/kg were fitted by a biexponential 
equation (Equation 2:2). The pharmacokinetic parameters shown in 
Table 9:3 were, therefore, calculated using equations 2:3 - 2:13 
for a two-compartment open model with elimination from the central 
compartment (Scheme 2:2). Plasma concentrations of pentobarbitone 
predicted by the two-compartment model were generally in good 
agreement with the observed values (Figures 9:1- 9:3). These 
parameters were compared to those estimated by f.i.tting a one-compartment 
open model to the data (Equation 1:1, 2:4, 2:13, 2:14) and the 
parameters estimated by both m9dels were found to be similar except 
for the half-life values for the rhesus monkey and the cynomolgus 
monkey (Table 9:4). 
The contribution of the distribution phase, A/«, to the total 
area under the plasma concentration-tLme curve was only small 
(8, 7 and 6% in the rhesus monkey, the cynomolgus monkey and the 
baboon respectively) and does not therefore make an important 
contribution to the total disposition of pentobarbitone. However, 
inspection of the data shows that the one-compartment model provides 
a poor fit to the observed concentrations at early times after injection. 
- 146 -
Analysis of variance showed that areas under the plasma 
pentobarbitone concentration time curves for the baboon were 
significantly lower (P< 0.05, non-parametric version of Newman-
Keuls multiple comparison procedure) and that the clearance of 
pentobarbitone in the baboon was significantly higher (P< 0.05, 
Newman-Keuls multiple comparison procedure) than in the other two 
species. When adjusted for bodyweight differences, the adjusted 
clearance in the baboon (mean 6.0 ~g/ml/kg) was not significantly 
different from that in the other two species (mean 4.6 ~g/ml/kg) 
in both the rhesus monkey and the cynomolgus monkey, (P> 0.05 
Newman-Keuls multiple comparison procedure). No other significant 
species related differences were observed in the pharmacokinetics 
of pentobarbitone in these non-human primate species. 
The mean total volume of distribution of pentobarbitone was 
equivalent to 82, 96 and 86% of the total bodyweight in the rhesus 
monkey, the cynomolgus monkey and the baboon respectively, suggesting 
that pentobarbitone does distribute beyond the body water and into the 
tissues. In this respect the non-human primate is similar to man (99-
170% of total bodyweight, Ehrnebo, 1974; Wagner et al, 1977), the rat 
(90-120% of total bodyweight, Ossenberg et al, 1975; Buice, 1978) and 
the rabbit (63-83% of total bodyweight, Kozlowski et al, 1977). In the 
dog, also, concentrations of pentobarbitone were similar in the plasma, 
plasma water, cerebrospinal fluid, red cells, liver, brain, muscle, kidney, 
heart, lung, spleen and lumbodorsal fat, suggesting extensive distribution 
(Brodie et al, 1953). 
Adopting the two-compartment model the compartmental volume ratio 
(central:peripheral) was 2.3, 1.9 and 2.6 in the rhesus monkey, cynomolgus 
monkey and baboon respectively, suggesting that there was relatively 
free transfer of pentobarbitone between the two compartments. 
In man, the compartment volume ratio is 0.6 - 0.8 (Ehrnebo, 1974; 
Ossenberg et al, 1975) and it can be seen from equation 2:9 (page 27) 
that this ratio implies that in man the rate of transfer of pentobarbitone 
from the central compartment to the peripheral compartment is greater 
than that from the reverse transfer process. Thus, if the site of 
action of this drug (the brain) is in the central compartment and if 
the fat is in the peripheral compartment, these findings would then 
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support the view that deposition into fat and not elimination from 
the body might be responsible for the short duration of action of 
this type of barbiturate in man as suggested by Goldstein and 
Aronow (1960). 
Pentobarbitone distributes rapidly in the non-human primate, 
the mean rate constants for the rapid distribution phase corresponding 
to an apparent half-life of 12 minutes, 9 minutes and 8 minutes in the 
rhesus monkey, cynomolgus monkey and baboon respectively. These 
values are similar to those in man (10 minutes, Ehrnebo, 1974) 
but are three to fourfold 
Ossenberg et al,l975). 
longer than those in the rat (3 minutes, 
The mean elimination half-lives of pentobarbitone of 132 minutes, 
153 minutes and 106 minutes in the rhesus monkey, the cynomolgus 
monkey and thebaboon, respectively were shorter than those in man 
<>22 hours, Brodie et al, 1953; Ehrnebo, 1974; Misra et al, 1971; 
Smith et al, 1973 and Wagner et al, 1977), butwere,similar to those 
in the rat (2 hours, Ossenberg et al, 1975; Buice, 1978) and other 
laboratory animals (0.6 - 3 hours, Brodie et al, 1953; Kazlowski 
et al, 1977). 
The total volume of distribution estimated after attainment of a 
pseudo-distribution equilibrium multiplied by the plasma concentration 
indicates that only 65, 77 and 77% of the administered drug remained 
in the body of the rhesus monkey, cynomolgus monkey and baboon 
respectively at 1, 1.0 and 0.67 hours respectively. 
The mean ratio of~/Kel of 0.72, 0.62 and 0.64 for the rhesus 
monkey, cynomolgus monkey and baboon respectively indicates that if 
a two-compartment open model is assumed these fractions of the 
pentobarbitone in the body were in the central compartment and 
available for elimination at any time during the terminal linear 
phase of the disposition curve (Gibaldi et al, 1969). 
- 148 -
---------
Concentrations of pentobarbitone in the peripheral compartment 
simulated for a two-compartment open model with pharmacokinetic 
parameters shown in Table 9:3,using equation 2:16,showed that equilibrium 
between the central and peripheral compartments was rapidly achieved. 
Peak concentrations of pentobarbitone of 11.4 )lg/ml, 11.3 )lg/ml and 
12.6 )lg/ml in the rhesus monkey, cynomolgus monkey and the baboon,. 
respectively were reached at 40 minutes post-administration in all 
three species of non-human primates. Thereafter, plasma concentrations 
of pentobarbitone in the central and peripheral compartments were 
similar (Table 9:5, Figures 9:1- 9:3). 
Discussion 
In man (Brodie et al, 1953; Ehrnebo, 1974; Smith et al, 1973) and 
the rat (Ossenberg et al, 1975) pentobarbitone has been shown to 
distribute according to a two-compartment open model. In non-human 
primates, the distribution phase does not contribute more than 8% to 
the total area under the plasma concentration-time curve, suggesting 
that pentobarbitone kinetics could be described by a one-compartment 
open model in the non-human primate species without introducing notable 
errors in the estimation of the pharmacokinetic parameters (Gibaldi and 
Perrier, 1975). However, inspection of the data shows that the rapid 
distribution phase is clearly defined and that distribution into the 
peripheral compartment does appear to be a feature of pentobarbitone 
disposition in the non-human primate. 
The total systemic clearance of pentobarbitone, adjusted for bodyweight· 
differences, in the non-human primate is approximately tenfold higher than 
in man (0.5 ~g/ml/kg, Ehrnebo, 1974; Wagner et al, 1977) but was similar 
to that in the rat (5 ~g/ml/kg - 9 ~g/ml/kg, Ossenberg et al, 1975; Bruice, 
1978) and in the rabbit (18.6 ~g/ml/kg, KOzlowski et al, 1977). Since 
pentobarbitone is eliminated almost exclusively by metabolism, the total 
systemic clearance presumably reflects metabolic clearance. If, after 
intravenous administration biotransformation occurs predominantly in 
the liver, the values for the clearance of pentobarbitone reflect 
hepatic clearance in the non-human primate species, therefore clearance 
values of sevenfold lower than in the liver blood flow imply that it 
is unlikely that an hepatic first-pass effect would be an important 
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feature of pentobarbitone disposition in the non-human primate after 
an oral dose and this would be true also if there were eKtra-hepatic 
sites of biotransformation except for biotransformation in the gut wall. 
Inspection of the half-lives of elimination of pentobarbitone 
in the non-human primate, the rat and the dog, shows that during the 
once-daily dosage regimen common to most chronic toxicity studies, 
pentobarbitone would not accumulate in the body of these commonly 
used laboratory animals, since each dose would have been eliminated 
before the next is received. In contrast, some accumulation of this 
drug would occur in man when administered once-daily for the treat-
ment of insomnia. For a normal human subject receiving 200 mg of 
pentobarbitone once·daily a steady state plasma concentration of 
approximately 4.0 ~g/ml would be achieved one week after commence-
ment of treatment. To achieve this same steady state plasma con-
centration of pentobarbitone in the non-human primate it would be 
necessary to inject pentobarbitone 13.3 mg, 9.8 mg and 15.2 mg 
intravenously to the rhesus monkey, cynomolgus monkey and baboon 
respectively at intervals of 124 minutes, 126 minutes and lOO minutes, 
respectively or tc adopt a similar dosing regimen. Alternatively, a 
more practical dosing regimen would·be the administration of 154.5 mg, 
112.0 mg and 218.9 mg orally, to the rhesus monkey, cynomolgus 
monkey and baboon respectively, once daily, assuming complete 
availability of pentobarbitone from the G.I. tract. However, even when 
completely absorbed, the total dose would have been eliminated from the 
body of the non-human primate after 12·tcl5 hours, if given once-daily. 
It would, therefore be necessary to administer this compound at intervals 
of about 12 hours to maintain concentrations of pentobarbitone in the 
plasma of non-human primates throughout the day. 
Using pharmacokinetic criteria, therefore, it canbe concluded that 
the non-human. prim;tte. is. not. a more suitable model to use to study 
the fate of pentobarbitone in man than are the other commonly used 
laboratory animal species. 
- 15 0 -
TABLE 9:2 
Mean observed concentrations of pentobarbitone (~ SD) in the pl~sma 
of the rhesus monkey, the cynomolgus monkey and the baboon after a 
single bolus intravenous injection of pentobarbitone at a level of 
12 mg/kg. Results are expressed as pg/ml. 
---------------- --------------------------------------------------
Time -------~~~=~~=--------------------
Rhesus monkey Cynomolgus monkey Baboon 
---------------- ---------------
------------------ ---------------
2 minute 13.3 + 2.5 18.3 + 3.8 19.8 + 7.2 
-
5 minute 17.8 + 1.8 17.0 + 1.1 19.0 + 5.3 
-
10 minute 17.1 + 1.6 15.0 + 1.6 15.9 + 4.0 
-
20 minute 13.9 + 1.8 12.8 + 1.1 13.4 + 2.8 
40 minute 11.8 + 2.4 11.0 + 1.2 10.4 + 1.2 
1 hour 9.7 + 2.6 9.3 + 1.1 8.8 + 1.2 
1.5 hour 7.9 + 2.2 7.4 ~ 0.9 7.2 + 1.1 
2 hour 6.6 + 2.2 6.2 ~ o. 7 5.8 + 1.1 
3 hour 4.6 + 2.0 5.0 ~ 0.8 4.0 + 1.0 
4 hour 3.6 + 2.1 4.0 + 0.8 2.4 + 0.6 
5 hour 2.7 + 1.7 2.9 + o. 7 1.6 + 0.8 
7 hour 1.8 + 1.3 1.6 ~ 0.4 1.1 + 0.5 
---------------- --------------- ------------------ ---------------
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TABLE 9:3 
Mean pharmacokinetic parameters (~ SD) determined for a two-compartment 
model after a single intravenous injection of pentobarbitone (12 mg/kg) 
into the rhesus monkey, the cynomolgus monkey and the babcon. The 
data are presented as means of results from individual animals. 
Parameter a Species ---------------~------------------ ---------------
Rhesus monkey Cynomolgus monkey Baboon 
Bodyweight(kg) 5.0 + 0.8 3.5 + 0.3 6.1 + 0.9 
Dose (mg) 60.0 + 11.2 41.4 + 4.5 72.0 + 85 
Dose (mg/kg) 12.1 + 0.4 12.1 + 2.2 12.0 + 0.6 
A 
B 
"' 
[3 
Kl2 
K21 
Kel 
AUC 
Cl 
t'1 
vl 
v2 
vd(ss) 
vd(f3J 
A/<l< 
B/[3 
(lJg/ml) 
(\lg/ml) 
-1 (hour ) 
-1 (hour ) 
(minute -l) 
-1 (minute ) 
-1 (minute ) 
( \Jg /ml/hour) 
(ml/minute) 
(minutes) 
(litres) 
(litres) 
(litres) 
(litres) 
(l!g/m1/hour) 
(\lg/m1/hour) 
5.9 + 3.6 
12.9 + 3.6 
3.530 ~ 3.579 
0.375 + 0.242 
0.013 + 0.015 
0.045 + 0.046 
0.008 ~ 0.004 
48 + 24 
23 + 10 
132 + 63 
3.2 ~ 0.6 
0.9 + 0.6 
4.1 + 1.2 
4.0 + l. 7 
4 + 4 
45 + 21 
8.1 + 3.3 
11.5 + 2.1 
4.5 + 4.308 
0.283 + 0.060 
0.026 + 0.026 
0.046 + 0.045 
0.008 + 0.002 
44 + 7 
16 + 3 
153 + 35 
2.1 + 0.2 
1.1 + o. 5 
3.3 + 0.4 
3.4 + 0.1 
3 + 1 
41 + 6 
8.7 + 7.5 
13.2 ~ 2.4 
5. 390 ~ 3. 706 
o. 409 + 0.089 
0.028 ~ 0.026 
0.058 + 0.037 
0.011 + 0.004 
35 + 6b 
36 + 9b 
106 ~ 24 
3.7+1.6 
1.4 + 0.8 
5.2 + 1.8 
5.3 + 1.3 
2 + 2 
32 + 6 
·-
-----------------------------------------------------------------------------
a 
b 
For details of abbreviations used see Chapter 2. 
Significance level (analysis of variance) baboons compared 
to the other two species (P < 0. 05) • 
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TABLE 9:4 
Mean pharmacokinetic parameters of pentobarbitone in the rhesus monkey, 
the cynomolgus monkey and the baboon for a one-compartment open model 
compared to those for a two-compartment open model following a single 
intravenous injection of pentobarbitone (12 ng/kg), The data are 
presented as means of results from individual animals. 
Parametera ------------------------~~~c!~~----------------------
One-compartment Two-compartment 
-------------------
------- -------
-----------------
Rhesus Cynomolgus Baboon Rhesus Cynomolgus Baboon 
monkey monkey monkey monkey 
-------------------
-------
-----------
------- -------
----------
------
AUC 
Cl 
tl:! 
vd 
Kel 
a 
b 
c 
(\lg/ml/hour) 45 44 36b 48 44 35b 
(ml/minute) 25 16 34b 23 16 36b 
(minutes) 124 126 lOO 132 153 106 
(litres)' 4.1 2.8 4.9 4.1 3.3 5.2 
-1 (minute ) 0.006 0.006 0.007 0.008 0.008 0.011 
For details of abbreviations used see Chapter·2. 
Significance level (analysis of variance),baboons compared to the 
other two species (P <. 0. OS) • 
vd = total volume of distribution = vd(ss) for the two-compartment 
model. 
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TABLE 9:5 
Calculated concentrations of pentobarbitone in the peripheral 
compartment after bolus intravenous injection of pentobarbitone 
12 )lg/ml to non-human primates. Results calculated from mean data 
and expressed as )lg/ml. 
Time 
Rhesus monkey Cynomolgus monkey Baboon 
----------------- --------------- ------------------ --------------
2 minute 1.5 1.9 1.6 
5 minute 3.6 4.2 3.7 
10 minute 5.8 7.0 6.3 
20 minute 9.5 10.0 9.5 
40 minute 11.4 11.3 12.6 
1 hour 11.1 10.8 10.9 
1.5 hour 9.6 9.5 9.4 
2 hour 8.2 8.3 7.9 
3 hour 5.8 6.2 5.5 
4 hour 4.1 4.7 3.9 
5 hour 2.9 3.5 2.7 
7 hour 1.4 2.0 1.3 
----------------- --------------- ------------------ ---------------
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Mean concentration-time curves after single intravenous injection of 
pentobarbitone 12 mg/kg to rhesus monkeys. Observed concentrations in 
the central compartment ( e e ) , and predicted concentrations in the 
central compartment (solid line) and in the peripheral compartment( a a 
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FIGURE 9:2 
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5 6 7 
Mean concentration-time curves after single intravenous ~njection of 
pentobarbitone 12 mg/kg to cynomolgus·monkeys. Observed concentration 
in the central compartment ( 0 0 ) , and predicted concentration in 
the central compartment (solid line) and in the peripheral compart-
ment ( • . ) . 
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FIGURE 9:3 
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Mean concentration-time curves after single intravenous injection of 
pentobarbitone 12 mg/kg to baboons. Observed concentrations { e . ) ' 
and predicted concentrations in the central compartment {solid lines) 
and in the peripheral compartment { • • ) • 
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CHAPTER 10 
GENERAL DISCUSSION 
After single intravenous injection of antipyrine, diazepam, 
frusemide, ibuprofen, isosorbide dinitrate, paracetamol and pento-
barbitone, plasma drug concentration-time curves were fitted by a 
biexponential equation in the rhesus monkey, the cynomolgus monkey 
and the baboon suggesting that the pharmacokinetics of-these compounds 
could be aescribed by a two-compartment: open model. However, the non-
linear least squares curve fitting programme used, BLUD, described these 
curves by a bicxponen~ial equation even though the initial distribution 
phase was short. For those compounds, i.e. antipyrine, frusemide, 
isosorbide dinitrate and pentobarbitone, for which an inspection of 
the plasma concentration-time curve suggested that a one-compartment 
might be more appropriate, the data was also fitted by normal regression 
techniques and the parameters predicted by both models were compared. 
Whichever model was appropriate, either a one-compartment open model 
or a two-compartment open model there were no species differences 
in the kinetic model that was most suitable for these compounds. 
A review of the literature of the pharmacokinetics of the compounds 
studied, in man and the commonly used laboratory animal species, reveals 
that in general, the same kinetic model applies in non-human primate 
species and other species. 
Analysis of variance of pharmacokinetic parameters showed that 
there were few significant pharmacokinetic differences between the 
rhesus monkey, the cynomolgus monkey and the baboon. Table 10:1 shows 
the apparent total volume of distribution expressed as a percentage of 
bodyweight for the non-human primate, man, the rat and other commonly 
used laboratory animals such as the dog, rabbit and guinea pig. From 
Table 10:1 it can be seen that the volume of distribution per kg body-
weight is similar in the non-human primate species and in man, the rat 
and other species, for each compound except diazepam and isosorbide 
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TABLE 10:1 
Volumes of distribution (Vd(ss)) expressed as a percentage of 
bcdyweight. A summary of individual results reported in Chapters 3-9. 
Compound 
Rhesus Cynomolgus Baboon 
monkey monkey 
Man a 
------------------ ------ ---------- ------ ------- ------ --------
Antipyrine 88 73 66 76 40-60 60-99 
Diazepam 
(0. 2 mg/kg) 
Desmethyldiaze~am 
(0. 2 mg/kg)D 
Diazepam 
(l.O mg/kg) 
Desmethyldiaz5pam 
(l mg/kg) 
Frusemide 
Isosorbide 
dinitrate 
Paracetamol 
Ibuprofen 
Pentobarbitone 
so 
171 
142 
ll 
273d 
82 
14 
82 
53 
183 
81 
182 
ll 
168 
106 
8 
96 
39 
128 
.63 
288 
9 
84 
98 
10 
86 
784 70-200 400-1300 
NA 64 lOO 
16 7-21 ll 
NA 3-6 NA 
85 85-95 58 
NA NA NA 
90-120 99-170 63-83 
-------------------- ------ ---------- --------------------- --------
a 
b 
c 
d 
NA 
For references see Chapters 3 - 9. 
Estimated, assuming that all the administered diazepam is 
primarily metabolised to desmethyldiazepam before elimination. 
Significant difference (analysis of variance) rhesus monkey 
compared with the cynomolgus monkey and baboon (P <.. 0.05). 
Significant difference (analysis of variance) rhesus monkey 
compared with the cynomolgus monkey and baboon (P < 0.01). 
value not available. 
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dinitrate. The relatively low values obtained for diazepam in the 
non-human primate are possibly attribut&ble to-the method of analysis 
of plasma concentrations, which was by high pressure liquid chro-. 
matography. This technique is presumably more accurate at low 
concentrations than the previously used gas chromatographic methods. 
For fuller discussion see Chapter 4. 
The large differences in the apparent volume of distribution 
per kg bodyweight of isosorbide dinitrate in the non-human primate 
and man are difficult to explain. However, it does appear that in 
the nonThuman primate following intravenous injection at a high dose 
level (1 mg/kg), that isosorbide dinitrate might be sequestered into 
a deep peripheral compartment and this does not seem to be detected 
in man after infusion of this compound (12 mg in 2.5 hours; Taylor et al, 
1980). 
Clearance is dependent on the organ extraction efficiency 
(extraction ratio) and on the supply of compound (i.e. blood flow) 
to the eliminating organs. For those compounds with clearance rates 
less than 45 ml/min, antipyrine, N-desmethyldiazepam, frusemide, 
ibuprofen and pentobarbitone, the clearance in the lighter cynomolgus 
monkey is lower than in the other two species (Table 10:2) and 
presumably reflects the corresponding activities of the drug 
metabolising enzymes responsible for the biotransformation of these 
compounds. Those compounds with higher clearance rates, diazepam, 
isosorbide dinitrate and paracetamol, were cleared at a similar rate 
in all three species although it might have been expected that the 
lighter cynomolgus monkey would have a lower rate of clearance because 
of its smaller organ size; the sizes of the organs being approximately 
proportional to (bodyweight) 2/3 (Dedrick, 1972). 
As antipyrine is eliminated almost exclusively by oxidative 
metabolism,this compound has been used as a model compound for the 
measurement of oxidative enzyme activity (Conney, 1967; Hunter and 
Chasseaud, 1976; Vesell, 1979). Using antipyrine clearance as an 
indicator of oxidative enzyme activity, Table 10:2 implies that the 
cynomolgus monkey has a significantly lower enzyme activity than the 
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TABLE 10:2 
Total systemic clearance values observed in the rhesus monkey, the 
cynomolgus monkey and the baboon. A summary of individual results 
reported in Chapters 3 - 9. 
Compound 
Antipyrine 
Diazepam(0.2 mg/kg) 
Desmethyldiazepam(0.2mg/kga) 
Diazepam (l.Omg/kg) 
Desmethyldiazepam(lmg/kga) 
Frusemide 
Isosorbide dinitrate 
Paracetamol 
Ibuprofen 
Pentobarbitone 
Rhesus 
monkey 
(ml/minute) 
--------------
26 
66 
11.2 
59 
13.3 
18 
188 
46 
15 
23 
Cynomolgus 
monkey 
(ml/minute) 
-----------
16b 
65 
8.5 
60 
7.1 
lOb 
200 
49 
7c 
16 
Baboon 
(ml/minute) 
28 
43d 
21.9e 
58 
13.8 
23 
169 
51 
13 
36d 
a Estimated assuming that all the administered diazepam is primarily 
metabolised to desmethyldiazepam before elimination. 
b 
c 
d 
e 
Significant difference (analysis of variance) cynomolgus monkey 
compared to the other two species (P < 0.05). 
Significant difference (analysis of variance) cynomolgus monkey 
compared to the other two species (P < 0.01). 
Significant difference (analysis of variance) baboon compared to 
the other two species (P < 0. 05) • 
Significant difference (analysis of variance) baboons compared to 
the other two species (P < 0.01). 
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other two species. However, when adjusted for bodyweight differences, 
the clearance of antipyrine in the cynomolgus monkey was only slightly 
less than in the other two species (Table 10:3), and this difference 
was not statistically significant (P<O.OS). The oxidative enzyme 
activity per kg bodyweight, therefore, would appear to be similar in 
these three species of non-human primate. 
Isosorbide dinitrate has been shown to have a high hepatic 
extraction ratio (Needleman et al, 1972) and, therefore, the clearance 
of this compound approximates to hepatic blood flow. If isosorbide 
dinitrate clearance is taken as a measure of hepatic blood flow this 
suggests that the liver blood flow is similar in the rhesus monkey, 
cynomolgus monkey and baboon and is approximately 30 ml/minute/kg 
(Table 10:2). Isosorbide dinitrate clearance is, however, only an 
approximate measure of the hepatic clearance which is approximately 
50 ml/minute/kg (see page lOO). 
When adjusted for bodyweight, clearances tended to be different 
in the cynomolgus monkey compared with the other two species of non-
human primates (Table 10:3), but in general adjusted clearances were 
similar in the non-human primate species to those in other commonly 
used laboratory animal species except for the rat. However, with the 
exception of frusemide and possibly ibuprofen, clearances were higher 
in animal species than in humans (Table 10:3). 
The biological half-life is frequently used to compare the rate 
animal species. of elimination of foreign compounds by different 
Inspection of Table 10:4 shows that with respect to this parameter, the 
non-human primate species are closer to the rat and to other commonly 
used laboratory animal species, than to man. In particular, antipyrine, 
diazepam, desmethyldiazepam and pentobarbitone which have biological 
half-lives greater than 12 hours in man, have got considerably shorter 
half-lives in the commonly used laboratory animal species. A similar 
comparison of other compounds reported in the literature shows the same 
trend, whereby, with the possible exception of indomethacin, isoniazid and 
- 162 -
TABLE 10:3 
Total systemic clearance adjusted for differences in bodyweight. A summary of individual results reported in Chapters 3-9. 
---------------------------------------------------------------------------------- . 
----------- ------------
---------~2~~!~~---------
-------------------------------Rhesus Cynomolgus Baboon Rata Man a Others a 
Compound monkey monkey 
(ml/minute (ml/minute (ml/minute (ml/minute (ml/minute (ml/minute/kg) 
/kg) /kg) /kg) /kg) /kg) 
--------.--------------------
----------- ------------ ------------ ------------ ------------ ------------------
Antipyrine 5.5 4.4 s.o 9.0 0.9 9.0 
Diazepam (0. 2 mg/kg) 14.3 18.lc 7.5 81.6 0.4 19-31 
Desmethyldiazepam(0.2mg/kgb) 2.4 2.4 3.8h NA 0.2 33.4 
Diazepam (1.0 mg/kg) 13.1 17.6d,e 10.2 
,.... 
Desmethyldiazepam(lmg/kgb) 
"' 
2.8 2.0 2.6 
w 
Frusemide 4.0 2.9d 3.7 7 .o 2.4 4.3 
Isosorbide dinitrate 39 59f 29 NA o.2-o.s NA 
Paracetamol 9.2 14.0 8.5 34. s· 18 
Ibuprofen 3.lg 2.0 2.1 NA NA NA 
Pentobarbitone 4.6 4.6 6.0 5-9 o.s 6-18 
NA Value not available. 
a For references see Chapters 3 - 9. 
b Estimated, assuming that all administered diazepam is primarily metabolised to desmethyldiazepam before elimination. 
c Significant difference (analysis of variance) cynomolgus monkey compared with the other two non-human primate species (P<O.Ol). 
d Significant difference (analysis of variance) cynomolgus monkey compared with the rhesus monkey (P<O.OS). 
e Significant difference (analysis of variance) cynomolgus monkey compared with the baboon (P<O.Ol). 
f Significant difference (analysis of variance) cynomolgus monkey compared with the baboon (P<O .05) . 
g Significant difference (analysis of variance) rhesus monkey compared with the other two non-human primate species (P<O.OS). 
h Significant difference (analysis of variance) baboon compared with the other two non-human primate species (P<O.OS). 
,_. 
"' 
"" 
TABLE 10:4 
Half-lives of elimination in non-human primates, the rat, man and other commonly used laboratory animal species. 
A summary of individual results reported in Chapters 3-9. 
---------------------------- ----------------------------------------------------------------------------
----------- .,------------- ----------~12eS:!!:'~---·------------------
Compound Rhesus cynomolgus Baboon 
monkey monkey Rata Man a 
(minutes) (minutes) (minutes) (minutes) (minutes) 
---------------------------- ----------- ------------- ------------ ------------ ------------
Antipyrine b 108 lOB 90 144 12c 
Diazepam (0. 2 mg/kg) 54 43 60 60 24-48c 
Diazepam (1.0 mg/kg) 45 50 64 
Desmethyldiazepam(0.2mg/kg) 7.9c 9.3c 4.5c 30-200C 
Desmethyldiazepam(l.Omg/kg) 5.Bc l0.5c l0.6c 
Frusemide b 26 28 14 22 26-72 
Isosorbide dinitrated 62e 23 24 <1 9 
Paracetamol 72 59 75 37 2-3c 
Ibuprofen 91 70 49 84 2c 
Pentobarbitone 132 153 106 123 >22c 
a For references, see Chapters 3-9. 
b Half-lives estimated for a one-compartment open model. 
c Half-lives are expressed in hours. 
d llalf-lives shown are possibly associated with slow release from a deep peripheral 
compartment (see Chapter 6). 
-----------
Others a 
(minutes) 
-----------
110 
80-456 
lOc 
25 
7 
32 
3.5c 
36-180 
e Significant difference (analysis of variance) rhesus monkey compared to the other two non-human primate species 
(P<O.Ol) • 
I ____ _ 
caffeine, the plasma biological half-lives are shorter in the common 
laboratory animals than in man (Table 10:5). In particular, there 
does not appear to be a suitable kinetic model for man amongst these 
species for those compounds with half-lives greater than 30 hours in 
man. 
The relatively short half-lives found in the non-human primate 
species and other commonly used laboratory animal species indicate 
that during the once-daily dosing regimen common to most chronic 
toxicity studies, most compounds would not accumulate in the body of 
the laboratory animal species. This is because each dose would have 
been eliminated before the next is received ; thus the toxic 
effects of the compound may be under-estimated relative to human use. 
In contrast some accumulation of foreign compounds with half-lives 
longer than 4 hours would occur in humans during a once-daily dosing 
regimen. In clinical practice, however, drugs are administered at 
intervals throughout the day that are too short to allow complete 
elimination of the administered dose before the next is received. It 
is possible, therefore, with such a dosing regimen, that drug would 
always be present in the body to produce advantageous pharmacological 
effects, but also possibly undesirable side effects. Equations 2:16 and 
2:17 can be used to estimate the steady state plasma concentrations 
of drug that would be achieved during normal therapy in humans; and 
also to define a dosing regimen that needs to be followed during the 
administration of compounds to non-human primates to achieve the same 
steady state plasma concentrations as those observed in man. 
Table 10:6 shows the intravenous doses required, if administered 
at intervals of one elimination half-life to achieve the normal steady 
state drug concentrations in the rhesus monkey, the cynomolgus 
moneky and the baboon, for the compounds described in this thesis. 
From Table 10:6 it can be seen that it would be necessary to administer 
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TABLE 10:5 
Plasma half-lives in the rhesus monkey, rat, man and dog (from 
Smith and Caldwell, 1977). 
----------------- -----------------------------------------------
----------------------
~E~~~~~-----------------Compound Rhesus Rat Man Dog 
monkey 
_l!!~!:E!!L (hours) (hours) (hours) 
------------------ ----------- ------------ -----------
Indomethacin 1.5 4 2 1.5 
Isoniazide 5 10 5 5 
Caffeine 2.4 2 3.5 5 
Pethidine 1.2 5.5 o. 9 
Halofenate 16 26 24 24 
Diazoxide 19 29 
Myalex 3 29 31 30 
Oxisuran 21 10 55 12 
Phenylbutazone 8 72 6 
Oxypnenylbutazone 8 72 0.5 
------------------ ---------- ----------- ------------ -----------
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TABLE 10:6 
Possible dosing regimes to achieve normal steady state concentrations of drug in the plasma of rhesus monkeys, 
cynomolgus monkeys and baboons. 
==================-============~~~f~~=-===================-==================-----Pr--e-d-i~-t~-d--
' 
Drug Rhesus monkey Cynomolgus monkey Baboon 
Dose (mg) ·r(minutes) Dose(mg) ~(minutes) Dose(mg) r(minutes) Dose(mg) 
Human 
1:' (hours) 
mean steady 
state plasma 
concentration 
Antipyrine 16.6 lOB 10.4 lOB 14.3 90 250 12 5500 
Diazepam ·1.9 45 2.5 So 2.9 64 30 24 750 
Frusemide 
Isosorbide dinitrate 
0.2 
ll.6a 
26 
62 
0.1 
4.6a 
28 
23 
14 
24 
80 
10 
24 
6 
400 
l 
Paracetamol 19.9 75 17.3 59 23.0 75 1000 8 6000 
Ibuprofen 0.6 91 0.2 70 0.3 49 400 8 400 
Pentobarbitone 13.3 134 9.8 153 15.2 106 200 24 4000 
Dose 
a 
Amount of drug injected intravenously. 
D,osing interval. 
Dose administered in ~g quantities. 
-- -------------------------------------------------------------------------------------------
relatively more drug per day to non-human primates than to man to 
maintain the same steady state plasma concentrations of drug in both 
non-human primates and humans and it would be necessary to administer 
the drug at frequent intervals to ensure that some drug remains in 
the body of the non-human primate throughout the day. For example, 
.it would be necessary to administer 61 mg. (1.9 mg every 45 minutes) of 
diazepam to the rhesus monkey to maintain the same steady state plasma 
concentration of diazepam observed in man following a once-daily 
administration of 30 mg diazepam. 
In most pharmacology and toxicology studies, however, the drug 
is given orally. The amount of drug that will reach the systemic 
circulation will therefore partly depend on the dose matrix and 
would be impossible to predict. Table 10:6 is, therefore, intended 
to be a primary standard dosing regimen to obtain the steady state 
concentrations aimed for. 
Using pharmacokinetic criteria, therefore, it can be concluded 
that the cynomolgus monkey and the baboon are possible replacement 
species for the rhesus monkey for use in pharmacological and 
toxicological studies, but that the non-human primate is not a more 
suitable model for man than are the other commonly used laboratory 
animal species. However, it is possible to design a dosing regimen 
to compensate for species differences in the rate of elimination if 
the pharmacokinetic parameters are known. Other factors in the 
choice of animal model for man for use in safety testing of foreign 
compounds are differences in the pattein and nature of biotransformation, 
distribution of drug into target tissue and protein binding. It is 
not possible to compensate for species differences with respect to 
these latter factors, but it has been suggested that with respect 
to biotransformation of foreign compounds, the non-human primate is 
a more suitable model for man than are other commonly used laboratory 
animal species (Smith and Caldwell, 1977). 
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APPENDIX 
Concentrations of antipyrine in the plasma of rhesus monkeys after 
intravenous injection of antipyrine 92 mg/kg. Results are expressed 
as )Jg/ml. 
--------------
-----------------------------------------------------
ANIMAL 
--------------------
----------
----------
--------
TIME 
1 2 3 4 5 
--------------
---------- -------- ----------
----------
--------
2 minute 157 79 86 136 107 
5 minute 186 129 93 143 107 
10 minute 157 lOO 79 129 107 
20 minute 136 86 64 121 93 
40 minute 107 79 57 107 79 
1 hour 93 71 50 86 64 
2 hour 71 43 36 57 43 
3 hour 50 36 21 36 36 
4 hour 36 21 14 21 21 
5 hour 29 14 ND 14 14 
7 hour 14 ND ND ND ND 
-------------------------- ---------- ------------------------------
ND: Less than the limit of detection (2\lg/ml) • 
Concentrations of antipyrine in the plasma of cynomolgus monkeys 
after intravenous injection of antipyrine 92 mg/kg. Results are 
expressed as jJ g/ml. 
-------------- -----------------------------------------------------
TIME 
2 minute 
5 minute 
10 minute 
20 minute 
40 minute 
1 hour 
1.5 hour 
2 hour 
3 hour 
4 hour 
5 hour 
7 hour. 
1 
137 
141 
137 
125 
108 
94 
75 
65 
41 
29 
24 
14 
2 
137 
149 
143 
137 
116 
98 
80 
71 
45 
33 
22 
18 
ANIMAL 
3 
98 
131 
131 
118 
112 
92 
75 
67 
43 
31 
24 
16 
4 
67 
133 
133 
114 
84 
86 
69 
57 
31 
24 
18 
4 
5 
82. 
133 
129 
110 
90 
75 
63 
49 
35 
27 
16 
8 
-------------- ---------- ---------- ---------- -------------------
Concentrations of antipyrine in the plasma of baboons after intravenous 
injection of antipyrine 92 mg/kg. Results are expressed as ~g/m1. 
-------------- -----------------------------------------------------
ANIMAL 
TIME -------- ----------
---------- -------------------
1 2 3 4 5 
------------- ------ --------- ---------- --------- --------
2 minute 108 167 123 144 167 
5 minute 148 179 121 150 175 
10 minute 129 121 144 131 190 
20 minute 117 121 131 121 129 
40 minute 102 76 106 115 112 
1 hour 79 76 79 104 97 
1.5 hour 69 50 79 77 96 
2 hour 40 49 62 67 67 
3 hour 29 19 55 39 46 
4 hour 14 12 30 22 35 
5 hour 10 8 16 17 21 
7 hour 4 4 4 7 10 
--------------- ---------- ---------- ---------
----------
--------
-- --------------------------------------------------------------------------------
Concentrations of diazepam in plasma after bolus intravenous 
injection of diazepam 0.2 mg/kg to rhesus monkeys. Results are 
expressed as ng/m1. 
--------------- ---------------------------------------------------
. 
ANIMALS 
TIME 
l 2 
I 
----------r-------------------1 
3 I 4 5 j 
~ 
----------------- ----------
--------
----------;---------- ---------; 
2 minute 450 399 414 417 478 I I 
I 
5 minute 401 419 368 343 401 I 10 minute 346 300 ,310 160 315 
20 minute 213 201 173 66 196 
40 minute 91 79 84 33 117 
1 hour 43 43 38 15 48 
1.5 hour NS NS NS NS NS 
2 hour 15 5 5 5 18 
4 hour 2 ND ND ND 7.5 
6 hour ND ND ND ND 3 
----------------
----------
-------
---------- --------------------
ND: Less than the limit of detection (2 ng/ml). 
NS: No sample taken at this time. 
-- ---------------------------------------------------------------------------------------
Concentrations of diazepam in plasma after intravenous injection of 
diazepam 0.2 mg/kg to cynomolgus monkeys. Results are expressed 
as ng/ml. 
---------------
-----------------------------------------------------
ANIMAL 
TIME ----------
-----------
----------
---------
--------
l 2 3 4 5 
--------------- ---------
---------
---------- ---------
--------
2 minute 428 439 266 602 298 
5 minute 395 323 279 375 254 
10 minute 267 231 249 356 215 
20 minute 198 190 157 220 112 
40 minute 115 82 85 113 56 
l hour 54 46 41 46 34 
1.5 hour 30 15 18 2l 21 
2 hour 20 3 16 13 11 
3 hour 3 NO 8 5 3 
4 hour ND NO 3 2 NO 
5 hour ND ND NO ND ND 
---------------
---------
--------- ----------
--------------------
ND: Less than the limit of detection (2 ng/ml) • 
Concentrations of diazepam in plasma after bolus intravenous injection 
of diazepam 0.2 mg/kg to baboons. Results are expressed as ng/m1. 
TIME 
2 minute 
5 minute. 
10 minute 
20 minute 
40 minute 
1 hour 
1.5 hour 
2 hour 
3 hour 
4 hour 
5 hour 
7 hour 
884 
740 
572 
488 
200 
108 
72 
48 
22 
11 
5 
ND 
ANIMAL 
2 3 4 5 
630 
700 
530 
458 
331 
210 
148 
116 
76 
46 
26 
10 
450 
460 
400 
304 
194 
124 
80 
48 
20 
8 
ND 
ND 
520 
440 
416 
304 
207 
128 
90 
82 
36 
18 
9 
3 
458 
440 
348 
300 
173 
138 
82 
44 
10 
ND 
ND 
ND 
ND Less than the limit of detection (2 ng/ml). 
Concentrations of diazepam in plasma after bolus intravenous injection 
of diazepam 1.0 mg/kg to rhesus monkeys. Results are expressed as ng;fnl, 
---------------~------------------------------------------------------
ANIMAL 
TIME ----------- --------- ---------- ---------- --------
2 minute 
5 minute 
10 minute 
20 minute 
40 minute 
1 hour 
1.5 hour 
2 hour 
3 hour 
4 hour 
5 hour 
7 hour 
1 
3071 
2274 
1677 
1326 
556 
356 
191 
130 
66 
30 
8 
ND 
2 
2879 
2696 
2066 
1390 
605 
340 
124 
86 
44 
16 
5 
ND 
3 
3338 
2355 
1966 
1105 
310 
226 
102 
51 
15 
2 
ND 
ND 
ND Less than the limit of detection (2 ng/ml) • 
4 
2599 
2759 
1946 
1369 
696 
417 
183 
94 
16 
4 
ND 
ND 
5 
3092 
2604 
1804 
1026 
478 
226 
135 
86 
32 
16 
ND 
ND 
Concentrations of diazepam in plasma after intravenous injection 
of diazepam 1.0 mg/kg to cynomolgus monkeys. Results are expressed 
as ng/ml. 
ANIMAL 
TIME ----------- ---------- ---------- ---------- --------
2 minute 
5 minute 
10 minute 
20 minute 
40 minute 
1 hour 
1.5 hour 
2 hour· 
3 hour 
4 hour 
5 hour 
7 hour 
1 
2705 
2148 
1721 
1016 
475 
269 
131 
66 
33 
12 
5 
ND 
2 
779 
902 
787 
533 
344 
180 
98 
66 
33 
16 
7 
ND 
3 
1918 
1853 
1541 
1098 
426 
295 
148 
82 
35 
16 
5 
ND 
ND Less than the limit of detection (2 ng/ml) 
4 
2197 
2082 
1557 
1131 
557 
298 
131 
66 
25 
7 
ND 
ND 
5 
1607 
1475 
1197 
656 
443 
230 
148 
82 
49 
16 
7 
ND 
Concentrations of diazepam in plasma after bolus intravenous 
injection of diazepam 1.0 mg/kg to baboons. Results are expressed 
as ng/ml. 
----------------,--------------------------------------------i 
ANIMAL 
TIME -------- ------- -------- -------- --------
1 2 3 4 5 
----------------
-------- ------- ------- -------- --------
2 minute 3300 2320 1950 1530 1760 
5 minute 3360 2500 1920 1980 2030 
10 minute 2700 2000 1750 1320 1670 
20 minute 1100 1000 1440 1350 1740 
40 minute 630 600 780 628 670 
1 hour 286 262 476 444 472 
1.5 hour 220 145 250 279 255 
2 hour 186 86 194 200 150 
3 hour 76 55 108 120 86 
4 hour 42 24 50 56 55 
5 hour 24 10 25 25 32 
7 hour 7 2 7 7 12 
----------------- -------- -------- -------- --------~-------
Plasma concentrations of diazepam metabolite after bolus intravenous 
injection of diazepam 0.2 mg/kg to rhesus monkeys. Results are 
expressed as ng/ml 
TIME 
2 minute,. 
5 minute 
10 minute 
20 minute 
40 minute 
1 hour 
2 hour 
4 hour 
6 hour 
24 hour 
30 hour 
48 hour 
72 hour 
1 
ND 
23 
14 
42 
89 
94 
80 
69 
56 
10 
7 
NO 
NO 
2 
NO 
13 
76 
94 
127 
156 
142 
121 
92 
25 
17 
3 
ND 
ANIMAL 
3 
ND 
0 
30 
58 
73 
105 
94 
so 
63 
20 
12 
3 
NO 
NO: Less than the limit of detection(2 ng/ml) 
4 
ND 
9 
23 
78 
106 
112 
101 
80 
62 
18 
11 
3 
NO 
5 
NO 
10 
28 
71 
99 
105 
175 
146 
110 
28 
20 
3 
NO 
Plasma concentration~ of diazepam metabolite after bolus intravenous 
injection of diazepam 0.2 mg/kg to cynomolgus monkeys. Results are 
expressed as ng/ml. 
--------------------------------------------------------------------
ANIMAL 
TIME 
---------------------------------------- ---------
1 2 3 4 5 
----------------- --------- --------- --------- ---------- ---------
2 minute ND ND ND ND ND 
5 minute ND 41 ND 24 7 
10 minute 50 70 17 13 27 
20 minute 53 67 57 53 67 
40 minute lOO 69 71 99 90 
1 hour 121 107 74 121 113 
1.5 hour 147 93 87 97 104 
2 hour 131 79 101 94 101 
3 hour 119 69 91 86 97 
4 hour 106 61 84 75 99 
5 hour 96 57 80 69 93 
7 hour 81 40 65 63 75 
24 hour 26 7 29 21 30 
30 hour 16 4 21 14 21 
48 hour 4 ND 7 3 7 
72 hour ND ND ND ND ND 
----------------- --------- --------- --------- ----------
----------
ND: Less than the limit of detection (2 ng/ml). 
Plasma concentrations of diazepam metabolite after bolus intravenous 
injection of diazepam 0.2 mg/kg to baboons. Results are expressed 
as ng/ml. 
-------------- ---------------------------------------------------
ANIMAL 
TIME 
------------------------------
---------- ---------
1 2 3 4 5 
--------------- ----------
--------
---------- ---------- ---------
2 minute ND NO NO 4 ND 
5 minute ND NO 45 14 NO 
10 minute 5 4 so 58 ND 
20 minute 32 93 79 72 22 
40 minute 76 lOO 114 84 60 
1 hour lOO 106 110 107 86 
1.5 hour 94 116 120 104 126 
2 hour 89 118 lOO 90 117 
3 hour so 106 lOO so 112 
4 hour 76 90 84 62 lOO 
5 hour 66 so 70 47 84 
7 hour 48 55 46 22 60 
24 hour 4 4 3 3 5 
30 hour ND NO ND NO ND 
---------------
----------
--------
--------------------------------
ND: Less than the limit of detection (2 ng/ml). 
Plasma concentrations of diazepam metabolite after bolus intravenous 
injectibn of diazepam 1.0 mg/kg to rhesus monkeys. Results are 
expressed as ng/ml. 
ANIMALS 
TIME --------- -------------------- ---------- --------
2 minute 
5 minute 
10 minute 
20 minute 
40 minute 
1 hour 
1.5 hour 
2 hour 
3 hour 
4 hour 
5 hour 
7 hour 
24 hour 
30 hour 
48 hour 
72 hour 
1 
ND 
179 
465 
466 
565 
520 
487 
465 
499 
444 
430 
422 
160 
133 
44 
10 
2 
22 
310 
410 
731 
1174 
1152 
1041 
953 
753 
665 
563 
443 
66 
44 
4 
ND 
3 
ND 
22 
177 
465 
709 
665 
675 
642 
554 
443 
400 
310 
44 
22 
2 
ND 
ND: Less than the limit of detection (2 ng/m1). 
4 
ND 
89 
244 
509 
731 
864 
797 
720 
665 
576 
457 
377 
44 
22 
ND 
ND 
5 
ND 
89 
377 
665 
886 
742 
709 
642 
598 
487 
396 
265 
15 
5 
ND 
ND 
Plasma concentrations of diazepam metabolite after bolus intravenous 
injection of diazepam 1.0 mg(kg to cynomolgus monkeys. Results are 
expressed as ng/ml. 
---------------- ---------------------------------------------------
ANIMALS 
TIME ---------- --------- --------- ---------- --------
1 2 3 4 5 
--------------- ---------- --------- --------- ---------- --------
2 minute 
5 minute 
10 minute 
20 minute 
40 minute 
1 hour 
1.5 hour 
2 hour 
3 hour 
4 hour 
5 hour 
7 hour 
24 hour 
30 hour 
48 hour 
72 hour 
14 
114 
229 
343 
400 
471 
471 
486 
443 
471 
457 
414 
214 
171 
71 
25 
ND 
ND 
143 
157 
357 
429 
529 
471 
457 
457 
443 
314 
61 
39 
4 
ND 
ND 
27 
171 
429 
429 
543 
514 
600 
571 
457 
407 
350 
106 
71 
14 
2 
ND 
ND 
103 
414 
686 
700 
757 
700 
643 
543 
543 
457 
186 
150 
49 
19 
ND 
6 
so 
33 
457 
486 
486 
486 
471 
471 
486 
486 
200 
170 
57 
14 
____________________ :_ _________ : 
Plasma concentrations of diazepam metabolite after bolus intravenous 
injection of diazepam 1.0 mg/kg to baboons. Results are expressed as 
ng/ml. 
----------------- ---------------------------------------------------
ANIMAL 
TIME ---------- --------- ------------------- ---------
2 minute 
5 minute 
10 minute 
20 minute 
40 minute 
l hour 
1.5 hour 
2 hour 
3 hour 
4 hour 
5 hour 
7 hour 
24 hour 
30 hour 
48 hour 
l __ :~ ____ ::~: ___  
l 
ND 
32 
128 
277 
330 
336 
324 
366 
344 
258 
162 
96 
48 
35 
13 
4 
2 
ND 
10 
66 
222 
434 
403 
456 
426 
430 
350 
330 
282 
200 
66 
24 
3 
ND 
20 
86 
258 
500 
760 
780 
720 
700 
760 
770 
750 
340 
248 
104 
4 
4 
79 
llO 
180 
260 
282 
312 
360 
360 
350 
310 
268 
136 
106 
60 
5 
ND 
ND 
20 
190 
560 
670 
no 
700 
670 
680 
600 
520 
177 
106 
32 
----~----l---~~---l----~~----~-----~---
ND: Less than the limit of detection (2 ng/ml). 
Concentrations of frusemide in plasma after bolus intravenous 
injection of frusemide 3.0 mg/kg to rhesus monkeys. Results are 
expressed as ~g/ml. 
--------------------------------------------------------------------
ANIMALS 
TIME 
---------- ------------------- ----------
--------
1 2 3 4 5 
---------------- ---------- --------- --------- ----------
--------
2 minute 33 33 32 34 26 
5 minute 29 22 22 22 14 
10 minute 23 17 16 19 12 
20 minute 16 10 11 12 8 
40 minute 9 3 4 7 3 
1 hour. 5 3 3 4 2 
1.5 hour 3 2 ND 2 ND 
2 hour 2 ND ND ND ND 
3 hour ND ND ND ND ND 
----------------- ---------- --------- -----------------------------
ND: Less than the limit of detection (2 ~g/ml). 
Concentrations of frusemide in plasma after bolus intravenous injection 
of frusemide 3.0 mg/kg to cynomolgus monkeys. Results are expressed 
as \lg/ml. 
----------------- ------------------------------------------------
ANIMAL 
TIME 
---------
--------
---------- ----------
-------
1 2 3 4 5 
----------------- ---------
--------
---------- ----------
-------
2 minute 34 35 33 32 34 
5 minute 28 30 25 27 22 
10 minute 18 25 21 16 17 
20 minute 15 21 16 15 14 
40 minute 11 14 8 8 5 
1 hour 6 8 5 4 2 
1.5 hour 2 4 3 2 2 
2 hour 2 3 2 ND ND 
3 hour ND ND ND ND ND 
----------------- ---------
--------
---------- ----------
--------
ND: Less than the limit of detection (2 pg/ml). 
Concentration of frusemide in plasma after bolus intravenous injection 
of frusemide 3.0 mg/kg to baboons. Results are expressed as ~g/ml. 
---------------- -------------------------------------------------
ANIMALS 
TIME 
------------------- --------- ----------
-------
l 2 3 4 5 
---------------- --------- --------- --------- ----------
-------
2 minute 52 46 38 42 40 
5 minute 28 29 30 29 32 
10 minute 18 22 23 23 22 
20 minute 10 13 15 14 15 
40 minute 3 4 5 3 5 
1 hour ND NO 2 2 2 
1.5 hour ND NO ND ND ND 
----------------- --------- ---------
--------
----------
-------~ 
ND:, Less than the limit of detection (2 ~g/ml}. 
Concentration of isosorbide dinitrate in the plasma of the rhesus monkey 
after a single bolus intravenous injection of isosorbide dinitrate at a 
level of 1.0 mg/kg. Results are expressed as ng/ml. 
~----------------- -------------------------------------------------~ 
ANIMAL 
TIME 
--------
--------- --------- ---------- ----------
1 2 3 4 5 
-----------------
--------
--------- --------- ---------- ----------; 
2 minute· 658 514 530 506 557 
5 minute 648 428 317 434 457 
10 minute 481 394 288 386 420 
15 minute 285 300 280 317 343 
30 minute 232 157 215 211 214 
45 minute 149 146 151 160 157 
1 hour 99 106 126 123 94 
1.5 hour 71 86 so 106 69 
2 hour 56 43 55 57 43 
3 hour 40 20 28 31 20 
17 7 7 11 6 I 4.5 hour 
' ' ____________________________________________________________________ j 
Concentrations of isosorbide dinitrate in the plasma of the cynomolgus 
monkey after a single bolus intravenous injection of isosorbide dinitrate 
at a level of 1.0 mg/kg. Results are expressed as ng/m1. 
--------------------------------------------------------------------
ANIMAL 
TIME 
----------------------------- -------------------
1 2 3 4 5 
-----------------
--------
--------- --------- --------- ---------
2 minute 630 527 608 608 556 
5 minute 660 673 478 586 508 
10 minute 530 421 350 430 502 
15 minute 420 332 299 354 463 
30 minute 234 179 251 181 201 
45 minute 150 75 98 102 119 
1 hour 90 50 52 63 68 
1.5 hour 39 22 20 33 25 
2 hour 18 9 8 10 10 
3 hour 5 2 2 3 2 
4 hour 3 ND ND 1 ND 
5 hour ND ND ND ND ND 
----------------- ----------------------------- ---------~---------
ND: Less than the limit of detection (1 ng/ml). 
I 
I 
Concentrations of isosorbide dinitrate in the plasma of the baboon 
after a single bolus intravenous injection of isosorbide dinitrate at 
a level of 1.0 mg/kg. Results are expressed as ng/ml. 
---------------- -------------------------------------------------
ANIMALS 
TIME 
-------
---------r--------- ----------- ---------
l 2 i 
I 
3 4 5 
----------------
-------
------------------- -----------
---------
2 minute 1475 1478 1344 2003 1561 
5 minute 831 1134 1127 1548 1249 
10 minute 771 694 742 771 774 
15 minute 599 659 570 532 633 
30 minute 368 353 378 347 3?6 
45 minute 188 195 290 185 213 
l hour 167 125 163 128 143 
1.5 hour 67 67 67 55 61 
2 hour 29 29 29 23 26 
3 hour 6 7 7 3 6 
4 hour l l l ND l 
5 hour ND ND ND ND ND 
-------------------------- --------- -------------------------------
ND: Less than the limit of detection (l ng/ml). 
Concentrations of paracetamol in the plasma of the rhesus monkey 
after a single bolus intravenous injection of paracetamol at a 
level of 70 mg/kg. Results are expressed as ~g/ml. 
----------------- -------------------------------------------------
ANIMAL 
TIME 
---------
--------
------------------------------
1 2 3 4 5 
-----------------
-------- --------
--------- -----------
--------
2 minute 112 lOO 116 lOO 98 
5 minute 100 90 102 86 77 
10 minute 89 84 93 84 68 
20 minute 72 68 75 77 58 
40 minute 53 54 64 53 42 
1 hour 34 36 42 40 29 
1.5 hour 26 31 27 24 22 
2 hour 14 22 18 15 14 
3 hour 10 13 12 10 12 
4 hour 7 8 8 6 7 
5 hour 4 3 4 4 2 
7 hour 2 ND ND ND ND 
----------------- ---------
--------
--------- --------------------
ND: Less than the limit of detection (1 l!g/mlf. 
Concentrations of paracetamol in the plasma of the cynomolgus monkey 
after a single bolus intravenous injection of paracetamol at a level 
of 70 mg/kg. Results are expressed as ~g/ml. 
-------------------------------------------------------------------
ANIMAL 
TIME 
------------------ ---------------------
--------
l 2 3 4 5 
----------------
-------- --------
---------- ----------
--------
2 minute 85 76 67 80 79 
5 minute 123 95 116 61 60 
10 minute 97 74 95 55 39 
20 minute 85 44 74 36 37 
40 minute 49 41 52 23 32 
l hour 42 28 32 l3 28 
1.5 hour 19 18 18 lO 22 
2 hour 15 lO ll 6 18 
3 hour 8 4 10 3 7 
4 hour 5 4 5 l 4 
5 hour 4 2 3 ND 2 
7 hour l ND 2 ND ND 
j 
I 
I 
------------------ ------------------ ---------- ----------
---------· 
ND: Less .than the limit of detection (l ~g/ml). 
Concentrations of paracetamol in the plasma of the baboon after a single 
bolus intravenous injection of paracetamol at a level of 70 mg/kg. Results 
are expressed as ~g/ml. 
----------------
---------------------------------------------------] 
ANIMAL 
TIME 
-------------------- ------------------------------
1 2 3 4 5 
--------------- ----------- ---------
--------
----------
--------
2 minute 67 90 84. .87 109 
5 minute 80 87 77 71 77 
10 minute 79 87 80 68 91 
20 minute 77 75 59 65 75 
40 minute 58 53 52 55 52 
l hour 38 28 48 45 41 
1.5 hour 32 17 32 39 34 
2 hour 28 10 27 31 28 
3 hour 14 3 16 20 18 
4 hour 10 ND 8 13 12 
5 hour 4 ND 5. 9 8 
7 hour ND ND 2 4 3 
--------------------------- --------- --------------------
--------..J 
ND: Less than the limit of detection (1 ~g/ml). 
Concentrations of ibuprofen in the plasma of the rhesus monkey after 
a single bolus intravenous injection of ibuprofen at a level of 15 mg/kg. 
Results are expressed as ~g/ml. 
---------------- --------------------------------------------------
ANIMAL 
TIME 
--------
---------- --------- -------------------
1 2 3 4 5 
-----------------
--------
----------
--------
----------
--------
2 minute 242 157 164 169 124 
5 minute 191 129 134 218 122 
10 minute 161 90 88 125 105 
20 minute 83 67 so 65 61 
40 minute 34 27 24 35 37 
1 hour 17 14 14 24 17 
1.5 hour 13 8 6 10 9 
2 hour 10 6 4 7 6 
3 hour 6 4 3 5 2 
4 hour 4 2 2 4 2 
5 hour 2 2 2 2 1 
7 hour 1 1 1 1 1 
------------------ ------------------- ---------L---------- ---------
Concentrations of ibuprofen in the plasma of the cynomolgus monkey 
after a single bolus intravenous injection of ibuprofen at a level of 
15 mg/kg. Results are expressed as l.lg/ml. 
---------------- -------------------------------------------------
ANIMAL 
TIME 
--------- ---------
--------- ---------
--------
1 2 3 4 5 
---------------- --------- --------- --------- ---------
--------
2 minute 202 230 181 230 260 
5 minute 203 344 191 211 228 
10 minute 148 187 154 142 170 
20 minute 90 95 116 102 130 
40 minute 51 33 69 61 77 
1 hour 36 24 40 39 43 
1.5 hour 19 21 18 14 32 
2 hour 10 7 6 7 19 
3 hour 6 3 4 4 12 
4 hour 5 1 3 3 7 
5 hour 2 1 2 1 2 
7 hour 2 ND ND ND 2 
----------------- --------- --------- --------- ----------
--------
NO: Less than the limit of detection (0. 4 1Jg/ml). 
Concentrations of ibuprofen in the plasma of the baboon after a single 
bolus intravenous injection of ibuprofen at a level of 15 mg/kg. Results 
are expressed as ~g/ml. 
-------------------------------------------------------------------
ANIMAL 
TIME 
-------- ---------- --------- ------------------
l 2 3 4 5 
---------------- -------- ---------- --------- ---------- -------
2 minute 
5 minute 
10 minute 
20 minute 
40 minute 
l hour 
1.5 hour 
2 hour 
3 hour 
4 hour 
5 hour 
7 hour 
------------------
200 
167 
143 
so 
35 
lO 
8 
4 
1 
ND 
ND 
ND 
200 
167 
134 
so 
48 
23 
17 
7 
2 
l 
ND 
ND 
151 
133 
119 
94 
68 
55 
28 
28 
7 
5 
2 
l 
-----------------------------
186 
170 
129 
lOO 
70 
58 
22 
14 
4 
3 
i 
I 
159 
154 
119 
91 
64 
49 
28 
8 
6 
2 
----~-----l ___ :~--
ND: Less than the limit of detection (0.4 ~g/ml). 
Concentrations of pentobarbitone in the plasma of the rhesus monkey 
after a single bolus intravenous injection of pentobarbitcne at a 
level of 12 mg/kg. Results are expressed as vg/ml. 
----------------- ------------------------------------------------
ANIMAL 
TIME 
--------- ---------
---------
----------
-------
1 2 3 4 5 
-----------------
--------- ---------
---------
----------
-------
2 minute. 13.8 11.6 11.1 17.4 12.4 
5 minute 20.0 16.3 16.3 19.4 17.1 
10 minute 18.2 16.9 14.5 18.7 17.1 
20 minute 13.1 13.7 11.8 16.6 14.4 
40 minute 9.7 11.1 10.6 15.8 11.6 
1 hour 7.9 9.0 7.3 13.8 10.3 
1.5 hour 7.5 5.5 6.6 11.1 9.0 
2 hour 6.9 4.4 4.4 9.7 7.4 
3 hour 5.9 2.5 2.4 6.9 5.1 
4 hour 5.2 1.5 1.4 5.9 4.1 
5 hour 4.5 1.0 0.8 4.1 3.0 
7 hour 3.3 0.5 0.4 2.2 2.4 
----------------- --------- --------- ----------------------------
Concentrations of pentobarbitone in the plasma of the cynomolgus 
monkey after a single bolus intravenous injection of pentobarbitone 
at a level of 12 mg/kg. Results are expressed as ~g/ml. 
------------------------------------------------------------------
ANIMAL 
TIME 
---------- ------------------ ------------------
1 2 3 4 5 
---------------- --------- ---------
--------
----------
-------
2 minute 17.9 22.4 14.5 15.9 20.7 
5 minute 17.9 17.9 16.6 15.2 17.3 
10 minute 14.2 17.3 15.2 13.1 15.2 
20 minute 11.3 13.1 13.6 12.1 14.1 
40 minute 9.0 11.7 11.9 10.6 11.7 
1 hour 7.9 9.1 :10.4 8.6 10.4 
1.5 hour 6.9 6.5 8.6 6.9 8.3 
2 hour 5.2 5.9 6.9 5.9 6.9 
3 hour 3.7 5.5 5.5 4.8 5.4 
4 hour 2.8 4.8 4.1 4.0 4.5 
5 hour 1.9 3.9 2.8 2.8 3.1 
7 hour 1.2 1.9 1.2 2.0 1.7 
----------------- ---------- ------------------- ----------
-------
Concentrations of pentobarbitone in the plasma of the baboon after a 
single bolus intravenous injection of pentobarbitone at a level of 
12 mg(kg. Results are expressed as ~g/ml. 
--------------------------------------------------------------------
ANIMAL 
TIME 
--------- ------------------- ----------r-------
1 .2 3 4 5 
---------------- --------- ---------
-------- ----------L-------
2 minute 31.2 20.4 19.9 14.2 13.2 
5 minute 26.9 17.0 21.0 17.3 12.7 
10 minute 22.6 15.0 14.6 14.4 12.0 
20 minute 17.8 12.2 13.5 13.4 10.1 
40 minute 10.1 11.3 11.0 11.1 8.4 
1 hour 8.9 9.3 9.9 9.2 6.7 
1.5 hour 7.1 6.9 8.3 8.0 5.5 
2 hour 5.2 5.8 7.7 5.2 5.2 
3 hour 3.0 4.5 5.6 3.6 3.5 
4 hour 1.9 2.3 3.5 2.0 2.4 
5 hour 1.2 1.1 3.0 1.3 1.6 
7 hour 0.7 1.8 1.6 0.8 0.8 
----------------- ------------------- --------- ----------
--------

